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Glioma epidemiology & clinical presentation
Gliomas are brain tumors that arise from glial cells and are molecularly classified 
following the updated World Health Organization (WHO) 2016 Classification of Tumors 
of the Central Nervous System. The main types of diffuse, non-circumscript glioma are 
oligodendroglioma, astrocytoma and glioblastoma. It is estimated that in 2020, over 
20,000 patients will be newly diagnosed with some type of glioma in the United States.(1) 
Glioblastoma account for the majority of these tumors (57.3%) and are the most aggressive 
type. The age-adjusted incidence rate of glioblastoma is 3.22 per 100,000 population. 
The median age of patients diagnosed with glioblastoma is 65 years, with highest rates 
between 75-84 years. Glioblastoma is 1.58 times more common in men than in women. 
The etiology of glioblastoma is unknown.
 The clinical presentation of brain tumors depends on tumor localization and growth 
rate. Diffuse astrocytoma and oligodendroglioma (low grade glioma) tend to grow more 
slowly than glioblastoma; they present less commonly with focal neurological deficits and 
more often with seizures. Glioblastoma patients present in general more often with sub-
acute symptoms that progress over days to weeks, which include persistent headache, 
fatigue, and focal neurological symptoms, such as memory loss, motor, speech or visual 
deficits, cognitive and personality changes.(2,3) Seizures are less common in glioblastoma 
than in low grade gliomas. Magnetic resonance imaging (MRI) is needed for the radiological 
diagnosis of a cerebral mass lesion. 
 Patients with a glioma as seen on MRI are referred for surgery on a short term with 
the aim to undergo maximal safe tumor resection to reduce symptoms, increase survival 
and ultimately to obtain definitive histopathological and molecular diagnosis. If resection 
is deemed not feasible, a biopsy is required for tissue diagnosis. After surgery, patients 
are treated with a radiotherapy and/or chemotherapy scheme, which depends on factors 
such as age, neurological status, extent of tumor resection and molecular classification of 
the tumor. 
Molecular classification
The WHO 2016 classification is predominantly based on molecular characteristics, in 
particular mutations in the gene encoding for isocitrate dehydrogenase (IDH) 1 and 2 and 
1p/19q codeletion.(4,5) Oligodendroglioma are now defined as diffuse glioma with 1p19q 
codeletion and IDH mutation; astrocytoma are classified according to their IDH mutational 
status as either IDH mutated (mt) or wildtype (wt). The 2016 WHO currently distinguishes 
between glioblastoma IDHwt and IDHmt.(4,6) 
 More recently, low grade astrocytoma IDHwt with certain molecular characteristics 
(combined gain of chromosome 7 and loss of chromosome 10 and/or EGFR amplification 
and/or TERT promoter mutations) are called astrocytoma with molecular features of 
14
Chapter 1
glioblastoma. Another more recent change is the renaming of glioblastoma IDHmt as 
grade IV astrocytoma IDHmt.(7,8)
 IDH mutations are early mutations affecting codon 132 in 90 percent of all IDH 
mutations in diffuse glioma. The mutation leads to changes in the enzyme and consequently 
in increased levels of 2-hydroxygluteratate and decreased levels of α-ketogluterate and 
NADPH.(9) Due to these alterations, and due the MGMT promotor methylating effect of 
IDH mutation, these tumors become more sensitive for alkylating chemotherapy and 
radiotherapy.(6,10,11) In tumors that accumulate IDH mutation, a combined deletion of 
the short arm of chromosome 1 and the long arm of chromosome 19 may occur as a 
result of balanced translocation (oligodendroglioma).(12,13) Next to IDH mutation, 1p19q 
codeletion is also associated with increased sensitivity for alkylating chemotherapy.(14,15) In 
glioblastoma, another alteration that is associated with improved prognosis is methylation 
of the promoter region of the gene O6-methylguanine-DNA methyltransferase (MGMT).(16-18) 
MGMT is a DNA repair enzyme, which is expressed by the MGMT gene located on 
chromosome 10q26. Promoter methylation of this gene reduces MGMT protein expression 
and consequently decreases DNA repair and increases alkylating chemotherapy induced 
tumor death. Therefore, patients with MGMT methylated glioblastoma are more sensitive 
to temozolomide than those without MGMT methylated glioblastoma and thus have a 
better prognosis. MGMT promoter methylation is present in approximately 35-50% of 
patients with newly diagnosed glioblastoma.(19) IDH mutation, 1p19q codeletion and 
MGMT promoter methylation are all associated with more favorable prognosis in patients 
with glioma.(13,15,20-23)





Diffuse olidogdendroglioma and astrocytoma are hypointense on T1-weighted MRI scans 
and hyperintense on T2-weighted MRI scans. Radiogenomics research has the main 
goal to correlate anatomical and physiological MRI features with molecular subtypes, 
increasingly with an artificial intelligence approach.(24-31) Studies have indicated that 
oligodendroglioma with 1p/19q codeletion and IDH mutation are typically located in 
the frontal lobes with calcification, cortical-subcortical involvement, a heterogeneous 
appearance on T2-weighted MRI scans with indistinct borders and minimal or patchy 
contrast enhancement on contrast-enhanced T1-weighted MRI scans. In contrast, 
astrocytomas with IDH mutation and without 1p/19q codeletion are more often located 
in the temporal lobe or insular regions. They are homogenous on T2-weighted MRI 
scans with distinct borders, and they lack calcifications, cortex involvement or contrast-
enhancement on contrast-enhanced T1-weighted MRI scans.
 Glioblastoma typically appear as a contrast enhancing lesion with central necrosis 
on post-contrast T1-weighted MRI scans.(29) Glioblastoma infiltrate far beyond the margins 
of contrast enhancement and together with edema, this infiltration appears as a non-
contrast enhanced, hyperintense area on a T2-weighted or T2-FLAIR MRI scan.(32) Advanced 
and physiological MRI (diffusion weighted imaging and PET-MRI) is shown to be useful to 
detect glioma infiltration more accurately.(33) There are currently no reliable MRI features 
that can distinguish MGMT promotor methylated glioblastoma from unmethylated 
tumors.
Figure 2. Glioblastoma in the right temporal lobe as seen on post-contrast T1-weighted MRI scan (left) and 




In glioblastoma, complete resection of contrast-enhancing tumor on post-contrast 
T1-weighted MRI has consistently been associated with longer overall survival.(34-39) A 
systematic review and meta-analysis of 37 articles with over 41.000 glioblastoma patients 
showed that complete tumor resection decreased the risk of one and two year mortality, 
when compared to subtotal resection.(34) In addition, more recent studies have shown 
that resection beyond the borders of contrast enhancement is associated with improved 
overall survival in patients with glioblastoma. (35, 36, 40-42). However, complete tumor resection 
and maximizing resection beyond the borders of contrast enhancement should not be 
achieved at all cost. Reports on the safety of supratotale resection (beyond the contrast 
enhancing borders) are still limited in numbers and therefore, needs further investigation.(42) 
Intraoperative imaging technologies can be used to achieve safe and maximal tumor 
resection during glioblastoma surgery.(43-45) Intraoperative, real time imaging is needed, 
since neuronavigation systems are typically based on preoperative MRI scans and 
due to brain shift, their accuracy in representing the actual situation during surgery 
decreases. Two randomized controlled trials have shown that 5-aminolevulinic acid and 
intraoperative MRI guided surgery improves the extent of glioblastoma resection.(43-45) 
However, an intraoperative MRI system is expensive and prolongs surgery time with 
approximately one hour.(45) Alternative time- and cost- effective imaging technologies 
may be useful, such as intraoperative Raman spectroscopy or intraoperative ultrasound 
guidance.(43,46,47) However, no randomized controlled trial has assessed their value to 
improve the extent of glioblastoma resection and overall outcome.(43)
 Despite improved surgical and imaging techniques, maximization of the extent of 
resection and the addition of temozolomide to radiotherapy over the past few decades, 
glioblastoma patients still have a poor prognosis of 15 months (6.8% five-year overall 
survival rate).(1,48-50) Patients eventually show disease progression and die due to mass 
effect or extensive brainstem infiltration.(51,52) There is currently no cure for glioblastoma.
Aims and outline of thesis
In this thesis, we assessed the value of glioblastoma imaging and resection in light of 
molecular markers. 
In Part I of this thesis, our aim was to predict molecular markers of glioma on preoperative 
MRI scans. In Chapter 2 we voxel-wise analyze whether there is a difference in anatomical 
localization between IDH wildtype glioblastoma with vs. without MGMT promoter 
methylation. In Chapter 3 and 4 we predict molecular subtypes of glioma (i.e. 1p/19q 




machine and deep learning algorithms. In Chapter 5 we evaluate cognitive functions of 
patients with glioma prior to surgery using white matter fiber tracking. 
In Part II of this thesis, we assessed the value of image guided glioblastoma resection. In 
Chapter 6 we present the results of the ultrasound trial, which is a randomized controlled 
trial that assesses the value of intraoperative ultrasound guided surgery on the extent of 
glioblastoma resection. The question whether intraoperative ultrasound guided surgery 
enables complete tumor resection more often than standard surgery will be answered. 
In Chapter 7 we evaluate the clinical feasibility of a wearable mixed reality device for 
planning glioblastoma surgery, presenting the first proof of concept.
Part III of this thesis consists of studies providing a postoperative evaluation of 
glioblastoma resection. In Chapter 8 we assess the association between the resection of 
contrast enhancing and non-contrast enhancing parts of the tumor and survival in light of 
MGMT promoter methylation in a cohort of patients with newly diagnosed IDH wildtype 
glioblastoma. We answer the question whether complete resection is associated with 
improved survival in patients with molecularly defined glioblastoma. In relation to this, in 
Chapter 9 we perform an international, multicenter, observational study, including over 
one thousand patients with a newly diagnosed IDH-wildtype glioblastoma, in which we 
develop and externally validate a survival prediction model. In Chapters 10.1 and 10.2 
we systematically review and assess the value of supratotal resection on patient survival, 
we present a meta-analysis and an editorial letter on this concept.
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O6-methylguanine-methyltransferase (MGMT) promoter methylation and isocitrate 
dehydrogenase (IDH) mutation status are important prognostic factors for patients with 
glioblastoma. There are conflicting reports about a differential topographical distribution 
of glioblastoma with vs. without MGMT promoter methylation, possibly caused by 
molecular heterogeneity in glioblastoma populations. We initiated this study to re-
evaluate the topographical distribution of glioblastoma with vs. without MGMT promoter 
methylation in light of the updated WHO 2016 classification. 
Methods
Pre-operative T2-weighted/FLAIR and post-contrast T1-weighted MRI scans of patients 
aged 18 year or older with IDH wildtype glioblastoma were collected. Tumors were semi-
automatically segmented and the topographical distribution between glioblastoma with 
vs. without MGMT promoter methylation was visualized using frequency heatmaps. Then 
voxel-wise differences were analyzed using permutation testing with Threshold Free 
Cluster Enhancement.
Results
Four hundred thirty-six IDH wildtype glioblastoma patients were included; 211 with and 
225 without MGMT promoter methylation. Visual examination suggested that when 
compared with MGMT unmethylated glioblastoma, MGMT methylated glioblastoma 
were more frequently located near bifrontal and left occipital periventricular area and 
less frequently near the right occipital periventricular area. Statistical analyses, however, 
showed no significant difference in topographical distribution between MGMT methylated 
vs. MGMT unmethylated glioblastoma. 
Conclusion
This study re-evaluated the topographical distribution of MGMT promoter methylation in 
436 newly diagnosed IDH wildtype glioblastoma, which is the largest homogenous IDH 
wildtype glioblastoma population to date. There was no statistically significant difference 
in anatomical localization between MGMT methylated vs. unmethylated IDH wildtype 
glioblastoma.
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Introduction
Patients with glioblastoma have a poor prognosis with a median overall survival of 
15 months, despite standard of care consisting of safe and maximal surgical resection 
followed by chemo- and/or radiotherapy.(1) This prognosis varies based on factors such as 
age, Karnofsky Performance Status, extent of resection and molecular markers, in particular 
isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-methyltransferase 
(MGMT) promoter methylation status.(2)
 MGMT is a DNA repair enzyme, which is expressed by the MGMT gene located on 
chromosome 10q26. Promoter methylation of this gene reduces MGMT protein expression 
and consequently decreases DNA repair and increases alkylating chemotherapy induced 
tumor death. Therefore, patients with MGMT methylated glioblastoma are more sensitive to 
neo-adjuvant temozolomide than those without MGMT methylated glioblastoma. MGMT 
is methylated in approximately 50% of patients with newly diagnosed glioblastoma.(3) 
 There are conflicting results in the published literature on a possible differential 
topographical distribution of glioblastoma with vs. without MGMT promoter methylation.(4) 
Ellingson et al. suggested that when compared with those without MGMT promoter 
methylation, glioblastoma with methylation are more frequently located in the left 
temporal lobe and less frequently in the right temporal lobe.(5) However, other studies 
found the reverse lateralization pattern(6) or did not find any lateralization at all.(7-9) 
These conflicting results could be ascribed to heterogeneity of molecular subtypes of 
glioblastoma in the studied populations, for instance when IDH wildtype glioblastoma 
are mixed with the genetically and prognostically distinct IDH mutated glioblastoma, 
or to variation in statistical methods that were used across studies. Therefore, the 
question whether glioblastoma with vs. without MGMT promoter methylation have 
a different anatomical localization remains unanswered. In light of the updated WHO 
2016 classification(10), a molecularly homogenous glioblastoma population must be used 
to re-evaluate the topographical distribution of MGMT methylated vs. unmethylated 
glioblastoma.
 Therefore, we have initiated this study to re-evaluate the topographical distribution 
of glioblastoma with and vs. without MGMT promoter methylation in the largest 
homogenous IDH wildtype  glioblastoma population to date.
METHODS
Patient inclusion
All consecutive patients aged 18 years or older newly diagnosed with a contrast-
enhancing and histopathologically confirmed glioblastoma IDH wildtype who underwent 
tumor resection or biopsy between January 2011 and May 2018 at the Erasmus MC, 
University Medical Center Rotterdam or Haaglanden MC were retrospectively included in 
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this study. Patients were eligible if pre-operative T2-weighted/fluid-attenuated inversion 
recovery (FLAIR) and post-contrast T1-weighted MRI scans as well as molecular data on 
IDH mutation and MGMT methylation status were available. Recurrent glioblastoma or 
confirmed IDH mutated glioblastoma were excluded. The study design was approved 
by the Medical Ethical Committee of Erasmus MC and Haaglanden MC. The study was 
performed in accordance with the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards.
Image acquisition, tumor segmentation and registration
From clinical pre-operative MRI scans, which were obtained according to clinical brain 
tumor protocols on either a 1.5T or 3.0T scanner, T2-weighted/FLAIR and post-contrast T1-
weighted images were collected. For glioblastoma segmentation, we first imported both 
the post-contrast T1-weighted and T2-weighted/FLAIR scans into BrainLab (BrainLab, 
Feldkirchen, Germany, version 2.1.0.15). We semi-automatically segmented all tumor-
related contrast-enhancement (including the central necrotic part, if present) using the 
SmartBrush tool in Brainlab Elements and manually adapted the segmentation if needed. 
We then used the T2-weighted/FLAIR scan to semi-automatically segment all tumor-
related non-enhancing hyperintense abnormalities (extra-lesional hemorrhage were 
excluded).
 All tumor segmentations were then registered to the Montreal Neurological 
Institute (MNI) International Consortium for Brain Mapping 152 nonlinear atlas. The 
post-contrast T1-weighted scans were registered to the T1-weighted atlas and the T2-
weighted/FLAIR scans to the T2-weighted atlas. Registration was done using SimpleElastix 
(version 72b7e81), based on a mutual information metric using an affine registration.(11) 
The resulting transformation parameters were used to transform the 3D segmentations to 
the atlas space. Registration results were visually checked to ensure that  for all cases the 
registered masks lay entirely within the brain mask of the atlas. No adjustments were made 
to the initial registration settings for individual patients. We created voxel-wise frequency 
maps for all glioblastoma combined, and frequency difference maps of glioblastoma with 
versus without MGMT promoter methylation.
Molecular analysis
Tumor tissue samples were obtained from patients through surgical resection or biopsy. 
Histopathological examination was performed by neuropathologists. DNA was extracted 
from microdissected FFPE tissue fragments by proteinase K digestion for 16 h at 56 C in the 
presence of 5 % Chelex 100 resin and used after inactivation of proteinase K and removal 
of cell debris and the Chelex resin. IDH mutational analysis was assessed with Sanger 
sequencing of PCR-amplified fragments from IDH1 and IDH2 mutational hot spots, essentially 
as previously described.(12) M13-tailed primers for PCR amplification of IDH1 codon 132 
were forward 5’-TGTAAA ACGACGGCCAGTCTCCTGATGAGAAGAGGGTTG-3’ and reverse 
5’–CAGGAAACAGCTATGACCCATT CTCTGGTTTTCGCATGCAAAATCACATTATTGCC-3’. After 
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initial denaturation at 95 C for 3 min, 35 cycles of 95 C for 30 s, 60 C for 45 s, and 72 C for 45 
s were performed, followed by 10 min at 72 C. Subsequent sequence analyses of the PCR 
products was carried out with M13 forward and reverse primers on an 3730 XL Genetic 
Analyzer (Applied Biosystems, Foster City, CA, USA). 
 Targeted NGS was performed by semiconductor sequencing with the Ion Torrent 
platform using supplier’s materials and protocols (Thermo Fisher Scientific) with a 
dedicated panel for detection of glioma-specific aberrations, including IDH1 and IDH2 hot 
spot mutations essentially as previously described.(13) Library and template preparations 
were performed consecutively with the AmpliSeq Library Kit 2.0-384 LV and the Ion 
510/520/530 Chef kit. Sequencing was performed on a 530 or 540 chip with the Ion S5 XL 
system. Data was analyzed with the Torrent variant caller (Thermo Fisher Scientific) and 
variants were annotated in a local Galaxy pipeline using ANNOVAR. Details of the glioma 
panel are described in the supplementary data of Dubbink et al.(13)
 MGMT promoter methylation status was assessed by methylation-specific PCR 
essentially as described by Esteller et al.(14) Bisulfite conversion and subsequent purification 
is performed with the EZ DNA Methylation-Gold Kit (Zymo Research) according to the 
supplier’s protocol. Methylation-specific PCR was performed with primers specific for 
either methylated or the modified unmethylated DNA. Converted primer sequences for 
unmethylated DNA were forward 5’-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3’ and reverse 
5’-AACTCCACACTCTTCCAAAAACAAAACA-3’, and for the methylated reaction, forward 
5’-TTTCGACGTTCGTAGGTTTTCGC-3’ and reverse 5’-GCACTCTTCCGAAAACGAAACG-3. 
PCR was performed after initial denaturation at 95 C for 5 min by 35 cycles of 92 C for 
45 s, 59 C for 65 s, and 72 C for 45 s, followed by 7 min at 72 C. Five microliters of each 15 
µl methylation-specific PCR product was loaded onto a 1.5 % agarose gel stained with 
GelRed (Biotium) and examined under ultraviolet illumination. SW48 cell line DNA and 
tonsil DNA was used as a positive control for methylated and unmethylated alleles of 
MGMT, respectively. Controls without DNA were used for each set of methylation-specific 
PCR assays.
Statistical analysis
We first tested the differences between pre-operative enhancing and non-enhancing 
tumor volumes as well as their ratio with the Kruskal-Wallis test. We mapped the anatomical 
localization of all MGMT methylated and unmethylated glioblastoma by iterating over all 
voxels in the MNI atlas and counting the number of tumor frequencies for each group in 
each voxel. To test for differences in spatial distribution between glioblastoma with vs. 
without MGMT promoter methylation, we assessed the cluster-wise significance at the 
voxel-level between distributions, using permutation testing with Threshold Free Cluster 
Enhancement (15) in the software package “FSL Randomize” (version 5.0.9, using 10,000 
permutations).(16) This approach corrects p-values for the family-wise error in testing 




In total, 769 patients with newly diagnosed, contrast enhancing glioblastoma were 
screened, of which we excluded 333 patients: 22 were excluded due to IDH mutation and 
311 were excluded due to insufficient or missing molecular data on IDH mutation or MGMT 
methylation status. Final analysis included 436 patients with IDH wildtype glioblastoma 
(see flowchart, Supplementary Material); 211 with and 225 without MGMT promoter 
methylation. 340 patients had undergone a surgical tumor resection and 96 a diagnostic 
biopsy. In all patients pre-operative post-contrast T1-weighted MRI scans were available; in 
90 patients T2-weighted FLAIR scans and in 346 patients T2-weighted scans were available. 
When compared with MGMT unmethylated glioblastoma, MGMT methylated glioblastoma 
had a significantly higher ratio of non-enhancing versus contrast-enhancing volume (2.09 
(inter quartile range 2.6) and 2.5 (inter quartile range 3.3), p=0.045, respectively).  Patient 
and tumor characteristics are further presented in Table 1.   
Table 1. Patient and tumor characteristics.
Characteristics n %





≤ 65 227 52.1
> 65 209 47.9
Mean, years (SD) 61.5 (16.2)
Karnofsky Performance Status
≤ 70 142 32.6
> 70 294 67.4
Mean (SD) 80 (12.5)
Pre-operative MRI scans
T1 post-contrast 436 100
T2-weighted 346 79.4









Contrast-enhancing 30.1 (39.5) 35 (45.8) .130
Non-enhancing 75.5 (105.0) 65.5 (84.2) .338
Non-enhancing/contrast-enhancing Ratio 2.5 (3.3) 2.09 (2.6) .045
SD standard deviation, IQR Inter Quartile Range, CE contrast enhancement, FLAIR Fluid-attenuated inversion recovery. 
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Topographical mapping of 436 IDH wildtype glioblastoma
For visual inspection, heatmaps based on post-contrast T1-weighted and T2-weighted/
FLAIR segmentations were created for all 436 patients combined (Figures 1 and 2), 
as well as frequency difference maps between MGMT methylated vs. unmethylated 
glioblastoma (Figure 3). Visual inspection of maps in Figure 1 suggests that glioblastoma 
were most frequently located in the right temporal, insular and parietal area, and near 
the periventricular area both frontally and occipitally. Visual inspection of Figures 2 and 
3 indicates that when compared with MGMT unmethylated glioblastoma, methylated 
glioblastoma were more frequently located near bifrontal and left occipital periventricular 
area (up to 6.5% frequency difference) and less frequently near the right occipital 
periventricular area (up to 9.1% frequency difference).
Figure 1. Heatmaps of all 436 IDH wildtype GBM.
 To test whether this difference was statistically significant, voxel-wise analyses of 
both the post-contrast T1-weighted and T2-weighted/FLAIR segmentation heatmaps 
were performed. Although statistical analysis of the post-contrast T1-weighted scans 
marked a region near the right occipital periventricular area as a potentially discriminating 
area between MGMT methylated vs. unmethylated glioblastoma, this difference was not 
statistically significant (Figure 4, together with corresponding p-values). This figure in fact 
shows that not any statistically significantly discriminating brain area between MGMT 
methylated and unmethylated glioblastoma could be found. Scroll-through video clips 




Figure 2. Heatmaps of MGMT methylated (N=211) and unmethylated (N=225) GBM.
Figure 3. Frequency difference maps between MGMT methylated (N=211) and unmethylated
(N=225) GBM.
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Discussion
This study voxel-wise analyzed post-contrast T1-weighted and T2-weighted/FLAIR 
heatmaps and showed that there was no statistically significant difference in anatomical 
localization between MGMT methylated vs. unmethylated IDH wildtype glioblastoma.  
 The primary reason to initiate this study was to re-evaluate the anatomic localization 
of MGMT methylated vs. unmethylated glioblastoma in light of the updated WHO 2016 
classification era following conflicting reports on this topic.(4) Ellingson et al. (2013) 
reported that glioblastoma with MGMT methylation were lateralized to the left hemisphere 
(temporal lobe) and that those without were lateralized to the right hemisphere(17), which 
was in line with their previous article (2012) and in which they included a substantial 
portion of their previously studied glioblastoma population.(5) However, in contrast 
to these findings there are also studies that found the reverse pattern of hemispheric 
lateralization, in which glioblastoma with MGMT methylation were located more 
frequently in the right hemisphere, while those without MGMT methylation lateralized to 
the left hemisphere.(6) Additionally, there are conflicting reports on lobar distribution, in 
which glioblastoma with MGMT methylation were more frequently located in the parietal 
Figure 4. P-value maps of MGMT methylated (N=211) and unmethylated (N=225) GBM.
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and occipital lobes, while those without were located more frequently in the temporal 
lobes.(8) A recent study suggested after qualitative analyses that subventricular zones were 
more frequently spared with MGMT methylated glioblastoma, but found no difference 
in hemispheric lateralization between glioblastoma with and without MGMT promoter 
methylation.(9) Finally, there are also studies that report no differences in localization 
between glioblastoma with and without MGMT methylation,(7, 18) in concordance with the 
findings of our study.
 These conflicting results in the literature can potentially be ascribed to two 
methodological issues. First, inconsistencies may arise from variations in glioblastoma 
patient populations across studies, many of which were performed in the pre-WHO 2016 
classification era when the impact of molecular subtyping of glioblastoma according 
to IDH mutation status was less of a consideration.(10) Ellingson et al. (2013) included a 
series of 507 de novo glioblastoma with mixed IDH subtypes, including 366 IDH wildtype, 
34 IDH mutated glioblastoma and also 107 glioblastoma without data on IDH mutation 
status.(17) Moreover, the majority of the studies did not report the IDH mutation status of 
included glioblastoma.(5, 6, 8, 18)
 Mixing molecular subtypes or not knowing IDH mutation status of glioblastoma is 
undesirable when assessing topographical distribution of molecular subtypes,(10) since 
it is now known that IDH mutated glioblastoma represent a distinct molecular subtype 
of glioblastoma from a distinct precursor lesion which have a predominantly frontal 
lobe involvement when compared with IDH wildtype glioblastoma.(19) This topographic 
link between IDH mutation and MGMT methylation was also suggested by Ellingson 
et al. (2013) by demonstrating that IDH mutated and MGMT methylated glioblastoma 
were indeed more frequently localized in the frontal lobe.(17) This has not only been 
demonstrated in glioblastoma, but also in non-contrast enhancing low grade glioma in 
which IDH mutated low grade glioma (both oligodendroglioma and astrocytoma) were 
more frequently located in the frontal lobes, while non-contrast enhancing IDH wildtype 
astrocytoma were more frequently located in the basal ganglia of the right hemisphere.(20) 
This topographical link thus suggests IDH mutation status as (confounding) factor 
between MGMT methylation status and localization. Therefore, studies must be 
conducted based on homogeneous tumor populations with respect to IDH mutational 
status. This hypothesis was recently supported by Roux et al, who assessed a homogenous 
IDH wildtype glioblastoma population (n = 392) and found no difference in localization 
between glioblastoma with and without MGMT methylation, in line with our study.(21)
 Second, the conflicting results in the literature may arise from different statistical 
methods that were used across studies. Studies often investigated the anatomic 
localization of glioblastoma with and without MGMT promoter methylation with visual 
examination, qualitatively, without a statistical, voxel-wise quantitative analysis.(7-9,18) 
Ellingson et al. (2013) used frequency difference maps to demonstrate that MGMT 
methylated glioblastoma were more frequently localized in the left temporal lobe.(17) 
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Using similar frequency difference maps, we also found topographical differences, 
which indicated that when compared with MGMT unmethylated glioblastoma, MGMT 
methylated glioblastoma were more frequently localized near bifrontal and right occipital 
periventricular area and less frequently near the right occipital periventricular area. 
However, we showed that these apparent differences did not survive rigorous statistical 
testing. Ellingson et al. report the use of ‘Analysis of Differential Involvement’ for their 
statistical analysis, which is based on the Fisher exact test.(5) We used ‘FSL randomize’, 
which is different from the Fisher exact test because it does not make any assumptions 
about the underlying distribution of the variables.(16) Another methodological difference 
can be found in the correction for multiple comparisons. Ellingson et al. used random 
permutations based on Bullmore et al. instead of the more recently proposed and widely 
accepted method of doing random permutations employed in ‘FSL randomize’ based 
on Smith et al.(15,22) Furthermore, the method by Bullmore et al. requires a user-defined 
threshold for clustering, which can impact the results substantially.(22) Instead, we used 
‘Threshold Free Cluster Enhancement’, which does not require thresholding to determine 
the clusters, and which has been shown to have a higher sensitivity compared to other 
methods.(15) Our stringent methodology of rigorous statistical testing and applying new 
insights in glioblastoma molecular subtyping to a large studied patient population are the 
strengths of our study. 
Limitations
The main limitation of this study is its retrospective design, which may have introduced 
selection and confounding biases. Selection bias may occur when patients who receive 
diagnostic biopsies are excluded from analysis, since these tumors are often large, 
multifocal, located deep within the basal ganglia, or crossing midline. This may skew 
the results on tumor localization of glioblastoma, which is our main outcome. We have 
therefore attempted to limit this bias first by consecutive inclusion of all glioblastoma 
patients operated upon between 2011 and 2018 in our cohort, including diagnostic 
biopsies. In addition, it is known that tumor localization is associated with IDH mutation 
status, with IDH mutated tumors located more frequently in the frontal lobes, as 
mentioned earlier.(19) Since IDH mutation status is both associated with tumor localization 
and MGMT methylation status, it may function as a confounding factor. We therefore have 
also attempted to limit this potential bias by excluding all IDH mutated tumors. Another 
limitation is that we included patients from two medical centers from a period of over 
seven years. This introduced variation of MRI scan protocols such as magnet strength, 
voxel size and slice thickness, which consequently may have negatively influenced 
registration accuracy and anatomical localization. Such registration inaccuracies can 
however be considered minor relative to the size of the tumor and it is therefore unlikely 
that our results were significantly impacted by scanner variations. Additionally, tumor 
volume assessment on these MRI scans were performed by one observer without 
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confirmation of a second, independent assessor. This may have introduced some degree 
of information bias. We have attempted to limit this bias during volumetric assessment 
by blinding the assessor for patients’ clinical and molecular characteristics. It is known 
that both the inter and intra-observer agreement for pre-operative tumor volumes in 
glioblastoma is relatively high.(23) Finally, it should be noted that the known intertest 
variability is a limitation of MGMT analyses, as assays used in other studies may produce 
slightly different MGMT methylation results.(24) This may partially explain the variety in the 
proportion of MGMT methylated tumors reported in literature.
Conclusion
In the largest homogenous IDH wildtype glioblastoma population to date, we showed 
that visual appearance of differences could not be confirmed with rigorous voxel-wise 
statistical testing and thus that there is no statistical difference in anatomical localization 
between IDH wildtype glioblastoma with vs. without MGMT promoter methylation.
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Patients with 1p/19q co-deleted low-grade glioma (LGG) have longer overall survival and 
better treatment response than patients with 1p/19q intact tumors. Therefore, it is relevant 
to know the 1p/19q status. To investigate whether the 1p/19q status can be assessed prior 
to tumor resection, we developed a machine learning algorithm to predict the 1p/19q 
status of presumed LGG based on preoperative magnetic resonance imaging (MRI).
Methods 
Preoperative brain MRI scans from 284 patients who had undergone biopsy or resection of 
presumed LGG were used to train a support vector machine algorithm. The algorithm was 
trained based on features extracted from T1-weighted and T2-weighted MRI scans, and 
on patient age and sex. The performance of the algorithm compared to tissue diagnosis 
was assessed on an external validation dataset of MRI scans from 129 LGG patients from 
The Cancer Imaging Archive (TCIA). Four clinical experts also predicted the 1p/19q status 
of the TCIA MRI scans. 
Results 
The algorithm achieved an area under the curve (AUC) of 0.72 in the external validation 
dataset. The algorithm had a higher predictive performance than the average of the 
neurosurgeons (AUC 0.52), but lower than that of the neuroradiologists (AUC 0.81). There 
was a wide variability between clinical experts (AUC 0.45-0.83).
Conclusion 
Our results suggest that our algorithm can non-invasively predict the 1p/19q status 
of presumed LGG with a performance that on average outperformed the oncological 
neurosurgeons. Evaluation on an independent dataset indicates that our algorithm is 
robust and generalizable. 
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Introduction
Low grade glioma (LGG) are primary brain tumors that originate from glial cells. The World 
Health Organization (WHO) 2016 criteria recognize three subtypes based on molecular and 
histological features:(1) diffuse IDH wildtype astrocytoma (IDH wildtype, 1p/19q intact),(2) 
diffuse IDH mutant astrocytoma (IDH mutated, 1p/19q intact); and (3) oligodendroglioma 
(IDH mutated, 1p/19q co-deleted).(1,2)
 Studies have shown that the distinction between these three categories is clinically 
relevant in terms of prognosis and management: in patients treated with optimal surgical 
resection followed by radiation therapy with or without chemotherapy, median survival 
is longest of those with oligodendroglioma.(3,4) Additionally, studies have suggested that 
residual tumor has a more negative impact on survival in 1p/19q intact, IDH mutated 
astrocytoma than on 1p/19q co-deleted, IDH mutated oligodendrogliomas.(5,6) Therefore, 
the ability to predict the molecular subtypes of LGG at an early stage could provide better 
guidance of risk-benefit assessment and clinical decision-making. 
 The recent shift from histopathology-based glioma classification to the molecular 
subtype-based WHO 2016 classification gave rise to neuro-oncological radiogenomics 
research in which features seen on preoperative magnetic resonance imaging (MRI) scans 
are used to predict the genetic mutation status of glioma.(7-9) Features such as frontal tumor 
localization, indistinct tumor borders, heterogeneous signal intensity on T2-weighted 
images, and both cortical and subcortical tumor infiltration all suggest the presence of 
1p/19q co-deletion.(7)
 One way of linking MRI features to 1p/19q co-deletion is through machine learning. 
While several studies have applied this method to datasets of patients with high grade 
glioma, few studies have developed radiogenomics methodology in LGG.(10-15) Of the 
ones that have, most have not used an independent test set and, therefore, it is difficult 
to estimate their actual performance in the real-world clinical setting.(10,11,13,14) Lu et al.(12) 
did use an independent test set, but this set contained a very limited number of LGG 
cases (N=12). Zhou et al.(15) used a test set consisting of IDH-mutated LGG and high-grade 
glioma to evaluate the 1p/19q co-deletion prediction performance. This is not an ideal 
test set as 1p/19q co-deletion status is not clinically relevant for high grade glioma, and 
there is a selection bias of IDH mutated tumors only. 
 The aim of this retrospective study was to develop a radiogenomics approach to 
predict the 1p/19q co-deletion status of presumed LGG based on pre-operative MRI 






All patients aged 18 years or older newly diagnosed with presumed LGG and who 
underwent tumor resection or biopsy between October 2002 and March 2017 at the 
Erasmus MC, University Medical Center Rotterdam (EMC) or Haaglanden Medical Center 
(HMC) were retrospectively included in the EMC/HMC dataset. Patients were eligible if 
histopathological diagnosis with molecular subclassification of the 1p/19q co-deletion 
status and pre-operative post-contrast T1-weighted and T2-weighted MRI scans were 
available. The study was approved by the Medical Ethical Committee of Erasmus MC, who 
waived the need for written informed consent from the patients due to the retrospective 
nature of this study and the (emotional) burden that would result from contacting the 
patients or their relatives to obtain consent. The study was performed in accordance with 
the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Histopathological diagnosis and molecular subclassification
Tumor samples were obtained from patients who underwent surgical resection or 
biopsy. Histopathological examination was performed by neuropathologists and further 
molecular subclassification of the 1p/19q co-deletion and/or IDH mutation status was 
performed as part of the diagnostic routine by molecular biologists using fluorescence 
in situ hybridization (FISH), Loss of Heterozygosity (LOH) analysis, targeted Next-
Generation Sequencing (NGS) panel using an Ion Torrent Personal Genome Machine (Life 
Technologies) or Ion S5XL or a Multiplex Ligation Probe Assay (MRC-Holland). (4,16-18) All 
tumors were subclassified based on the WHO 2016 criteria.
Imaging acquisition and post-processing
MRI scans were used that were acquired in the routine diagnostic process. T1-weighted 
and T2-weighted MRI sequences were used for the algorithm.  In many, but not all, patients 
T2-weighted fluid attenuated inversion recovery (T2w-FLAIR) imaging was also available. 
As scans were acquired at a number of sites, the imaging data were heterogeneous with 
a wide range of acquisition settings in voxel spacing, matrix size, echo time, repetition 
time, number of slices, slice thickness, and field strengths on scanners from three different 
manufacturers (General Electric, Philips and Siemens). An overview of the scanning 
settings is given in the Supplementary Materials, Appendix 1. 
 All scans were visually inspected by M.S. and excluded if MRI artefacts were present. 
Presumed LGG was defined as non-enhancing tumor, as seen on the presurgical post-
contrast T1-weighted MRI scan. Therefore, all post-contrast T1-weighted scans were 
reviewed and excluded if clear or solid enhancement was present. When available T1-
weighted pre-contrast scans were inspected for hemorrhage, to prevent false positive 
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assessment of enhancement. Although tumors with evident contrast enhancement were 
excluded, minimal enhancement was tolerated. Minimal enhancement was defined as 
punctiform (<1mm in diameter) or poorly defined faint enhancement, similar to Pallud et 
al.(16)
 Tumor segmentation was performed by two independent observers (F.I. and 
G.K.) using ITKSnap.(20) Segmentation was done on T2w-FLAIR when available (N=119), 
otherwise on the T2-weighted scans (N=165). Since in our institution LGG segmentations 
are preferably performed on T2w-FLAIR scans, we did not enforce the assessors to segment 
on T2-weighted scans in order to stick to the real-world clinical practice. The segmentations 
were then transformed to the T2-weighted scans (in the case of T2w-FLAIR segmentation) 
and the T1-weighted scans, using the image registration software SimpleElastix(21). For all 
patients, brain masks were automatically constructed using FSL’s BET tool with a fractional 
intensity threshold of 0.5.(22) These brain masks were subsequently used to normalize the 
intensity of the MRI scans. Details can be found in Appendix 2.
TCIA Dataset
Patients from The Cancer Imaging Archive (TCIA) “LGG-1p19qDeletion” dataset were 
screened for eligibility based on previously described inclusion and exclusion criteria, and 
used as the external validation dataset.(10,23,24)
 This data collection is a publicly available dataset that consists of histopathological 
proven LGG with co-registered T1- and T2-weighted preoperative MRI scans as well as 
biopsy proven 1p/19q co-deletion status. Molecular analysis of the 1p/19q co-deletion 
status was performed with FISH for all tumors; IDH mutation status was not determined. 
All MRI scans were visually inspected by M.S. as previously described. An overview of 
the MRI settings is listed in the Supplementary Materials, Appendix 1. All tumors were 
semi-automatically segmented by M.S. on the T2-weighted scans using ITKSnap. Since 
the T1-weighted and T2-weighted scans were already co-registered in this study, the 
segmentation could be directly used for the T1-weighted scans without the need for 
registration. Brain masks were made using FSL’s BET tool, with the same settings as for the 
EMC/HMC dataset.
Classification algorithm
To predict the 1p/19q status of the tumors based on MRI features, the PREDICT toolbox was 
used. This toolbox was used to extract a total of 78 image features (such as image intensity, 
tumor texture, tumor shape, and tumor location) from the T1-weighted and T2-weighted 
MR image. These features, as well as the age and sex of the patient, were then used to 
train a Support Vector Machine (SVM), resulting in a total of 80 features. All parameter 
optimization and classifier training were performed on the EMC/HMC training set dataset 
using 100 iterations of stratified random-split cross-validation, with 80% of the data set 
used for training and 20% used for validation. Once the algorithm was optimized, no more 
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changes were made to the algorithm and it was then evaluated on the TCIA dataset. To 
evaluate the algorithm, the accuracy, sensitivity (1p/19q co-deletion prediction), specificity 
(1p/19q intact prediction), area under the receiver-operating-characteristic curve (AUC), 
weighted F1-score, and precision were determined by comparing the predicted labels 
with the reference labels obtained from tissue diagnosis. Full details of the algorithm can 
be found in the Supplementary Materials, Appendix 2 with more information about the 
evaluation metrics in Appendix 3. An overview of the classification algorithm is provided 
in Supplementary Materials, Online Figure 1.
 To minimize the variance due to randomness in the algorithm training, an ensemble 
of 5 SVMs, which averages the predictions of the 5 independently trained models, was 
also constructed; the details can be found in Supplementary Materials, Appendix 2. One 
hundred different ensembles were constructed, and were evaluated on the TCIA dataset 
using the evaluation metrics described previously. Mean and standard deviation of the 
metrics over the 100 ensembles were computed.
 To evaluate the contribution of the different features to the final prediction, a 
sensitivity analysis using polynomial chaos expansions was performed, resulting in Sobol 
indices for each feature.(25) The total Sobol index was used to determine the relative 
feature importance of the individual features. The total Sobol index is relative measure 
of the sensitivity of the algorithm to the input features. The OpenPC toolbox was used to 
create the polynomial chaos expansions and to calculate the Sobol indices.(26,27)
 We also determined which patients from the TCIA dataset were considered as 
representative examples for the 1p/19q co-deleted and 1p/19q intact class by the 
algorithm. This was achieved by counting the number of times the algorithm correctly 
predicted the class for a specific patient in the 100 ensembles that were constructed. 
We evaluated the performance of the algorithm when the EMC/HMC and TCIA dataset 
were mixed instead of used as a separate train and validation set, to evaluate the effect of 
adding additional training data. 
Prediction of 1p/19q status by clinical experts
To compare the results of the algorithm with expert performance, the 1p/19q status of 
the TCIA tumors was also predicted by two neuroradiologists and two neurosurgeons 
at the Erasmus MC Brain Tumor Center. They were presented with the T1-weighted and 
T2-weighted images side by side for each patient as well as the sex and age to ensure 
that the algorithm and the raters had access to the same information. For each tumor 
the rater was then asked to choose whether they thought it was 1p/19q co-deleted or 
not, and to provide a confidence score ranging from 1 to 5 (1 indicating very unsure and 
5 indicating very sure). This confidence score was then turned into a prediction ‘score’ by 
dividing it by 5 and multiplying it by 1 if the predicted label was co-deleted or by -1 if 
the predicted label was not co-deleted. In this way an AUC could be determined for the 
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manual classification. The accuracy, sensitivity, and specificity were determined in the 
same way as for the algorithm.
Statistical analysis
Statistical analyses to test differences between the two datasets were performed with 
SPSS 21.0 statistical software (IBM Corp.). We tested whether the two datasets differed 
significantly from each other using the Mann–Whitney U test for continuous, non-normally 
distributed variables (age and volume) and the chi-squared test for all other categorical 
variables (sex, genetic analysis, presence of mild enhancement, codeletion status). 
Predictive performances (mean, 95% confidence interval (CI)) between the EMC/HMC 
training set and TCIA validation set were tested with the Welch t-test. Accuracy between 
the clinical experts and the algorithm were tested with the McNemar test. A p-value of 
< 0.05 was considered statistically significant. The 95% CIs were calculated such that if the 
entire experiment of training on EMC/HMC and prediction on TCIA would be repeated, in 
95% of the repetitions the result would lie within that interval.
Data Sharing
The data used in this study is available on Mendeley Data (http://dx.doi.org/10.17632/
rssf5nxxby.1). The code for the construction and evaluation of the prediction algorithm is 
available on GitHub (https://github.com/Svdvoort/PREDICT). The code used to construct 
the polynomial chaos expansions and calculate the Sobol indices is available on GitHub as 
well (https://github.com/Svdvoort/OpenPC).
Results
In the EMC/HMC dataset, 424 LGG were identified and screened for eligibility. Cases 
were excluded due to unknown 1p/19q co-deletion status (N=22), absence of T1- and/
or T2-weighted MRI scans (N=46), enhancement (N=58), and unacceptable image quality 
(N=14), which resulted in 284 patients included for final analysis (Flowchart, Figure 1). 
 From the TCIA database, all 159 patients were screened for eligibility. Patients were 
excluded because of enhancement (N=18), signs of prior biopsy/surgical procedure 
(N=7), no post-contrast T1-weighted imaging available (N=3), and patients being younger 
than 18 years (N=2), resulting in 129 patients included in the external validation dataset 
(Flowchart, Figure 1). An overview of the excluded patients from the TCIA database as well 
as the reason for exclusion is available as Supplementary Material Appendix 4.
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 There was no significant difference between the EMC/HMC and TCIA datasets for 
median age (43.0 years, 17.0 interquartile range (IQR) vs. 39 years, IQR 19.5 respectively; 
p=0.11) and sex distribution (56.7% vs 52.7% male respectively; p=045). Median tumor 
volume in the EMC/HMC dataset was significantly larger than in the TCIA dataset (median 
47.80 cm3, IQR 58.65 vs. median 35.70 cm3, IQR 49.10), p=0.04). There were fewer 1p/19q 
co-deleted tumors in the EMC/HMC compared with the TCIA dataset (35.20% vs. 65.40%, 
p<0.0001). Patient and tumor characteristics of both datasets are further presented in 
Table 1.
 The predictive performance of the algorithm on the EMC/HMC training dataset, 
obtained from the cross validation, and the TCIA validation dataset is given in terms of 
accuracy, AUC, F1-score, precision, sensitivity and specificity in Table 2. The accuracy, 
AUC and sensitivity did not differ significantly between training and validation datasets 
(p=0.886, p=0.746, p=0.146 respectively), while the specificity was significantly lower 
in the validation dataset (p=0.038). The predictive performances of the clinical experts 
compared to the algorithm can be found in Table 3, and their ROC curves in Figure 2. 
Figure 1. Flow diagram of the inclusion procedure for both the EMC/HMC training dataset and TCIA validation 
dataset.
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The algorithm had a higher AUC when compared with the average performance of the 
neurosurgeons, but a lower AUC when compared with the neuroradiologists. There was 
high variability in predictive performance between the clinical experts (AUC 0.449 - 0.830). 
 The results of mixing the EMC/HMC dataset and the TCIA dataset are shown in 
Appendix 5. Mixing the datasets leads to a slightly improvement performance, but 
still within the confidence interval of the EMC/HMC dataset cross-validation results. 
According to the algorithm, the most important features for accurate 1p/19q co-deletion 
status prediction were the cranial/caudal location of the tumor, the skewness of the T2-
weighted signal intensity (SI) histogram and one of the texture features, together with 
age and sex (Supplementary Materials, Online Figure 2). The algorithm identified a typical 
1p/19q codeleted glioma as a frontal heterogeneous tumor as seen on T1-weighted 
and T2-weighted scans, while a typical 1p/19q intact glioma was identified as a parietal 
homogenous tumor, as shown in Figure 3.  
Figure 2. ROC curves of clinical expert and algorithm performance. For the performance of the algorithm the 
95% confidence interval is plotted as well, representing the uncertainty due to randomness in model training.
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Figure 3. (A) and (B) show a frontally located glioma. It is non-enhancing on post-contrast T1-weighted MRI 
(A). A heterogeneous signal intensity with indistinct border is visible on the T2-weighted MRI (B). Correctly 
predicted as a 1p/19q codeleted glioma (oligodendroglioma) by the algorithm. (C) and (D) show a parietally 
located glioma. It is non-enhancing on post-contrast T1-weighted MRI (C). A homogeneous signal intensity with 
sharply demarcated border is visible on the T2-weighted MRI (D). Correctly predicted as a 1p/19q intact glioma 
(astrocytoma) by the algorithm.
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Table 1. Patient and tumor characteristics.
EMC/HMC - Training Set
(n = 284)
TCIA - Validation Set
(n = 129)
P value
Clinical  n (%) n (%)
Age median, [IQR] in years 43 [17] 39 [19.5] 0.11
Sex  0.45
Male  161 (56.7) 68   (52.7)
Female  123 (43.3) 61   (47.3)
Imaging  
Volume median, [IQR] in cm3  47.8, [58.7] 35.7, [49.1] 0.04
Mild Enhancement 0.005
Yes 27   (9.5) 25   (19.4)
No 257  (90.5) 104   (80.6)
Genetic  




Method of Analysis < 0.0001
NGS 214   (75.4)   0         (0)
FISH 45     (15.8) 129    (100)
MLPA 25     (8.8) 0         (0)
1p/19q codeletion  <0.0001
Yes 100    (35.2) 85   (65.9)
No 184    (64.8) 44     (34.1)
IDH mutation  n/a
Yes 214   (75.4) 0   (0.0)
No 35     (12.3) 0   (0.0)
Unknown 35     (12.3) 129 (100.0)
EMC  Erasmus MC, HMC  Haaglanden Medical Center, TCIA  The Cancer Imaging Archive, NGS  Next Generation 





In this study, we developed an algorithm that predicted the 1p/19q co-deletion status 
of presumed LGG non-invasively based on preoperative MRI scans with an AUC of 
approximately 0.75. We tested the algorithm on an external, independent validation 
dataset. To the best of our knowledge, this is the first time this has been done in presumed 
LGG, and thus sets a benchmark for the expected performance in the real-world clinical 
setting. The algorithm had a higher AUC than the averaged AUC of the neurosurgeons, 
but lower than the averaged AUC of the neuroradiologists.
 To the best of our knowledge, this is the first study performing a radiogenomics 
based machine learning study in LGG from the perspective of real-world clinical practice: 
we included all patients with presumed, non-contrast enhancing LGG, rather than a 
selection of histopathological defined LGG patients. This is important, since in a clinical 
setting the genetic mutation is unknown at first symptomatic presentation. Since it is only 
known after surgery and molecular analysis, we aimed to mirror this real-world situation 
as best as possible by not selecting patients based on histological tumor features, but on 
the imaging features that are available at the time of presentation. Note that subsequently 
all lesions were surgically resected to obtain the ground truth data based on confirmed 
Table 2. Predictive performances of the algorithm on the EMC/HMC training and TCIA validation datasets. The 
performances on the EMC/HMC training dataset were obtained by cross-validation, the performances on the 
TCIA validation dataset were obtained by training on the EMC/HMC dataset and then testing on the TCIA dataset.
EMC/HMC - Training Set
Mean (95% CI)
TCIA - Validation Set
Mean (95% CI)
P value
Accuracy 0.698 (0.636 - 0.760) 0.693 (0.657 - 0.729) 0.872
AUC 0.755 (0.694 - 0.817) 0.723 (0.708 - 0.737) 0.313
F1-score 0.701 (0.640 - 0.761) 0.697 (0.661 - 0.733) 0.896
Precision 0.570 (0.491 - 0.649) 0.787 (0.754 - 0.820) < 0.001
Sensitivity 0.657 (0.562 - 0.752) 0.732 (0.689 - 0.775) 0.123
Specificity 0.721 (0.628 - 0.813) 0.617 (0.544 - 0.691) 0.027
AUC  area under the curve. 


























AUC 0.580 0.449 0.515 0.830 0.792 0.811 0.723 
Sensitivity 0.370 0.459 0.415 0.610 0.459 0.535 0.732 
Specificity 0.820 0.455 0.638 0.840 0.795 0.818 0.617 
* statistical comparison (McNemar) of accuracy between clinical experts and algorithm. AUC area under the curve. 
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histological and molecular analysis. We trained the algorithm on a heterogeneous training 
dataset and used a separate, completely independent, publicly available dataset with 
data from an entirely different institute to validate the algorithm. As such, this study is 
the first to demonstrate that the performance of a radiogenomics algorithm in predicting 
the 1p/19q co-deletion status of presumed LGG based on MRI scans was robust and 
matched expert clinical performance. Furthermore, we were also able to show which 
image features were important in the classification, increasing the clinical understanding 
of the machine learning algorithm and potentially aiding better acceptance, as well as 
furthering fundamental research into understanding of glioma pathophysiology.
 Although other studies did already investigate the non-invasive prediction of the 
molecular subtype of LGG, these often focused on IDH mutations only and did not consider 
the 1p/19q co-deletion status.11,28,29 In comparison with studies that did look at the 1p/19q 
co-deletion, we used a larger cohort and an external validation dataset,10,13,14,15,30,31 which 
makes our results more robust and generalizable respectively. Although one study did 
use an independent dataset, this study used only five patients to externally validate the 
1p/19q co-deletion predictive performance of the algorithm, which severely limits the 
reliability of its predictive performance.12 Additionally, that specific study retrospectively 
selected patients with histopathological defined LGG only, which represents the 
diagnosis-treatment workflow in clinical practice less accurately. The starting point of 
decision making on the optimal treatment strategy for LGG is the initial diagnosis on 
first MRI, when a non-contrast enhancing space occupying lesion is seen, at which point 
knowledge on the histopathological grade is not yet available. 
 The optimal timing and effect of surgical treatment of LGG is extensively being 
debated within literature and has recently been re-evaluated in the light of molecular 
subclassification after the introduction of WHO 2016 criteria.5,6,32,33 Currently, the 
molecular subtype based on 1p/19q codeletion and IDH mutation can be diagnosed only 
after obtaining tissue with biopsy or surgery. Indeed, as our results suggests, it is even 
for experienced neuro-oncological surgeons and radiologists a challenge to accurately 
predict the codeletion status of non-enhancing tumors based on preoperative MRI scans 
(AUC 0.45-0.83). 
 There are two scenarios in which preoperative, non-invasive prediction of the 1p/19q 
codeletion status based on MRI would be clinically relevant. First, some patients are not 
eligible for surgical resection or diagnostic biopsy due to older age, poor neurological 
condition, or tumor localization in eloquent brain areas or basal ganglia.33 However, 
knowledge of the molecular LGG subtype might add to a more appropriate (timing of ) 
chemo- and/or radiotherapy regimes (immediate post-operative therapy vs watchful 
waiting).34 Therefore, non-invasive, accurate prediction of the molecular subtype on 
imaging could help clinicians to select the optimal treatment when tissue diagnosis is 
difficult to obtain. Second, it is suggested that post-surgical residual 1p/19q intact, IDH 
mutated tumor has a more negative impact on survival than residual 1p/19q co-deleted, 
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IDH mutated (oligodendroglioma) tumor.5,6 With pre-surgical knowledge of the specific 
molecular subtype the surgeon can make a better informed decision on whether or 
not to push the limits of resection at the time of surgery, avoiding on the one hand re-
resection in case of residual 1p/19q intact, IDH mutated tumor and less-justified post-
surgical deficits in 1p/19q co-deleted tumor on the other hand. Clearly, the diagnostic 
accuracy of our algorithm is as yet too low to rely on for clinical practice. However, the 
results are promising because they generalize through multiple datasets, encouraging 
future research in this direction.
 Our study had a few limitations. First, for the current study only the T1-weighted 
and T2-weighted images were used, while diffusion weighted and perfusion imaging also 
contain relevant features for the 1p/19q status. These sequences were not included in the 
development of the present algorithm, as these were scarcely available in both datasets. 
 Second, the IDH mutation status was undetermined in all of the TCIA cases and in 
35 cases of the EMC/HMC dataset. Since molecular subclassification according to the 
WHO 2016 guidelines is based on both the 1p/19q co-deletion status and IDH mutation 
status, it is important to predict both. Therefore, for our future work, we are expanding 
our database with more patients in whom the tumor IDH status is known, to eventually be 
able to predict all clinically relevant subtypes of presumed LGG. There was an imbalance 
between the EMC/HMC dataset and the TCIA dataset in terms of the number of co-deleted 
and intact cases. Despite this imbalance, our algorithm still shows similar performance 
between the cross-validation result of the EMC/HMC dataset and the performance on the 
TCIA test dataset.
Conclusion
Our results suggest that our algorithm can non-invasively predict the 1p/19q co-deletion 
status of presumed LGG with a performance that in general outperforms oncological 
neurosurgeons. We evaluated our algorithm on an independent, multicenter dataset, 
which demonstrated that our algorithm is robust and generalizable. The prediction of the 
1p/19q co-deletion status by our algorithm can eventually add value to clinical decision 
making by tailoring the treatment strategy for patients with presumed LGG even prior to 
surgery.
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An in-house radiomics pipeline, ‘PREDICT’, was used for the prediction of the 1p/19q 
co-deletion status (https://github.com/Svdvoort/PREDICT). This pipeline takes the T1- 
and T2-weighted MR images, tumor and brain segmentations on both scans, and labels 
indicating 1p/19q co-deletion status for each patient which can then be used to train 
a support vector machine (SVM)(1). This SVM can then be used to predict the labels for 
unseen images. In this appendix the different steps of the pipeline are explained.
Supplementary materials
Overview of MRI settings from the EMC/HMC and TCIA datasets.
Training dataset (EMC/HMC) Validation dataset (TCIA)








Voxel spacing in-plane (mm) 0.38 x 0.38 - 
1.13 x 1.13
0.23 x 0.23 - 
1.02 x 1.02
0.47 x 0.47 - 
1.1 x 1.1
0.43 x 0.43 - 
1.1 x 1.1
Matrix Size 256 x 176 - 
1024 x 307
256 x 224 - 
1024 x 1024
256 x 256 - 
512x512
256 x 256 - 
512x512
Echo Time (ms) 1.7 - 20 79.2 - 379 2.6 - 21 12.3 - 108.3
Repetition Time (ms) 3.8 - 1940 2000 - 13468.5 8.2 - 983.3 2033.3 - 8116.6
Slice Thickness (mm) 0.9 - 7.2 1.0 - 7.2 1.0 - 5.0 2.0 - 5.0
Number of Slices 19 - 248 19 - 304 20 - 196 20 - 84
Field Strength (Tesla) 0.5, 1.5 or 3.0 0.5, 1.5 or 3.0 1.5 or 3 1.5 or 3
# of 2D scans 147 264 33 129
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Data pre-processing
First, the segmentations were transformed to the T2-weighted scan and the T1-weighted 
scans. If the segmentation was done on T2w-FLAIR, the T2w-FLAIR scan was registered 
to the T2-weighted scan using SimpleElastix with an affine transform by maximisation 
of mutual information.(18) The computed transform was used to map the T2w-FLAIR 
segmentation to the T2-weighted scan. Then, the T2-weighted scans were registered 
to the T1-weighted scans. The computed transformation was used to transform the 
segmentation from the T2-weighted scans to the T1-weighted scan. This method was 
applied to both the segmentations originally done on the T2-weighted scans, and the 
ones that were registered to the T2-weighted scan from the T2w-FLAIR. All segmentations 
and registrations were checked by M.S., and manual adjustments of the segmentations 
were made by F.I. if necessary.
 The next step of the pre-processing was to obtain the brain masks, which were 
created by FSL BET(1) with a setting of 0.5. The brain masks were used to normalize the 
scans. This was done by extracting the intensity values that lie within the brain mask, after 
which Z-scoring was applied. In this way, the mean intensity within the brain mask was 0 
and the standard deviation of the intensities within the brain mask 1. These pre-processed 
images were then processed by the next step of the algorithm to extract the features.
Features
In total 80 features were used in our algorithm: 78 features from the T1-weighted and 
the T2-weighted images, and age and sex. These features were split into 5 groups: tumor 
intensity, tumor texture, tumor shape, tumor location, and demographic features. All of 
these features were only extracted within the tumor mask.
 Image intensity was described using 11 features: minimum, maximum, mean, 
median, standard deviation, skewness, kurtosis, range from the 2nd to 98th percentile, 
range from the 25th to 75th percentile (the quartile range), the mode position (the bin in 
the intensity histogram which had the highest occurrence) of the intensity and the energy 
defined as: 
 , where I is the image intensity
These features were calculated over the entire tumor in 3D. Rotation invariant Local Binary 
Patterns (LBPs) were used to describe the texture of the tumor(2). The advantage of LBPs 
is that they are grayscale invariant, meaning that not the intensity values themselves, 
but the differences between intensity values of different voxels are taken into account. 
This is an advantage when using MRI scans, because in weighted MRI scans the absolute 
values signal intensities themselves do not carry information, it is only the difference in 
gray values in the image. LBP features were determined for a radius of 1, 3 and 5 with 8, 
24 and 24 points, respectively. The LBP was determined for each slice of the MRI scan in 
E =#$%I + min(I)-!. 
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which tumor was present. The results over all pixels within the tumor and slices containing 
tumor were then concatenated and consequently the mean, standard deviation, median, 
kurtosis and skewness, and peak value were calculated for each setting, resulting in 18 
LBP features. The intensity features and the texture features were calculated on both the 
T1-weighted and T2-weighted scan, resulting in 58 features.
 Shape features were derived from the segmentation on the T2-weighted image. 
Shape features consisted of the compactness, radial distance, roughness, convexity, 
circular variance (cvar), ratio of principal axes (prax), elliptical variance (evar) and solidity (4,5). 
All of these features were calculated on a per-slice basis (only for slices that contained 
tumor), after which the mean and standard deviation of the features over the slices were 
included as features in the algorithm, resulting in 16 features. The volume was also taking 
as a 3D shape feature, resulting in 17 shape features.
 Tumor location was determined by using the center of mass (COM) from the brain 
mask and COM of the tumor segmentation. The anterior/posterior, left/right and inferior/
superior coordinate of the vector pointing from the COM of the brain to the COM of the 
tumor were then included as features, resulting in 3 location features. Patient age and 
patient sex were included as the demographic features. 
 An overview of all the features is given in Table 1, along with the Imaging Biomarker 
Standardization Initiative (IBSI) code when the feature matched with one included in 
the IBSI(6). Many of our features are based on local binary patterns, which are currently 
considered outside the scope of IBSI. However, preliminary experiments have indicated 
that  including these features improves the performance of the classifier (results not 
shown). Z-scoring was applied to the features (normalized such that the mean of the 
features was 0 and the standard deviation was 1). This was done based only on the training 
set; the resulting normalisation settings were saved to apply the same normalisation to 
the validation set.
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Table 1. Overview of the features included in the algorithm.
Modality Slice averaging Feature IBSI code
N/A N/A Age N/A
N/A N/A Gender N/A
N/A N/A Anterior/Posterior position None
N/A N/A Left/Right position None
N/A N/A Inferior/Superior Position None
Segmentation Average Compactness KRCK
Segmentation Standard deviation Compactness KRCK
Segmentation Average Convexity None
Segmentation Standard deviation Convexity None
Segmentation Average Circular variance None
Segmentation Standard deviation Circular variance None
Segmentation Average Elliptic variance None
Segmentation Standard deviation Elliptic variance None
Segmentation Average Ratio of principal axis None
Segmentation Standard deviation Ratio of principal axis None
Segmentation Average Radial distance None
Segmentation Standard deviation Radial distance None
Segmentation Average Roughness None
Segmentation Standard deviation Roughness None
Segmentation Average Solidity Inverse of 7T7F
Segmentation Standard deviation Solidity Inverse of 7T7F
Segmentation None Volume 2PR5
T1 None Energy Similar to N8CA, except min 
intensity is added
T1 None Kurtosis IPH6
T1 None Max 84IY
T1 None Mean Q4LE
T1 None Median Y12H
T1 None Min 1GSF
T1 None Peak None
T1 None Range Similar to 20JQ, except 
based on 2nd and 98th 
percentile
T1 None Skewness KE2A
T1 None Standard deviation Square root of ECT3
T1 None Quartile range SALO
T1 None LBP R1P8 Kurtosis None
T1 None LBP R3P24 Kurtosis None
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T1 None LBP R5P24 Kurtosis None
T1 None LBP R1P8 Mean None
T1 None LBP R3P24 Mean None
T1 None LBP R5P24 Mean None
T1 None LBP R1P8 Median None
T1 None LBP R3P24 Median None
T1 None LBP R5P24 Median None
T1 None LBP R1P8 Peak None
T1 None LBP R3P24 Peak None
T1 None LBP R5P24 Peak None
T1 None LBP R1P8 Skewness None
T1 None LBP R3P24 Skewness None
T1 None LBP R5P24 Skewness None
T1 None LBP R1P8 Standard deviation None
T1 None LBP R3P24 Standard deviation None
T1 None LBP R5P24 Standard deviation None
T2 None Energy Similar to N8CA, except min 
intensity is added
T2 None Kurtosis IPH6
T2 None Max 84IY
T2 None Mean Q4LE
T2 None Median Y12H
T2 None Min 1GSF
T2 None Peak None
T2 None Range Similar to 20JQ, except 
based on 2nd and 98th 
percentile
T2 None Skewness KE2A
T2 None Standard deviation Square root of ECT3
T2 None Quartile range SALO
T2 None LBP R1P8 Kurtosis None
T2 None LBP R3P24 Kurtosis None
T2 None LBP R5P24 Kurtosis None
T2 None LBP R1P8 Mean None
T2 None LBP R3P24 Mean None
T2 None LBP R5P24 Mean None
T2 None LBP R1P8 Median None
T2 None LBP R3P24 Median None
T2 None LBP R5P24 Median None
T2 None LBP R1P8 Peak None
T2 None LBP R3P24 Peak None
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T2 None LBP R5P24 Peak None
T2 None LBP R1P8 Skewness None
T2 None LBP R3P24 Skewness None
T2 None LBP R5P24 Skewness None
T2 None LBP R1P8 Standard deviation None
T2 None LBP R3P24 Standard deviation None
T2 None LBP R5P24 Standard deviation None
The IBSI column indicates the code of the feature if it is present in the IBSI. Abbreviations: IBSI: Imaging Biomarker 
Standardization Initiative, LBP: local binary pattern. 
Over-sampling of the minority class
There was an imbalance in the training dataset as there were more examples of 1p/19q 
intact than of 1p/19q co-deleted tumors. As a result, it was more difficult for the algorithm 
to correctly predict 1p/19q co-deleted tumors within the training dataset. To (partially) 
solve this problem we used Synthetic Minority Over-sampling Technique (SMOTE). SMOTE 
allows for the oversampling of the minority class and synthetically increased the number 
of samples for the 1p/19q co-deleted class(7). Here, an SVM with a polynomial kernel was 
used to create the synthetic examples, with a ratio of 1 (meaning that there will be an 
equal number of samples from both classes) using 5 neighbours.
Classification
Support Vector Machines (SVMs) were used as classification algorithm(7). SVMs were 
constructed using scikit-learn(8) with a polynomial kernel. The polynomial kernel was 
defined as:
SVMs were constructed with a maximum of 1⋅107 iterations. The hyperparameters of the 
SVM were optimized using a 5-fold cross-validation where 20% of the training dataset 
was used as an internal validation set. A random search of 50,000 iterations was used 
to find the optimal hyperparameters. This optimization search for the optimal C, the 
regularization parameter of the SVM, as well as three parameters of the polynomial 
kernel: γ, which defines how much each sample is weighted, C0 , a trade-off between high-
order and low-order terms, and P, the order of the polynomial kernel. The distributions for 
the parameters are presented in Table 1.
𝐾𝐾(𝑋𝑋, 𝑌𝑌) = (𝛾𝛾 < 𝑋𝑋, 𝑌𝑌 > +𝐶𝐶!)"  
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Table 2. Overview of the range of hyperparameters used in the optimization of the SVM.
Parameter Lower bound Upper bound
C 0 1•10 6
P 1 7
C0 0 1•10 
3
1•10 -5 1
SD standard deviation, IQR Inter Quartile Range, CE contrast enhancement, FLAIR Fluid-attenuated inversion 
recovery. 
The optimal hyperparameters were chosen based on the settings that gave the highest 
average area under curve over the 5 folds. Using these optimal hyperparameters, the final 
SVM was then constructed using the complete training dataset. 
Ensemble SVM
To increase the predictive performance and minimize the variability of the predictions, an 
ensemble of SVMs was constructed. Five trained SVMs were taken to form the ensemble. All 
5 SVMs were then used to predict a test sample. The posteriors of the SVMs were averaged 
for the sample. Based on this averaged posterior the final label was determined (positive 
class if posterior >=0.5, negative class if posterior <0.5). To form the 100 ensembles 500 
SVMS had to be trained. No single SVM was used in two different ensembles: all ensembles 
were completely unique. The resulting 100 ensemble SVMs could then be used to make a 
prediction of the 1p/19q status for a new sample.
Appendix 3
Evaluation metrics
The accuracy, area under the Receiver Operating Characteristic (ROC) curve (AUC), 
weighted F1-score, precision, sensitivity, and specificity were calculated to evaluate the 
performance of the algorithm and clinical experts. These were based on the variables 
extracted from the confusion matrix:
• True Positive (TP): number of true 1p/19q co-deleted predicted as 1p/19q co-deleted
• False Positive (FP): number of true 1p/19q intact predicted as 1p/19q co-deleted
• True Negative (TN): number of true 1p/19q intact predicted as 1p/19q intact
• False Negative (FN): number of true 1p/19q co-deleted predicted as 1p/19q intact
 











The ROC curve and AUC were obtained using scikit-learn. 
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Appendix 4
Table of excluded patients from TCIA-LGG dataset.



















LGG-500 Age < 18 years
LGG-506 Enhancement
LGG-532 Age < 18 years
LGG-545 No post-contrast T1-weighted image
𝑇𝑇𝑇𝑇! + 𝑇𝑇𝑇𝑇 ⋅ 𝐹𝐹𝐹𝐹 + 𝐹𝐹𝑇𝑇 ⋅ 𝑇𝑇𝐹𝐹 + 𝑇𝑇𝐹𝐹!
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹 + 𝐹𝐹𝑇𝑇 + 𝑇𝑇𝐹𝐹  
𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝑇𝑇 
𝑇𝑇𝑇𝑇
𝑇𝑇𝑇𝑇 + 𝐹𝐹𝐹𝐹 
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LGG-558 No post-contrast T1-weighted image
LGG-561 Enhancement







Results of mixing EMC/HMC and TCIA datasets.
We  evaluated the effect of mixing the EMC/HMC and TCIA datasets, instead of using 
them as separate training and validation set.  This was done using the same cross-
validation approach as was used for the EMC/HMC dataset cross-validation. In this case 
all 413 patients were pooled together. Then 100 iterations of stratified random-split 
cross-validation with 80% of the dataset used for training and 20% of the dataset used for 
validation was performed. The results are shown in Table 1.
The results for the combined EMC/HMC and TCIA dataset show a slight improvement over 
the cross-validation on the EMC/HMC dataset alone but they are still within the confidence 
interval of the EMC/HMC dataset results, except for the precision. This shows that although 
there is a slight improvement, our algorithm is already quite robust and adding more data 
(from a different source) does not lead to a large increase in performance.
Table 1. Predictive performances of the algorithm on the mixed EMC/HMC and TCIA dataset.
Cross-validation on combined 
EMC/HMC and TCIA dataset
Cross-validation on 
EMC/HMC dataset
Mean (95% CI) Mean (95% CI)
Accuracy 0.717 (0.670 – 0.764) 0.698 (0.636 - 0.760)
AUC 0.780 (0.729 – 0.830) 0.755 (0.694 - 0.817)
F1-score 0.717 (0.670 – 0.763) 0.701 (0.640 - 0.761)
Precision 0.676 (0.620 – 0.732) 0.570 (0.491 - 0.649)
Sensitivity 0.710 (0.637 – 0.783) 0.657 (0.562 - 0.752)
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The aim of this study was to determine whether cognitive functioning of presumed low-
grade glioma patients is associated with white matter (WM) tract changes. 
Methods 
We included 77 patients with presumed low-grade glioma who underwent awake surgery 
between 2005 and 2013. Diffusion tensor imaging (DTI) with deterministic tractography 
was performed pre-operatively to identify the arcuate (AF), inferior fronto-occipital 
(IFOF) and uncinate fasciculus (UF) and to obtain mean fractional anisotropy (FA) and 
mean diffusivity per tract. All patients were assessed pre-operatively with an extensive 
neuropsychological protocol, including the language, memory and attention/executive 
function domains. Linear regression models were used per cognitive domain and per DTI 
metric of the three WM tracts. 
Results 
Significant correlations (corrected for multiple testing) were found between FA of the AF 
and the repetition test of the language domain (β = 0. 59, p < 0. 0001), and between FA 
of the IFOF and the imprinting test of the memory domain (β = -0. 55, p = 0. 002) and 
attention test of the attention and executive function domain (β = -0. 62, p = 0. 006). 
Conclusion 
In glioma patients, language deficits in repetition of speech, imprinting and attention 
deficits are associated with changed microarchitecture of the arcuate fasciculus and the 
inferior fronto-occipital fasciculus.
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Introduction
Low grade gliomas (LGG) are World Health Organization (WHO) Grade I-II, slow growing, 
primary brain tumors that commonly show no or minimal contrast-enhancement. Patients 
often present with seizures, but headache and (mild) cognitive deficits are also frequently 
observed (31). Due to a widespread representation of cognitive functions, it is important to 
make use of a neuropsychological protocol in glioma patients to detect deficits (24). Satoer 
et al. showed with a neuropsychological assessment (NP) in a series of 45 glioma patients 
pre- and postoperative deficits in the domains of language, memory and the attention/
executive functions (26). We hypothesize that such cognitive deficits can – at least partly 
– be attributed to changes in white matter (WM) tract microarchitecture due to tumor 
effects such as edema or infiltration. 
 In vivo anatomical visualization of WM tracts, such as the arcuate fasciculus (AF), 
inferior fronto-occipital fasciculus (IFOF) and uncinate fasciculus (UF) can be obtained 
with the use of Diffusion Tensor Imaging (DTI) based tractography. DTI is a magnetic 
resonance imaging (MRI) modality in which the 3D diffusion of free water in the brain can 
be assessed. Since water diffuses preferentially along the direction of the white matter 
fibers instead of perpendicular to it, measuring the direction of free water diffusion 
allows for an approximation of the white matter fiber orientation. On a DTI-derived 
color-coded map, the white matter tracts are conventionally represented in green in 
the anterior-posterior direction (e.g. optical fibers), in red in the left-right direction (e.g. 
corpus callosum) and in blue in the ventral-dorsal direction (e.g. cortico-spinal tract). To 
delineate the specific white matter tracts, specific regions of interests (ROIs) are manually 
delineated on DTI images based on a priori anatomical knowledge. WM tracts of interest 
running through these ROIs are then visualized in 3D using tractography (5,32). The AF is an 
association bundle that is involved in language by connecting perisylvian language areas 
of the frontal, temporal and parietal lobes (5). Intraoperative stimulation of the AF elicits 
phonemic paraphasia (9). The IFOF is an association bundle that connects the occipital lobe 
and the orbitofrontal cortex. The IFOF seems to be involved in several cognitive functions 
such as language (semantics and reading) (10), but also attention and visual processing 
abilities (5,7). The UF is an association bundle that connects the orbitofrontal cortex with the 
anterior temporal lobe. The UF is suggested to be involved in memory and language. (24)
 Quantitative information on WM tract microarchitecture can be derived from 
tractography and expressed as fractional anisotropy (FA) and mean diffusivity (MD). FA is 
a measure of microstructural integrity with a value between 0 and 1, with 0 meaning the 
diffusion is the same in all directions (isotropic diffusion, such as seen in the ventricles) 
and close to 1 meaning diffusion of water is seen along a specific direction (anisotropic 
diffusion, such as seen along white matter tracts). A reduction of FA in a white matter 
tract is considered to be an indication of loss of tract integrity. MD is a measure of the 
average water diffusion and reflects membrane density. High MD is seen in free water 
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(the ventricles), and low MD in the white matter. An increase of MD in the white matter is 
considered an indication of the increase of the extracellular space, such as seen in edema. 
While derived from the same imaging sequence, FA and MD reflect different aspects of 
white matter tract structure, and can thus be used to assess the effects of tumor infiltration 
and edema. (2) Importantly, perilesional WM tracts and edematous zones around glioma 
show a reduction in FA values which suggests increased extracellular water and fiber 
disorganization due to tumor infiltration(1). Studies have shown that tumor infiltrated WM 
tracts such as the AF have a relationship with language impairment (3,15). However, to the 
best of our knowledge there is as yet no large-scale quantitative correlation of WM tract 
microarchitecture with cognitive functioning in LGG patients.  
 The purpose of this study was to determine whether cognitive functioning of 
presumed LGG patients is associated with changes in language WM tract microarchitecture. 
We analyzed FA and MD values of the AF, IFOF, UF in relation to three cognitive domains 
(language, memory and attention/executive functions) assessed with an extensive NP 
pre-operatively in patients selected for awake surgery.
METHODS
Study participants
A total of 131 patients (> 18 years) with presumed LGG who underwent awake surgery 
between April 2005 and May 2013 were considered for this retrospective study. Non-to-
mildly contrast enhancing tumors, i.e. presumed LGG, on pre-operative MRI scan were 
considered. Note that if upon histopathological examination – after resection – such 
tumors displayed high grade glioma features, patients were retained in the study, to ensure 
that our findings are valid for the real-life clinical situation of pre-operative assessment 
and selection of patients, when histopathology is not yet available. Hence the use of the 
term presumed LGG, based on clinical and radiological characteristics. All patients were 
native Dutch speakers. Patients with recurrent glioma (n=24), without pre-operative NP 
(n=3), without sufficient DTI data (n=25), or a time frame between NP and DTI longer than 
6 months (n=2) were excluded, resulting in a total of 77 patients available for data analysis 
(Table 1). Of the 77 patients (mean age 43 years, range 20-74), 49 were male (63.6%) with 
a mean age of 44 years (range 21 – 74), while all 28 females (36. 4%) had a mean age of 
40 years, (range 20 - 60). Although most tumors were localized in the left hemisphere, 
15 patients with right-sided tumors were also included in this study, because they had 
right dominance for language as seen on fMRI, which was performed pre-operatively. 
Therefore, these patients were selected for awake surgery to prevent damage to the Broca 
region. The study was approved by the Medical Ethical Committee, who waived the need 
for written informed consent from the patients due to the retrospective nature of this 
study and the (emotional) burden that would result from contacting the patients or their 
relatives to obtain consent.
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Table 1. Baseline patient characteristics.
Characteristics N (%) Characteristics N (%)
Age in years Tumor localization 
mean; range 43 ( 20 – 74 ) Right 15 (20.0)
Gender Frontal 3 (3.9)
male/female 49 (63.6) / 
28 (36.4)
Parietal 10 (13.0)
Handedness Temporal 2 (2.6)
Right 54 (70.1) Occipital 0 (0)
Left 5 (6.5) Left 62 (80.0)
Unknown 18 (23.4) Frontal 12 (15.6)
Karnofsky Performance Status Parietal 23 (29.9)
100-90 69 (90) Temporal 26 (33.8)
80-70 8  (10) Occipital 1 (1.3)
Tumor grade Pathological tumor growth
Low grade glioma 47 (61) Diffuse infiltrative 37 (48.1)
High grade glioma 30 (39) Circumscribed 40 (51.9)
Histopathological subtype
Oligodendroglioma WHO grade II 21 (27.3)
Astrocytoma WHO grade II 13 (16.9)
Oligoastrocytoma WHO grade II 11 (14.3)
Oligodendroglioma WHO grade III 16 (20.8)
Astrocytoma WHO grade III 12 (15.6)
Oligoastrocytoma WHO grade III 3 (3.9)
Glioblastoma WHO grade IV 1 (1.3)
WHO = World Health Organization. 
Tumor localization and characterization
Tumor localization was determined by a neuroradiologist (8 years of experience) on pre-
operative T1 and T2 weighted images. The histopathological type and grade of the tumor 
were determined by a neuropathologist from tissue obtained during tumor resection.
Image acquisition and preprocessing
Diffusion MR data were acquired using a single shot spin echo planar imaging (EPI) 
sequence at 1.5T (n = 20) and 3.0T (n = 57) (GE Healthcare, Milwaukee, USA) with an eight-
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channel head coil. In general, 25 non-collinear gradient directions at b = 1000 s/mm2 (n = 
71) and 3 images at b = 0 s/mm2 were acquired (n = 64). In six patients, all imaged at 3.0T, 
31 gradient directions were acquired with 4 images at b = 0 s/mm2. Slice thickness was 2.0-
3.5 mm and in-plane resolution 1.9-3.4 mm2. Raw diffusion MRI data were transferred to an 
offline workstation. All images were first visually inspected for the presence of apparent 
artefacts. MRI data were pre- and post-processed using ExploreDTI (17). Motion and eddy 
current correction of the DWI was not performed to avoid interpolation errors. Instead, 
the acquired native data and the data-quality-summary report were visually inspected 
in ExploreDTI. The gradient components in the x/y/z axes were manually checked and 
adapted if needed to the standard color-convention (left-right: red, top-bottom: blue, and 
front-back: green). Subsequently, the diffusion tensors were estimated using nonlinear 
least squares. The following thresholds were used to perform tractography: FA termination 
threshold of 0. 2, angle threshold of 45°, step length: 0/5. 
Tractography 
Deterministic tractography was used to identify the AF, IFOF and UF in the affected 
hemisphere according to standardized procedures (30).  From each of the reconstructed 
tracts, average FA and MD values were obtained. The rater was blinded for NP test results 
of the patients at time of tractography.
Arcuate fasciculus 
For the AF (Figure 1), a coronal slice was selected at the level of the primary motor cortex and 
the seed ROI was placed on the green (anterior-posterior) triangular shaped projections 
of the superior longitudinal fasciculus lateral to the blue projections of the cortical spinal 
tract in the posterior parietal lobe. For the target ROI, an axial slice was selected at the 
level of the genu of the corpus callosum. The blue (cranial-caudal) projections lateral to 
the sagittal stratum (green) in the posterior temporal lobe corresponding to the vertical 
portion of the AF were delineated (30).
Inferior fronto-occipital fasciculus
For the IFOF (Figure 2), the seed ROI was placed by delineating the green projections in 
the entire anterior part of the frontal lobe on the axial and/or coronal slices. The target ROI 
was placed by delineating the green projections in the entire posterior part of the occipital 
lobe up until the posterior crossing area between the genu of the corpus callosum (red) 
and the posterior part of the sagittal striatum (green) on the axial and/or coronal slices (30) .
Uncinate fasciculus
For the UF (Figure 3), the seed ROI was placed in the green projections in the temporal 
pole/ entire anterior part of the temporal lobe on the coronal slice. The target ROI was 
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placed by delineating the green projections in the inferior part of the frontal lobe on the 
coronal slice (30).
Neuropsychological assessment 
All patients were assessed once with a comprehensive NP test battery after initial diagnosis 
(mean= 9 days; SD= 20) and before surgery (mean= 44 days; SD= 30) by a clinical linguist 
(blinded for tractography results). As shown in Table 2 (12,14,18,20,27,33), the performance of 
the patients was examined within three main cognitive domains (language, memory and 
attention/executive functions). This combination of NP tests has shown to be sensitive to 
detect cognitive deficits and has been validated in glioma patients in earlier studies (24,26,31). 
All test-scores of the patients were transformed into z-values to compare the performance 
of patients to a normative group and to facilitate comparisons between tests. 
Statistical Analysis
Statistical analyses were performed with the SPSS statistical software (SPSS version 21.0, 
SPSS Inc. Chicago, IL, USA). We determined whether patients’ mean scores by cognitive 
domain and by test differed from the normative group, using either a one-sample t-test 
with 0 (the mean score of the normal group) as test value or the Wilcoxon Signed Rank 
Test. Post-hoc, mean FA/MD of the three WM tracts and three cognitive domains were 
compared between histopathological established LGG and HGG by using a one-way 
ANOVA. First the relationship between the three main cognitive domains (language, 
memory and attention/executive functions) of the NP and FA/MD values of three WM 
tracts (AF, IFOF, UF) was analyzed in linear regression models which included all three 
WM tracts, with age and histopathological grade as regressors of no interest. The analyses 
were done separately for each main cognitive domain and each DTI metric (FA, MD). 
Bonferroni correction was used to adjust for multiple testing on main cognitive domain 
level (6 tests): a p value of ≤ 0.008 was considered to be statistically significant. Then, 
further analyses were done on subtest level, only within the cognitive domain(s) that were 
significantly correlated with WM tract measure(s). Bonferroni correction was not used for 
these analyses: a p value of <0. 05 was considered to be significant. 
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Figure 1. The first ROI is placed on the green triangular shaped projections lateral to the blue projections of the 
cortical spinal tract in the posterior parietal lobe. The second ROI is placed on the blue projections laterally to 
the sagittal stratum (green). The tumor is delineated in red. The 3D-reconstruction of the AF is shown at the most 
right figure.
Figure 2. The first ROI is placed on the green projections in the anterior part of the frontal lobe. The second ROI 
is placed on the green projections in the posterior part of the occipital lobe. The tumor is delineated in red. The 
3D-reconstruction of the IFOF is shown at the most right figure.
Figure 3. The first ROI is placed on the green projections in the anterior part of the temporal lobe. The second 
ROI is placed on the green projections in the inferior part of the frontal lobe. The tumor is delineated in red. The 
3D-reconstruction of the UF is shown at the most right figure.
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N a Cognitive Abilities Description Mean 
z-score (SD)
P-value
Language domain -0.78 (0.98) <0.0001
Aachener Aphasia 




severity of language 
disorder
Pointing to and 
manipulating geometric 
forms on verbal 
commands
-0.40 (1.97) 0.740
Aachener Aphasia  
repetition (AAT rep) 
(14)
72 Repetition Repeating phonemes, 
words and sentences
-0.11 (0.81) 0.013
Boston Naming Test  
(BNT) (15)
75 Naming (word 
finding)
Naming 60 pictures, pre-
sented in order of word 









Producing words of a 
given category (animals 
and processions) within a 
limited time span
-1.04 (0.84) <0.0001
Letter fluency (LET) 
(17)





beginning with a given 
letter (D,A,T) within a 
limited time span
-0.89 (1.19) <0.0001
Memory domain -1.49 (1.35) <0.0001
15 Words test (WT) 
imprinting
62 Verbal learning; 
immediate and 
delayed recall
Learning a list of 15 
words, with 6 recall 
trials; 5 immediate and 1 
delayed,
-1.82 (1.43) <0.0001
15 Words test (WT) 
recall (18)




Trail Making A 65 Visuomotor speed, 
attention
Connecting numbers 
placed randomly in 
ascending order as 
rapidly as possible
-0.60 (1.14) <0.0001
Trail Making B 63 Mental flexibility, 
divided attention
-0.37 (1.28) 0.027
Trail Making BA (19) 62 -0.12 (1.23) 0.459
Stroop I 53 Mental speed; selec-
tive attention
Reading colour words, 
naming colours and 
naming colours of 
printed words, denoting 
another colour
-1.09 (1.39) <0.0001
Stroop II 53 -1.12 (1.35) <0.0001
Stroop III 51 -0.64 (1.06) <0.0001
Stroop interference 48 -0.31 (1.09) 0.056
a Number of patients assessed before surgery. In some cases, the full protocol could not be applied to all patients 






Successful tractography was performed in 68 patients of the AF (88%), in 76 of the IFOF 
(99%), and in 74 of the UF (96%). In total, 13 (17%) WM tracts could not be tracked due to 
very large tumor volume causing extensive brain shift. These WM tracts were not included 
in the analysis of association with NP tests. Mean FA was 0. 456 (SD = 0. 059) in the AF, 
0.474 (SD = 0. 056) in the IFOF, and 0. 395 (SD = 0. 094) in the UF. Mean FA and MD of the 
three WM tracts was not significantly different (p  >  0. 05) between LGG (N = 47) and high-
grade glioma (HGG, N = 30). 
Patients’ performance on NP 
Patients had impairments in all cognitive domains (language, memory and attention/
executive functions) compared to the normative group (p<0. 05), except for three (sub) 
tests (Table 2). These were in the language domain (AAT Token Test) and in the attention/
executive functions (TMTBA and Stroop interference) (p > 0. 05). Post-hoc analyses showed 
that language impairments were significantly worse in patients with histopathological 
determined high grade than those with low grade tumors (p = 0.025). Memory and 
attention/executive functions were not significantly different between these groups (p 
> 0.05).
Relationship between NP and WM tracts
The relationship between the three main cognitive domains and the FA and MD values of 
the three WM tracts is presented in Table 3. Significant correlations were found between 
the AF (FA only) and the language domain (β = 0. 44; R = 0. 40; p = 0. 003) and between the 
IFOF (FA only) and the memory domain (β = -0. 48; R = 0. 44; p = 0. 006) and the attention/
executive function domain (β = -0. 49; R = 0.45; p = 0. 008). Additional correlations that 
approached significance were seen between both the FA and MD of the AF, IFOF and memory 
and attention/executive functions domain (0. 008 < p < 0. 05). No significant correlations 
were found between the UF and any of the three cognitive domains assessed with the NP 
(p > 0. 05). 
Within the language domain, a strong significant correlation was found between the FA 
in the AF and the “Aachener Aphasia Repetition Test (AAT rep) ” (β = 0. 59; R = 0. 53; p < 
0. 0001). The IFOF was significantly correlated with a subtest of the memory domain for 
verbal memory: “15 Words Test Imprinting” (β = -0. 55; R = 0. 48; p = 0. 002) and with a 
subtest for selective attention within the attention/executive function domain: “STROOP I” 
(β = -0. 62; R = 0. 50; p = 0. 006) (Table 4). 
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Table 3. Relationship between 3 neuropsychological domains (language, memory, attention/executive 
functions) and FA/MD values of 3 white matter tracts (AF,IFOF,UF).
 Arcuate Fasciculus Inferior fronto-occipital 
fasciculus
Uncinate fasciculus
Domain FA  MD  FA  MD FA MD  
LANG
n=65
β = 0.44 
P = 0.003b
R=0.40









β  = 0.06 
P = 0.665
R=0.40

























β = 0.39 
P = 0.014a
R=0.45
β = -0.33  
P = 0.036a
R=0.32
β = -0.49  
P = 0.008b
R=0.45
β = 0.04  
P = 0.847
R=0.32
β = 0.17 
P = 0.339
R=0.45
β = 0.09 
P = 0.656
R=0.32
Linear regression models with NP as a dependent factor, FA/MD and age as independent 
factors. β = standardized coefficient R = correlation coefficient. LANG = language, 
MEM = memory, ATT/EX = attention/executive function, FA = fractional anisotropy, 
MD = mean diffusivity a indicates statistical significance at level of p<0.05 b indicates 
statistical significance at level of p≤0.008, see table 4 for subtasks associations
Table 4. Association between the significant subtasks of the significant cognitive domains and fractional 
anisotropy in the arcuate fasciculus and inferior.
Domain Subtask White matter Tract
Language AAT REP AF, β = 0.59 P = 0.000 R=0.53
Memory 15 WT IMPR IFOF, β = - 0.55 P = 0.002 R=0.48
Attention and executive functions STROOP I IFOF, β = - 0.62 P = 0.006 R=0.50
SD standard deviation, IQR Inter Quartile Range, CE contrast enhancement, FLAIR Fluid-attenuated inversion 
recovery. 
Linear regression models with NP as a dependent factor, FA, grade and age as independent 
factors. β = standardized coefficient. R = correlation coefficient.  AAT REP = Aachener 
Aphasia Repetition Test,  15 WT IMPR = 15 Words Test Imprinting AF = arcuate fasciculus, 




We performed a large-scale quantitative analysis of language WM tract microarchitecture 
and cognitive performance in patients with presumed LGG. Patients had deficits in all 
assessed cognitive domains, i.e. language, memory and attention/executive functions. 
A significant correlation was found between FA in the AF and the language domain, 
specifically with a repetition test, which is associated with phonological abilities. The FA 
in the IFOF was significantly correlated with deficits in verbal learning (imprinting) and 
selective attention. In this cohort of patients with tumors that radiologically appear to be 
low grade (i.e. presumed LGG), language impairments were significantly worse in patients 
with tumors that turned out to be high grade upon histopathological examination.
DTI measures within the language WM tracts
We found that lower FA, but not MD, was significantly correlated with language and 
verbal memory deficits in patients with presumed LGG. FA is a measure of directionality 
of molecular motion classically known to be sensitive to microstructural changes, but 
not specific to the type of changes. MD is a measure of magnitude of diffusion and is 
sensitive to cellularity, edema and necrosis 2. Several tumor associated mechanisms are 
described that influence FA and MD. Tumor infiltration in WM tracts as well as edema may 
cause a decrease in FA and increase in MD, while compression of WM tracts due to tumor 
causes an increase in FA and decrease in MD 15 . Lee et al showed that purely vasogenic 
edema, composed purely of extracellular water (e.g. with meningiomas) causes a more 
relative increase in MD than a decrease in FA. On the other hand, tumor infiltrated edema 
- infiltration of tumor (e.g. glioma) cells in WM tracts - causes a more relative decrease in FA 
than an increase in MD 16. We can therefore speculate that our findings may reflect tumor 
infiltration into the white matter tracts. 
Arcuate fasciculus and language deficits
We demonstrated an association between microarchitectural changes of the AF and 
impaired language repetition abilities. The AF, also known as the dorsal pathway in the dual 
stream model of Hickok & Poeppel 13, is associated with mapping sound to articulatory-
based representations (e.g. phonology), which explains the functional association 
between microstructural changes and phonological deficits observed here. Our findings 
also support recent results from Sierpowska et al. 29. They reported that monitoring 
(non) word repetition is relevant near the AF during electro(sub)cortical stimulation for 
preservation of language production, in particular phonological performance 25,29. 
 Deficits in language repetition in combination with relatively intact comprehension, 
as observed in our patient group, is “classically” known as conduction aphasia in the stroke 
literature. Several studies in patients with different etiologies have demonstrated a link 
between this specific aphasia type and damage to the AF (e.g. tumor infiltration, WM 
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tract compression) 4. In addition, damage to AF may be predictive for persistent language 
deficits 6,22 at test level, but also in relation to the quality of communication, underlining 
the importance of a repetition task. 
Inferior fronto-occipital fasciculus and cognition
Another important pathway, apart from AF, that is reported to be related to language 
is the IFOF, which is part of the so-called ventral stream according to Hickok & Poeppel 
13.  The ventral stream (IFOF) is involved in mapping sound on meaning (e.g. semantics, 
comprehension). In our study, the participants had no comprehension deficits, as 
measured with the Token Test, when compared with healthy people, and it is therefore 
not surprising that no association was found between DTI measures within the IFOF and 
the language domain. Within the semantic level, there were impairments in category 
fluency, but the multidimensional background of this test, i.e. language (lexical retrieval), 
semantic memory and in part also attention/executive functioning, may be responsible 
for the lack of a correlation. While it is possible that there were indeed no (clear) semantic 
deficits in our patient population, this finding may also indicate a limitation in our NP 
test procedure in that the applied tests for language functioning were not equivalent 
to the main linguistic components: semantics, syntax and phonology. In contrast with 
phonology, semantics and syntax were more globally examined by means of the Token 
Test. We have therefore developed a more elaborate test-battery for language functioning 
in glioma patients: the Dutch Linguistic Intraoperative Protocol (DuLIP) 7. This is currently 
in the phase of evaluation.
 Besides language deficits, it is suggested that damage to this WM tract can also cause 
other cognitive deficits. According to the model proposed by Duffau 8 , the IFOF could be 
relevant for attention and/or (working) memory. Our study showed a correlation between 
FA in the IFOF and both imprinting and attention deficits, which provides additional 
support for previous suggestions on the involvement of the IFOF in memory. 
 The lack of clear cognitive deficits in other domains could be explained by neural 
plasticity, i.e. functional reorganization. Tumors in all our patients were presumed to be 
LGG (non-to-mild contrast enhancing), and in more than half of these patient’s low-grade 
tumor was confirmed upon histopathological examination. LGG is typically associated 
with relatively slow tumor growth rate facilitating neural plasticity. As a result, functional 
reorganization could have taken place, which would lead to less severe deficits than 
expected from the degree of tract infiltration. More sensitive tasks to detect mild cognitive 
deficits in LGG patients would therefore be useful.
Tumor grade
Of note in this context is the finding that a large proportion (41. 6%) of non-to-mild 
enhancing glioma in this study turned out to be HGG upon histopathological examination. 
This could have influenced our findings if compared to a purely LGG group. However, 
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whether and how LGG influences FA/MD values in perilesional WM tracts differently 
from HGG is still under debate 19,23. In this study, language impairments were significantly 
worse in histopathological established HGG than in LGG, while there was no significant 
difference in FA or MD values of the three WM tracts between these two groups. The 
former is consistent with the more aggressive nature of these tumors, the latter with their 
radiological characteristics. We can speculate that the higher grade of these tumors allows 
for less plasticity and hence worse deficits. 
Limitations
There were some limitations to our study. Deterministic tractography was used to identify 
three WM tracts per patient by placing two ROIs per WM tract. It is important to note that 
the procedure of manually anatomical seed ROI placement is subject to variability within 
and between raters. Subjectivity depends on the location of ROI placement and the WM of 
interest, with a higher variability of tracking in cortical areas and higher variability within 
specific tracts such as the inferior longitudinal fasciculus21,28. This is even more relevant in 
the context of brain tumors, as Schonberg et al. showed that when WM tracts are displaced 
by excessive edema or shift due to tumor compression, the variability and subjectivity of 
tractography increases significantly when compared with the contralateral hemisphere 28. 
We attempted to keep the inter-subject variability low and success rate high, by using a 
single, well-trained rater who placed ROIs systematically on clearly identifiable anatomical 
landmarks on DTI maps using published approaches30 and who visually inspected each 
identified WM tract in three dimensions. Additionally, the exclusion of WM tracts that could 
not be tracked in this analysis could have introduced some selection bias, since these 
patients potentially have more or more severe cognitive deficits.  Furthermore, one could 
argue that the diffusion imaging acquisition is not fully state-of-the art in the context of 
neuroscientific research, which now includes multiple b-values and many more gradient 
directions. This study was performed within the constraints of a routine clinical context, in 
which longer scan durations are not feasible. This may have limited our sensitivity to more 
subtle changes or associations, which means our negative findings need to be interpreted 
with care. A further reason why to interpret findings in DTI studies with care is due to the 
possibility that the difference in magnet strength (1.5 T vs 3.0T) can cause a difference in 
FA/MD value in the WM tracts11. This subsequently is likely to cause reduced strengths of 
associations between FA/MD values and cognitive outcome. However, we did not find a 
difference in FA/MD values between the two magnet strengths in this study and we can 
fairly confidently state that the associations we did find were valid and strong findings.
 Finally, due to multiple testing, a stringent significance level was maintained. As a 
result, there is the risk of false-negative findings and relevant correlations could have been 
obscured. On the other hand, the risk of false-positive findings is low and correlations that 
did pass the stringent significance level can be considered clearly positive. 
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Conclusion
This clinical DTI study shows that pre-operative language deficits in repetition of speech, 
verbal learning and attention deficits are associated with changes in the microarchitecture 
of respectively the AF and the IFOF in patients with presumed LGG. This indicates that 
especially repetition tasks during surgery are very important and should be implemented 
in the NP as a standard. Verbal learning is difficult to monitor during surgery, which 
highlights the need for a careful pre-operative assessment of the IFOF with DTI, especially 
in patients with decreased performance on the 15WT. We emphasize that, especially in 
patients with deficits in speech repetition or verbal learning, performing extensive tumor 
resection will need to be balanced carefully against preserving infiltrated WM tracts (AF, 
IFOF). Further investigation is needed to assess the predictive value of pre-operative FA 
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Neuronavigation systems are routinely used during neurosurgical procedures. Currently, 
new imaging technologies are emerging such as virtual, augmented and mixed reality. 
With mixed reality devices, the user can analyze and interact with the real environment 
using virtual objects. The aim of this prospective pilot study was to offer a proof of concept 
by testing the clinical feasibility and accuracy of a wearable mixed reality device (Hololens) 
for pre-operative neurosurgical planning. 
Methods
In patients with an indication for brain tumor surgery, pre-operative planning of tumor 
localization with the Hololens was compared with standard neuronavigation in the 
operating room. Magnetic resonance imaging based 3D holograms of the patient’s head 
and tumor were created and projected on the physical patient’s head using the Hololens. 
The 2D projection of the tumor borders as perceived by the neurosurgeon on the skin of 
the patient’s head was outlined both with the Hololens and neuronavigation. Accuracy of 
the Hololens localization was assessed using neuronavigation as the gold standard.
Results
Twenty-five patients were included in this study. Holograms were successfully created in 
all cases. In nine patients, tumor localization with the Hololens did not differ from the 
standard neuronavigation system and the overall median difference was 0.4 cm (IQR 
0-0.8). 
Conclusion
This prospective clinical study offers a proof of concept of the clinical feasibility of the 
Hololens for brain tumor surgery planning in the operating room, with quantitative 
outcome measures. Further development is needed to improve the accuracy of this 
wearable mixed reality device.
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Introduction
In the early 1990s the first commercially available neuronavigation system was introduced.(1) 
Image guided navigation technologies have undergone several developments since 
then which have led to important improvements during both pre- and intra-operative 
neurosurgical procedures. Although limited evidence of an improvement of survival or 
quality of life of patients with neuronavigation guidance is available, neuronavigation is 
a highly practical and time efficient tool for pre- and intra-operative target localization.(2,3) 
Therefore, now almost 30 years later, the neuronavigation system has found its place in 
the operating room as a standard tool in cranial neurosurgery. Neuronavigation consists of 
several important applications, one of which is the pre-operative localization of the target 
lesion on the outer surface of a patient’s head. However, this system has a considerable 
setup time due to a coordinate-based registration procedure. Additionally, the surgeon 
needs to translate these coordinates from a monitor to the patient’s head for an accurate 
target localization.  
 Currently, we are seeing newly emerging imaging technologies which have a 
potential medical applicability by creating virtual objects in the real, physical world, and 
the ability of interaction between these objects and the real world. Virtual reality (VR), 
in which a real environment is replaced by a virtual one, and augmented reality (AR), in 
which virtual objects are overlaid on a real, physical environment, are such innovative 
technologies.(4,5) These new technologies are potentially of great benefit to neurosurgeons 
for complex surgical procedures. Meola et al. systematically reviewed AR studies within 
the field of neurosurgery and they concluded that AR has a potential benefit to improve 
current neuronavigation systems, but that prospective and clinical application studies are 
very limited.(6)
 In contrast to VR and AR, mixed reality can be used to analyze and interact with the 
real environment by placing a virtual object over the physical environment. Our hypothesis 
is that mixed reality can be used for pre-operative planning and localization of the tumor 
by placing 3D hologram reconstructions of pre-operatively acquired brain MRI or CT 
scans over the physical operating field. To the best of our knowledge, a wearable mixed 
reality device has as yet not been tested within the field of (oncological) neurosurgery 
in a prospective clinical study. The aim of this study was to test the clinical applicability 
and accuracy of a wearable mixed reality device for pre-operative neurosurgical tumor 





Patients with the age of 18 years and older, referred for neurosurgery of a newly diagnosed 
contrast enhancing intra- or extra-axial lesion as seen on a pre-operative T1 with contrast 
MRI scan, suspected for brain tumor, between December 2016 and December 2017 at 
the department of neurosurgery, Erasmus MC were eligible for this study. This study was 
approved by the IRB. Obtaining written informed consent was waived by the IRB, because 
participants were not subjected to any specific study procedures nor were they required 
to follow rules of behavior, and no additional risk was introduced by the study. 
Hologram creation
Tumor volumes were semi-automatically segmented on high-resolution 3D contrast 
enhanced T1 weighted MRI images using a free online toolkit (ITK-SNAP; www.itksnap.
org) and 3D objects (Figure 1) were reconstructed using free online software (Meshmixer; 
www.meshmixer.com). Then, 3D objects were sent online to the Hololens using a 
commercially available application (VertoStudio; www.vertostudio.com). The Microsoft 
Hololens is a commercially available, wearable computer integrated mixed reality device 
(www.microsoft.com/microsoft-hololens). 
Figure 1. 3D reconstruction of the head of the patient with the edges of the virtual craniotomy (blue) and the 
tumor (red). This model is converted to a hologram and send to the mixed reality device.
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Operative planning with the Hololens
From tumor segmentations, tumor volumes (cm3) were measured using ITK-SNAP. Tumors 
were categorized as superficial (distance of 0 cm) or deep tumors (distance > 0 cm), as 
measured from the tumor border closest to brain surface to brain surface. Additionally, 
based on their localization, tumors where categorized by hemisphere (right vs. left) and 
lobe (frontal, parietal, temporal and occipital). Planning time for both the Hololens as 
the standard navigation system were measured from time to system setup to the final 
tumor outline on the patient’s head. In the operating room, skin surface registration was 
performed manually by merging the 3D holograms of the patient’s head and tumor with 
the physical head of the patient. Then, the 2D projection of the holographic tumor borders 
and the center of the tumor were marked on the skin of the patient’s head as perceived by 
the neurosurgeon wearing the Hololens (Figure 2 and Figure 3). The center and outlines 
of the tumor were then marked again on the skin of the patient’s head using the standard 
neuronavigation system (BrainLab, Feldkirchen, Germany). The maximal extension of the 
borders of the tumors were marked in 4 directions: anterior, posterior, medial and lateral. 
The exact center of the tumor projection on the skin was determined by the crossing of the 
anterior-posterior line and the medial-lateral line. The same was done with the standard 
neuronavigation system. As an outcome for accuracy in tumor localization, the maximum 
distance (cm) between the center of the tumor determined with the Hololens versus with 
neuronavigation (as the gold standard) was measured on the patient’s skin. Eventually, 
skin incisions, craniotomy and surgery were performed based on tumor localization using 
the standard neuronavigation system. All measurements were performed by authors with 
prior Hololens experience (F.I and/or A.V). Cases were excluded from this study, if both of 
the authors could not attend surgery.
Figure 2. The head of the patient as seen through the Hololens. The 3D hologram is merged with the physical 
head of the patient. The tumor (red) is outlined first with the Hololens (light blue dots) and then with the 




To obtain an impression of the alignment of the Hololens tumor projection in full, the 
holographic tumor borders of a meningioma were compared qualitatively with the true 
meningioma borders as seen on the brain surface, after opening the dura, in one patient. 
This assessment was also compared with the pre-operative tumor outlines on the skin.
Statistical Analysis
Statistical analyses were performed with the SPSS statistical software (SPSS version 21.0, 
SPSS Inc. Chicago, IL, USA). A one-sample Wilcoxon signed rank test was performed to 
test whether there was a significant deviation between Hololens and neuronavigation. 
Differences in deviation between groups of the various tumor locations between the 
Hololens and neuronavigation system were tested with a one-way ANOVA test. The 
difference in deviation between superficial and deep tumors and between the first and 
second half of the study, as well as the difference in pre-operative planning time between 
Hololens and standard neuronavigation were tested with a t-test. A p value of <0. 05 was 
considered to be statistically significant. 
Figure 3. Neurosurgeon with the Hololens in the operating room.
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Figure 4. A scatterplot of deviation (cm) on the y-asis over time (days) on the x-asis, with t = 0 inclusion of first 
patient.
Results
Twenty-five patients were included in this study with a mean age of 57 years (range 22-
80). Tumors had a median volume of 34.8 cm3 (IQR 5.8 – 58.2) and 17 of 25 (68%) tumors 
reached the brain surface. Patient and tumor characteristics are further presented in Table 
1. Holograms were successfully created in all of the patients. Mean pre-operative planning 
time with the Hololens (mean 5 min 20 sec, SD 1 min 20 sec) was longer, when compared 
with the standard neuronavigation system (mean 4 min 25 sec, SD 1 min 20 sec, p < 0.001). 
In nine patients (36%) tumor localization with the Hololens did not differ from that of the 
standard neuronavigation system. Overall, there was significant deviation between the 
Hololens and neuronavigation (p < 0.0001), with a median deviation of 0.4 cm (IQR 0-0.8). 
There was no statistically significant difference in deviation between tumor location in 
the left (median = 0.3 cm, IQR0-0.5) and right hemisphere (median = 0.5 cm, IQR 0-1.1, 
p = 0.17) or between the frontal, parietal, temporal and occipital lobes (p = 0.74). 
Additionally, no significantly different deviation was found between superficial (median 
= 0.4 cm, IQR 0-0.8) and deep tumors (median = 0.25 cm, IQR 0-0.8, p=0.65). There was 
a trend towards more accurately localizing tumors towards the end of the study (Figure 
4), with a median deviation of 0.6 cm (IQR 0-1.1) during the first half (n=12) of the study 
and a median deviation of 0.3 cm (IQR 0-0.5) during the second half (n=13) of the study 
(p = 0.07). The qualitative assessment method showed that after opening the dura, the 
tumor as seen on the brain surface, was within the borders of the holographic tumor and 
also within the contour as marked on the patient’s head using the Hololens.  
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Table 1. Patient and tumor characteristics with deviation in tumor localization with Hololens, compared with 
neuronavigation system.








Pathology Time pre-operative 





71 Female Right parietal 5.2 2.3 Glioblastoma 6 | 4 0.5
80 Male Right temporal 9.4 0 Glioblastoma 5 | 3 0.8
38 Male Left temporal 72.5 0 Meningioma 3 | 4 0
48 Female Right frontal 29.1 0 Meningioma 7 | 5 1.2
67 Male Left frontal 2.0 0 Glioblastoma 3 | 5 0.4
64 Male Left temporal 94.4 1.2 Meningioma 5 | 4 0.9
54 Female Right occipital 34.8 0 Metastasis 6 | 8 0.7
73 Male Right frontal 1.8 0 Lymphoma 4 | 4 1.8
57 Male Right temporal 6.4 24.0 Glioblastoma 5 | 4 1.1
53 Female Left parietal 87.5 0 Glioblastoma 7 | 8 0
65 Male Left temporal 35.1 1.3 Glioblastoma 7 | 4 0
70 Female Left frontal 54.5 0 Metastasis 5 | 4 0
54 Male Right frontal 45.5 0 Glioblastoma 5 | 3 0,4
73 Female Right parietal 44.3 0 Glioblastoma 4 | 3 0
77 Female Left frontal 32.9 0 Glioblastoma 3 | 3 1.0
63 Female Left frontal 35.9 1.4 Glioblastoma 6 | 4 0
22 Female Left frontal 36.2 0.5 Astrocytoma 5 | 5 0.2
63 Female Right temporal 11.7 0.8 Meningioma 4 | 5 0
62 Female Left frontal 61.9 0 Glioblastoma 5 | 5 0.4
28 Female Left frontal 4.2 0.6 Astrocytoma 6 | 3 0.3
51 Male Left temporal 114.7 0 Metastasis 8 | 4 0.3
24 Female Left frontal 0.2 0 Hemangioblastoma 5 | 5 0.5
74 Male Right frontal 29.3 0 Meningioma 6 | 5 0
54 Female Left occipital 3.6 0 Glioblastoma 5 | 6 0.5
37 Female Right frontal 161.0 0 Meningioma 7 | 4 0
* Zero indicates that tumor reached brain surface. 
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Discussion
This prospective clinical study offers a proof of concept of the clinical feasibility of a 
wearable mixed reality device for pre-operative neurosurgical planning using 3D hologram 
reconstructions of brain tumors with quantitative outcome measures. This study shows 
that there was a median deviation of 0.4 cm in tumor localization, when the Hololens 
was compared with the standard neuronavigation system. In nine out of 25 patients the 
localization did not differ between both systems. Additionally, the measurement strategy 
used in this study, focusing on the tumor center, was qualitatively assessed for full tumor 
alignment and showed that the full tumor alignment on the patient’s head using the 
Hololens corresponds with the true tumor borders as seen on the brain surface.  
 Surgeons experienced benefits in terms of preservation of attention and focus on 
the patient, improved ergonomics, and an improved understanding of tumor-brain/skull 
relationship due to a direct 3D holographic representation. To the best of our knowledge, 
there have been no studies on wearable mixed reality devices with 3D virtual projections 
for brain tumor surgery to this date. We emphasize that spatial mapping and recognition 
of the physical environment is a crucial difference between augmented and mixed reality. 
Mixed reality with the Hololens provided an instant visualization of tumors by using 3D 
holograms. Due to a built-in computer in the Hololens, other devices such as camera, 
monitor or excessive technical preparation at the operating room were not necessary. 
In contrast to current neuronavigation systems, the Hololens subjectively improved 
ergonomics during surgical planning, because neurosurgeons could keep their focus on 
patient’s head, instead of having to look back and forth between patient and navigation 
screen. Importantly, during this study, there was a learning curve for neurosurgeons in 
using this wearable mixed reality device in localizing and marking tumor border on the 
patient’s head as evidenced by a trend towards more accurately localizing tumors towards 
the end of the study. 
 Within the field of neurosurgery, VR has played a limited role in pre- and intra-
operative application due to the fact that the neurosurgeon is isolated in a virtual world, 
while being in the operating room were situational awareness is crucial. However, for 
extra-operative pre-surgical planning and education, VR devices are useful to improve 
the understanding of both individual anatomy of patients 7, anatomical education 8 and 
neurosurgical traning5. Meola et al. reviewed 18 articles on AR in neurosurgery 6 published 
between 1996 and 2015. Microscopes 9-16 and monitors or tablets 17-24 were the most 
commonly used AR devices, which were all 2D visualizations of virtual objects such as 
aneurysms and brain tumors.  Monitors or tablets could be practical AR devices to use 
for pre-operative surgical planning. However, with these devices, an in-physical-space 3D 
visualization of virtual objects of complex anatomical structures is limited. Additionally, 
microscopes offer some 3D experience of virtual objects such as tumor, fiber tracts and 
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vessels trough the oculars. However, the microscope is commonly used after trepanation 
in the intra-operative phase, instead of a pre-operative planning device.
 Recently, Yoon et al. reviewed the literature between 1995 and 2017 extensively 
on several augmented reality devices within all surgical fields.25 Within the field of 
neurosurgery, they identified 10 studies, of which 5 performed surgery in a live setting 
and 5 performed simulated surgeries. There were no studies that had used the Hololens. 
The authors found that wearable augmented reality devices improved attention, focus 
and ergonomics compared to standard navigation systems in which the surgeon have 
to shift repeatedly from 2D images on a screen to the patient. The authors also state that 
the majority of the studies had not assessed any quantitative outcome measure. The 
experience and results in our study concerning the preservation of attention and focus 
by the surgeon on the patient, the improved 3D anatomical evaluation, and improved 
ergonomics are in line with the conclusions of this systematic review.
 This study provides a proof of concept that the Hololens has potential for operative 
planning of brain tumor surgery with quantitative outcome measures. However, we think 
that there are two important issues that need further development to improve the accuracy 
of the Hololens. Due to the manual skin surface registration, the accuracy was probably 
decreased and registration time longer as compared to the standard neuronavigation. The 
Hololens deviated with a median of 0.4 cm in localizing the tumor and prolonged median 
registration time with 45 seconds. In the setting of operative planning, this deviation is 
probably acceptable, it is however too large for intra-operative usage. Currently, we are 
working on a coordination-based skin surface registration system which is expected to 
improve spatial accuracy and decrease registration time. Additionally, there was an issue 
with respect to the point of view when marking tumor border on the skin of the patient’s 
head with the Hololens, when compared with standard neuronavigation. Since the 
holographic head is 3D and transparent, the tumor can be seen and marked from different 
angles. Any angle that is not exactly perpendicular to the head and tumor, will result in a 
deviation of localizing the lesion when compared with standard neuronavigation. 
 A limitation of this study is that a non-validated method was used in this study to 
outline the tumor. This method is standard practice with the use of the neuronavigation 
system in our neurosurgical center, and we therefore chose to use this method also in 
context of this study for the Hololens. Another limitation of this study is that patients 
were not consecutively included in this study, which could have introduced selection bias 
based on case complexity. Most of the tumors were superficially located. However, we did 
have some complex cases with tumors in the basal ganglia or skull base. We did not find 
any significant difference in accuracy between superficial and deep tumors. In cases with 
skull base tumors, surgeons reported a better understanding of tumor-brain/skull base 
relationship.
 Further research is needed to test the applicability and accuracy of mixed reality 
devices in several other neurosurgical fields such as pre and per-operative planning of 
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neurosurgery by visualizing neuroanatomical structures (such as more complex tumors, 
aneurysms, vascular malformations, skull base tumors, and disc herniations). Additional 
options of this technology should be explored, which includes overlaying patient (history, 
vital statistics) and imaging data (MRI and/or CT scan) directly over the field of view of the 
surgeon, which could further improve interpretation, attention and focus of the surgeon 
during surgery.
Conclusion
This prospective clinical study offers a proof of concept of the clinical feasibility of the 
Hololens for brain tumor surgery planning in the operating room with quantitative 
outcome measures. Further development is needed to improve the accuracy and clinical 
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Studies on the impact of contrast enhanced (CE) and non-contrast enhanced (NCE) tumor 
resection in patients with glioblastoma in light of molecular subtypes are limited. The aim 
of this study was to assess the impact of CE and NCE tumor resection in light of MGMT 
promoter methylation on survival in newly diagnosed IDH wildtype glioblastoma. 
Methods
Patients with newly diagnosed IDH wildtype glioblastoma who underwent surgery were 
eligible. CE and NCE tumor volumes were assessed on pre- and post-operative MRI scans 
and extent of resection was calculated. The impact of CE and NCE resection was evaluated 
using multivariable Cox proportional hazards models and Kaplan Meier analyses.
Results
326 patients were included: 177 (54.3%) with and 149 (45.7%) without MGMT methylation. 
Multivariable Cox proportional hazards models stratified for MGMT methylation identified 
age ≤ 65y (HR 0.63; 95% CI, 0.49-0.81; p < 0.0001), chemoradiation (HR 0.13; 95% CI, 0.09-
0.19; p < 0.0001), maximal CE resection (HR 0.58; 95% CI, 0.39-0.87; p = 0.009), extended 
NCE resection (HR 0.71; 95% CI, 0.53-0.93; p = 0.014) and minimal residual CE tumor 
volume (HR 0.64; 95% CI, 0.46-0.88 p = 0.007) as being associated with longer OS. Kaplan 
Meier analyses showed that extensive surgery was more beneficial for patients with 
MGMT methylated glioblastoma. 
Conclusion
This study shows an association between maximal CE resection, extended NCE resection, 
minimal residual CE tumor volume and longer OS in patients with newly diagnosed IDH 
wildtype glioblastoma. Intra-operative imaging and stimulation mapping may be used to 
pursue safe and maximal resection.
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Introduction
Patients with glioblastoma have a poor prognosis with a median overall survival of 10 - 15 
months, despite safe and maximal surgical resection followed by chemo- and radiotherapy.(1) 
This prognosis varies based on known factors such as age, KPS, extent of resection, 
isocitrate dehydrogenase (IDH) mutation status, and methylguanine methyltransferase 
(MGMT) promoter methylation status.(2,3) 
 Maximal resection of the contrast enhanced (CE) portion of glioblastoma has 
been associated with better overall survival and is currently part of standard surgical 
glioblastoma treatment.(3) However, glioblastoma is known to infiltrate far beyond 
the margins of CE as seen on MRI, into the surrounding non-contrast enhanced (NCE) 
edematous T2-weighted or FLAIR abnormality area.(4) This raises the question whether 
maximal CE resection should be extended beyond CE, into NCE area, to improve survival.(5) 
A recent meta-analysis and a systematic review suggested that there is an association 
between maximal CE resection with resection of NCE and overall survival.(6,7) However, 
the quality of evidence of the available studies was low due to confounding and selection 
biases. On top, studies investigating the impact of CE and NCE resection have reported 
limited molecular data on IDH mutation and MGMT promoter methylation of their studied 
glioblastoma population.(6,8) 
 Thus, in light of the WHO 2016 reclassification, which now includes such molecular 
data, the impact of CE and NCE glioblastoma resection needs to be re-evaluated in a 
molecularly homogenous glioblastoma IDH wildtype population, while considering the 
impact of MGMT promoter methylation.(9) The aim of this study therefore, was to assess 
the impact of CE and NCE tumor resection in light of MGMT promoter methylation on 
survival in a cohort of patients with newly diagnosed IDH wildtype glioblastoma.
Methods
Patients
All consecutive patients aged 18 years or older, newly diagnosed with a CE mass lesion 
as seen on post-contrast T1-weighted MRI scans, histopathological confirmed as IDH 
wildtype glioblastoma, who underwent tumor resection or biopsy between January 2012 
and May 2018 at […] were considered for this retrospective study. Patients were eligible 
if pre- and immediate post-operative (<48 hours) T2-weighted or FLAIR and post-contrast 
T1-weighted MRI scans were available together with complete molecular data on IDH 
mutation and MGMT methylation. Molecular analysis was post-hoc performed in patients 
with unknown IDH mutation or MGMT methylation status; patients without enough tumor 
material for molecular analysis or in whom assays failed to produce a test result were 
excluded. The study was approved by the Medical Ethical Committee of Erasmus MC, who 
waived the need for written informed consent from the patients due to the retrospective 
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nature of this study and the (emotional) burden that would result from contacting the 
patients or their relatives to obtain consent. The study was performed in accordance with 
the 1964 Helsinki Declaration and its later amendments or comparable ethical standards 
and reported following the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) guidelines.
 
Image acquisition, tumor segmentation and extent of resection 
From pre- and post-operative MRI scans, which were obtained in the clinical routine either 
on a 1.5T or 3.0T scanner, post-contrast T1-weighted and T2-weighted or FLAIR images 
were collected. 
 For glioblastoma segmentation, we imported both pre- and post-operative post-
contrast T1-weighted and T2-weighted or FLAIR scans into Brainlab (BrainLab, Feldkirchen, 
Germany, version 2.1.0.15). Using the SmartBrush tool in Brainlab Elements, we semi-
automatically segmented all tumor involved CE on pre-operative post-contrast T1-
weighted scans (including the necrotic part, if present) and all tumor involved CE on post-
operative post-contrast T1-weighted scans (excluding small vessels in the surgical cavity or 
hemorrhage). We then semi-automatically segmented all tumor-related NCE on both pre-
and post-operative T2-weighted or FLAIR scans (excluding extra-lesional hemorrhage). 
We attempted to minimize the inclusion of surgery induced new T2-weighted or FLAIR 
abnormality by overlaying and carefully comparing pre- and post-operative MRIs. We 
manually corrected all segmentations when needed using the manual Brush tool. All 
tumor volumes were assessed while being blinded for patients’ clinical outcome.
 We finally obtained four tumor volumes (cm3): pre-operative and residual CE volumes 
and pre-operative and residual NCE volumes. We calculated the CE surrounding NCE 
volumes by subtracting CE volumes from the total NCE volumes. We calculated the extent 
of resection (EOR, %) separately for both the CE and NCE portion with the formula: [(pre-
operative volume – residual volume)/pre-operative volume] * 100.(10) Maximal CE resection 
was categorized in our dataset as CE EOR >97% and extended NCE was categorized as 
NCE resection of ≥ 30% based on threshold analysis (Figure 1 and 2 of Supplementary 
Material). Tumors that were biopsied were segmented only on pre-operative MRI scans 
and their EOR was imputed as being 0%. 
Molecular analysis
Tumor tissue samples were obtained from patients through surgical resection or biopsy. 
Histopathological examination was performed by neuropathologists; IDH mutational 
analysis was assessed with sequencing and MGMT methylation status with a methylation 
specific PCR, as described elsewhere.(11-13) 
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Statistical analysis
Overall survival (OS) was defined as time from surgery to death (primary outcome) and 
progression-free survival (PFS) was defined as time from surgery till clinical or radiological 
progression (secondary outcome). Patients were censored at time of last clinical follow 
up date. 
 Statistical analyses were performed with SPSS 25.0 statistical software (IBM Corp.). 
Pre-operative and post-operative residual tumor volume distributions were skewed and 
therefore log transformed prior to statistical analysis. Descriptive statistics were tested 
between MGMT methylation status groups with the Chi Squared Test or Fisher Exact test 
in case of categorical variables, with the Kruskal Wallis test in case of continuous non-
normal distributed data and with log rank tests to compare median OS and PFS when 
using Kaplan Meier analysis.
 The associations between each variable and outcome were first tested with 
univariable Cox proportional hazards models and all variables with p < 0.10 (entry 
significance threshold) were selected for multivariable Cox proportional hazards models. 
These models were stratified for MGMT, because this variable violated the proportional 
hazards assumption. Hazard Ratio’s (HR) with 95% Confidence Intervals (CI) were estimated 
for each variable within the model. A p-value < 0.05 was considered statistically significant. 
Results
There were 375 glioblastoma patients considered for this study. We excluded 36 (9.6%) 
due to insufficient tissue material for molecular analysis, and 13 (3.5%) because of the 
presence of IDH mutation. In total, 326 IDH wildtype glioblastoma were included in our 
analysis: 177 (54.3%) with and 149 (45.7%) without MGMT promoter methylation. Maximal 
CE resection was achieved in 61 patients (18.7%), while in 187 (57.4%) patients maximal 
resection of CE could not be achieved. Seventy-eight patients (23.9%) underwent biopsy. 
Extended NCE was achieved in 156 patients (47.9%) and no or limited NCE resection was 
performed in 170 patients (52.1%). Median OS and PFS was 309 days (95% CI, 278-340) 
and 174 days (95% CI, 159-209) respectively. Further patient and tumor characteristics are 
presented in Table 1. 
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Table 1. Patient and tumor characteristics.
MGMT promoter
All Methylated Unmethylated p value
n % n % n %
Characteristics 326 100 177 54.3 149 45.7
Sex 0.006 
Male 206 63.2 100 48.5 106 51.5
Female 120 36.8 77 64.2 43 35.8
Age, years 0.122
≤ 65 162 49.7 81 50.0 81 50.0
> 65 164 50.3 96 58.5 68 41.5
Mean, years (SD) 63.8 (10.5) 64.2 (10.9) 63.3 (10.1) 0.453
KPS 0.748
≤ 70 119 36.5 66 55.5 53 45.5
> 70 207 73.5 111 53.6 96 46.4
Mean (SD) 79.2 (12.4) 78.8 (12.2) 79.7 (12.6) 0.480
Pre-operative tumor volume, median cm3 (IQR)
CE 34.9 (15.5-55.8) 30.7 (13.8-52.5) 39.9 (17.1-26.2) 0.050
NCE 72.1 (29.4-127.5) 78.1 (27.8-133.8) 64.9 (32.3-113.4) 0.249
Residual tumor volume, median cm3 (IQR)
CE 5.0 (1.41-12.3) 6.1 (1.8-12.5) 3.8 (1.1-12.0) 0.097
NCE 39.7 (18.3-73.7) 42.2 (17.1-79.6) 36.5 (20.4-64.2) 0.699
Maximal CE resection 0.213
Yes 61 18.7 27 44.3 34 55.7
No 187 57.4 105 56.2 82 43.8
Biopsy 78 23.9 45 57.7 33 42.3
Median EOR (IQR) 83.4 (14.2-94.8) 79.6 (0-91.9) 88.0 (25-7-96.0) 0.075
NCE resection 0.609
≥ 30% 156 47.9 87 55.8 69 44.2
< 30% 170 52.1 90 52.9 80 47.1
Median EOR (IQR) 27.1 (0-57.1) 28.7 (0-58.4) 25.8 (0-55.0) 0.948
Adjuvant therapy 0.294
No therapy 61 18.7 38 62.3 23 37.7
Radio- or chemotherapy alone 56 17.2 27 48.2 29 51.8
Chemoradiation 209 64.1 112 58.4 97 41.6
Overall patient outcome x x x x x x x
Median overall survival (95% CI) 309 (278.0-340.0) 334 (266.8-401.2) 305 (275.2-334.8) 0.003 
Median progression-free survival (95% CI) 184 (159.3-208.7) 174 (131-2-216.8) 190 (162.0-218) 0.053
MGMT methylguanine methyltransferase, SD standard deviation, CE contrast enhancement, NCE non contrast 
enhancement, EOR extent of resection, IQR Inter Quartile Range, CI Confidence interval. 
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Univariable Cox proportional hazards regression analysis identified age ≤ 65y (HR 0.64; 
95% CI, 0.51-0.80; p < 0.0001), KPS >70 (HR 0.59; 95% CI, 0.47-0.74; p < 0.0001), MGMT 
promoter methylation (HR 0.72; 95% CI, 0.57-0.90; p < 0.004), adjuvant chemoradiation 
(HR 0.14; 95% CI, 0.11-0.19; p < 0.0001), smaller pre-operative CE tumor volumes (per cm3 
HR 0.92; 95% CI, 0.83-1.01; p < .094), maximal CE resection (HR 0.51; 95% CI, 0.36-0.72; p 
< 0.0001), and extended NCE resection (HR 0.72; 95% CI, 0.58-0.91; p = 0.005) as being 
associated with longer OS. As further presented in Table 2, the variables age ≤ 65y, KPS 
>70, adjuvant chemoradiation, maximal CE resection and extended NCE resection were 
also significantly associated with a longer PFS in univariable Cox regression analysis (p < 
0.05). Kaplan Meier curves for OS and PFS for each variable are presented in Figure 3 of 
Supplementary Material.
 Multivariable Cox proportional hazards regression analysis stratified for MGMT 
methylation status and risk adjusted for age ≤ 65y (HR 0.63; 95% CI, 0.49-0.81; p < 0.0001), 
KPS >70 (HR 0.92; 95% CI, 0.71-1.19; p = 0.545), adjuvant chemoradiation (HR 0.13; 95% 
CI, 0.09-0.19; p < 0.0001), and smaller pre-operative CE tumor volumes per cm3 (HR 0.85; 
95% CI, 0.75-0.95; p = 0.007) identified maximal CE resection (HR 0.58; 95% CI, 0.39-0.87; 
p = 0.009) and extended NCE resection (HR 0.71; 95% CI, 0.53-0.93; p = 0.014) as being 
associated with longer OS (Table 2). Variables that remained significantly associated 
with a longer PFS were KPS >70 (HR 0.59; 95% CI, 0.45-0.77; p < 0.0001) and adjuvant 
chemoradiation (HR 0.09; 95% CI, 0.06-0.14; p < 0.0001). Explorative multivariable Cox 
proportional hazards regression analyses showed that higher NCE resection thresholds 
(e.g. ≥50%) were not associated with a favorable OS (p > 0.05) (for threshold analysis, see 
Figure 1 of Supplementary Material).
 The impact of maximal CE resection on survival was more beneficial for patients with 
MGMT methylated glioblastoma and significantly improved median OS (572 days; 95% 
CI, 424-720), when compared to STR (342 days; 95% CI, 282-402; p = 0.014) or biopsy (112 
days; 95% CI, 36-42; p = 0.001) (Figure 1A). Patients with MGMT methylated glioblastoma 
also had a longer OS with extended NCE resection (425 days; 95% CI, 286-564) than when 
extended NCE was not achieved (190 days; 95% CI, 107-273; p = 0.001) (Figure 1B). In 
patients with MGMT unmethylated glioblastoma, no survival benefit was observed with 
extended NCE resection (p = 0.884). 
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Figure 1. Overall and MGMT-stratified Kaplan Meier curves for overall survival A) Maximal CE resection B) 
Extended NCE resection and C) Minimal residual volume.
We further assessed minimal post-operative CE residual volumes with a potential positive 
impact on OS. In MGMT methylated glioblastoma, when compared to >5 cm3 residual CE 
tumor (224 days; 95% CI 164-284), we observed a significantly longer median OS for a 
residual CE tumor volume of 1-5 cm3 (470 days; 95% CI 330-610; p <0.0001) and 0-1 cm3 
(536 days; 95% CI 319-752; p = 0.003) (Figure 1C). In MGMT unmethylated glioblastoma, we 
only observed a longer OS in residual CE volumes of 0-1 cm3 (427 days; 95% CI, 350-503), 
when compared to 1-5cm3 (299 days; 95% CI, 270-327; p = 0.006) or to >5 cm3 (200 days; 
95% CI, 102-298; p = 0.003) (Figure 1C). In these tumors, no difference in median OS was 
observed between 1-5 cm3 and >5 cm3 (p = 0.371) residual CE tumor volume. Multivariable 
Cox proportional hazards regression analysis stratified for MGMT and adjusted for age, 
KPS, adjuvant chemoradiation and pre-operative CE tumor volume, identified a residual 
CE tumor volume of 0-1 cm3 (HR 0.64; 95% CI, 0.46-0.88 p = 0.007) and 1-5 cm3 (HR 0.71; 
95% CI, 0.54-0.94; p = 0.016) as being associated with favorable OS. These analyses were 
also performed for post-operative residual NCE volumes, but here no minimal volume 
threshold with a positive impact on OS was identified.
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This study shows an association between maximal CE resection, extended NCE resection, 
minimal residual CE tumor volume and longer OS in 326 patients with newly diagnosed 
IDH wildtype glioblastoma. We observed that extensive resection was more beneficial for 
patients with MGMT methylated IDH wildtype glioblastoma.
 Maximal resection of CE has earlier been associated with longer OS in a large meta-
analysis of neurosurgical literature based on 37 studies and 41,117 unique glioblastoma 
patients.3 This association has recently been re-evaluated based on two new insights. 
First, studies performed before the WHO 2016 reclassification have included limited 
molecular data, because the impact of molecular subtyping of glioblastoma according 
to IDH mutation status was less of a consideration.(3,8,14-16) Although IDH mutation within 
newly diagnosed primary glioblastoma is rare (<5%, and 3.5% in our cohort) these tumors 
represent a distinct molecular type of glioma arising from a distinct precursor lesion.(17,18) 
Therefore, incomplete or absence of molecular data on IDH mutation and MGMT 
methylation or mixing molecular subtypes when evaluating the impact of glioblastoma 
resection on survival is undesirable. More recent studies did investigate the impact of 
glioblastoma surgery on survival in light of molecular markers. Senft et al. studied the 
impact of maximal CE resection and MGMT promoter methylation status in a homogenous 
IDH wildtype glioblastoma population (n = 175) and showed that both were significantly 
associated with longer OS.(2) Ellingson et al. showed in 1,054 glioblastoma patients (with 
partially available data on IDH mutation and MGMT methylation) that smaller residual 
CE tumor volumes (<12 cm3) and MGMT methylation were significantly associated with 
longer OS in patients receiving chemoradiation.(19) A recent study published by Molinaro 
et al confirmed the association between maximal CE resection and OS across all molecular 
subgroups of glioblastoma.(20) 
 Secondly, the association between glioblastoma resection and OS is also being 
reassessed by evaluating the value of NCE resection, because it is known that glioblastoma 
infiltrates beyond the margins of CE into the NCE area.(4) This aspect of glioblastoma 
surgery is also recently investigated by Molinaro et al.(20) The authors found that maximal 
resection of CE and NCE tumor was associated with longer OS in younger patients with 
IDH wildtype glioblastoma regardless of MGMT methylation status (subset of 190 patients 
with known IDH mutation and MGMT methylation status). In this study, maximal NCE 
resection that was associated with OS was defined as 92% NCE resection after maximal CE 
resection. Such an extensive surgical approach may only safely be achievable with use of 
intra-operative imaging, fluorescent guidance or stimulation mapping.(21,22) Other studies 
have associated lower NCE resection thresholds of 53% and 45% with OS.(8,23) We observed 
that a NCE resection threshold of 30% was associated with OS.  In exploratory threshold 
analysis, higher thresholds (e.g. minimal ≥60% NCE tumor resection) seemed not to be 
associated with OS anymore. This may suggest that resection of NCE tumor immediately 
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surrounding CE improves survival, but extending the resection on further distance from 
CE into NCE tumor does not provide survival benefit. It can be hypothesized that the 
direct peritumoral NCE area reflects a higher degree of tumor infiltration than the NCE 
area further away from the CE tumor, which is presumably more dominated by edema 
than tumor infiltration.(4) In future research, a combination of physiological imaging 
modalities - such as MR spectroscopy, diffusion and perfusion imaging or positron-
emission tomography - may be used to more accurately detect tumor infiltrated portions 
in NCE and to tailor surgical planning.(24) 
Limitations
The main limitation of this study is its retrospective nature. This may have introduced some 
degree of selection bias. We attempted to limit selection bias by consecutive inclusion of 
all glioblastoma patients operated upon between 2012 and 2018 in our cohort, including 
patients with complex glioblastoma localization (crossing midline or deep within the 
basal ganglia) who underwent diagnostic biopsies. We also performed IDH mutational 
and MGMT promoter methylation analyses on all glioblastoma included in our cohort. A 
second limitation is that only one observer assessed both pre- and post-operative tumor 
volumes. In this context, a stringent assessment of residual volumes in the resection cavity 
by one observer may explain the relatively low maximal CE resection percentage of 17.8%. 
Although the interobserver agreement is high for pre-operative volumes, it is known to 
be relatively low for residual tumor volumes. The intra-observer agreement nevertheless, 
is known to be high for both pre-operative as residual tumor volumes.(10,25) We have 
also attempted to limit bias during volumetric assessment by blinding the assessor for 
patients’ clinical outcome. In future research, our findings need to be validated in an 
external validation set.
Conclusion
This study shows an association between maximal CE resection, extended NCE resection, 
minimal residual CE tumor volume and longer OS in patients with newly diagnosed IDH 
wildtype glioblastoma. Extensive resection was more beneficial for patients with MGMT 
methylated glioblastoma. Intra operative imaging and stimulation mapping may be used 
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Figure S1. Kaplan Meier curves of OS for different EOR thresholds.
Figure S2. Hazard ratios with 95% CI for different NCE resection thresholds in explorative multivariable Cox 
proportional hazards models (stratified for MGMT methylation status, adjusted for age, KPS, adjuvant therapy, 
EOR and pre-operative tumor volume).
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Figure S3. Kaplan Meier curves of OS and PFS for (A) age, (B) gender, (C) KPS, (D) MGMT promotor methylation, 
(E) adjuvant therapy.
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Gross total resection (GTR) of contrast enhancement (CE) improves survival of glioblastoma 
(GBM) patients. However, GBM infiltrates into brain parenchyma, beyond CE. It remains 
unclear whether resection beyond CE (supratotal resection, SPTR) improves survival 
without causing additional neurological deficits. The aim of this meta-analysis was to 
study the association between SPTR and overall survival in GBM patients. 
Methods
Embase, Pubmed and other literature databases were searched for eligible studies 
until August 2018. Studies involving patients with GBM comparing SPTR with GTR were 
included in this study. The main outcome was overall survival as hazard ratios (HR) with 
95% confidence interval (CI) and median overall survival differences with 95% CI.
Results
Meta-analysis based on six studies and 1,168 unique patients with GBM showed that 
when compared with GTR, SPTR of GBM resulted in 53% lower risk of mortality at any time 
during follow-up (HR = 0.47, 95% CI = 0.31 - 0.72, P = 0.0005). The median overall survival 
of SPTR was 6.4 months (95% CI = 3.2 - 9.7) longer than GTR (P = 0.0001). Reports on post-
operative deficits were limited and the quality of evidence was moderate to very low. 
Conclusion
When compared with GTR, SPTR of GBM suggests lower risk of mortality and longer 
median overall survival. However, the quality of evidence of the available studies was 
poor. Therefore, it remains unclear whether SPTR is safe and whether it really improves 
survival of patients with GBM. Future prospective trials and a standardized definition of 
SPTR are needed.
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Introduction
Patients with glioblastoma (GBM) have a poor prognosis with a median overall survival 
of 15 months, despite safe and maximal surgical resection followed by chemo- and/
or radiotherapy.(1) GBM typically appears on a post-contrast MRI scan as a contrast 
enhancing (CE) tumor with central necrosis. Maximal and safe surgical resection or gross 
total resection (GTR) of the CE area is currently the main goal of GBM surgery. Both the 
survival benefit of GTR and the optimal way to achieve this are extensively debated in the 
neurosurgical literature. 
 Brown et al. showed in a systematic review and meta-analysis of 37 articles and 41,117 
unique patients, that in comparison with subtotal resection, GTR of CE area decreases 
the risk of mortality with 28% at 1 year and 16% at 2 years (P < 0.001).(1) Jenkinson et al. 
recently showed in a Cochrane review that resection with 5-Aminolevulinic Acid (5-ALA) 
fluorescence guidance or intra-operative MRI guidance may increase the extent of GBM 
resection.(2)
 However, GBM is known to infiltrate far beyond the margins of CE as seen on MRI, 
into the surrounding edematous T2-FLAIR hyperintense region.(3) This raises the question 
whether GTR of the CE portion is indeed a ‘total’ resection, or whether surgical resection 
should also include –part of the- hyperintense T2-FLAIR region to improve survival. It is 
suggested that 5-ALA fluorescence accumulates in cancer cells and not only corresponds 
with the CE portion on MRI but also exceeds this area as vague fluorescence, which 
corresponds with portions of GBM often infiltrating into eloquent brain area.(4)
 This concept of so-called supramarginal or supratotal resection (SPTR), is already 
known in the field of low grade glioma surgery,(5,6) because low grade gliomas commonly 
don’t enhance and therefore lack the CE target for surgical resection. However, SPTR of 
GBM is less extensively investigated, and up until this date no quantitative data analysis 
has been performed to clarify the association of survival with SPTR versus GTR in GBM 
patients, nor of associated post-surgical neurological complications. 
 The aim of this study was to investigate the association between SPTR and survival 




We searched for studies that included GBM patients who had received surgical resection, 
with pre- and post-operative MRI imaging. Letters, editorials, abstracts and non-English 
citations were excluded. The search query was designed together with an expert librarian 
at the Erasmus University Medical Center, Medical Library to capture all citations published 
until August 2018 within Pubmed [(Glioblastoma/ OR (glioblastom* OR (maligna* ADJ3 
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glioma*) OR (high* ADJ3 grade* ADJ3 glioma*) OR ((grade-iv OR grade-4) ADJ3 glioma*) OR 
gbm).ab,ti,kw.) AND (Surgical Procedures, Operative/ OR exp Neurosurgery/ OR Neurosurgical 
Procedures/ OR exp Brain Neoplasms/su OR (surg* OR neurosurg* OR resect*).ab,ti,kw.) AND 
(Margins of Excision/ OR (flair OR (Fluid ADJ3 attenuat* ADJ3  invers* ADJ3 recover*) OR t2 OR 
t-2 OR gross-total OR ((exten* OR Supratotal* OR Supramaxim*) ADJ3 (resect* OR remov*)) 
OR ((surg* OR excis* OR resect*) ADJ3 margin*) OR ((beyond OR additional*) ADJ6 (contrast 
OR boundar*))).ab,ti,kw.) NOT (letter* OR news OR comment* OR editorial* OR congres* OR 
abstract* OR book* OR chapter* OR dissertation abstract*).pt.] Embase, Web of Science, 
Cochrane Central and Google Scholar (search queries for these sources can be found in 
the Supplementary Materials). 
 After removing duplicate articles, two independent reviewers (F.I. and S.K.) 
screened the articles based on title and abstract, removing off-topic citations. Full texts of 
remaining articles were independently read by the reviewers to determine whether they 
were eligible for final inclusion. Articles that studied solely pediatric or non-glioblastoma 
cases, recurrent glioblastoma, non-surgery or surgery of enhancing tumor portion alone, 
biopsy-only or articles without survival data were excluded. The study was performed and 
presented according to the PRISMA guidelines.(7) 
Data collection
Main outcome of interest was overall survival as hazard ratio (HR) with 95% confidence 
interval (CI) and median overall survival with 95% CI of both GTR and SPTR groups. These 
data were collected from the included studies or calculated based on other available 
data or extracted based on data points created by a pixel-by-pixel method from survival 
curves. GTR and SPTR were defined by the authors of the studies that were included in our 
meta-analysis. We categorized GTR as 100% resection of CE and SPTR as every effort of 
resection beyond GTR of CE, which was qualitatively or quantitatively defined by authors 
of the included studies. Li et al. presented their data on survival and neurological outcome 
mainly by categorizing <53 % FLAIR resection and ≥53% FLAIR resection. However, after 
email correspondence with the senior author, we received additional survival data on the 
GTR and SPTR groups to perform our meta-analysis.(8)
 When available, data on post-operative new neurological deficits, surgical 
complications, or quality of life after surgery was collected to assess the safety of both 
SPTR and GTR. 
Meta-analysis
HR with 95% CI and median overall survival with 95% CI of both SPTR and GTR groups were 
collected or calculated for each study based on available data using the random effects 
model and presented in forest plots using Review Manager (RevMan, version 5.3; Cochrane 
Collaboration). The random effects model was used instead of the fixed effects model due 
to heterogeneity between the studies, in order to give a more conservative and a clinically 
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reliable interpretation of the summarized statistics and the confidence intervals. The HRs 
were corrected by the authors of the individual papers for several prognostic factors 
across studies such as age, Karnofsky Performance Status (KPS), adjuvant therapy, tumor 
volume and location and methylguanine-DNA methyltransferase (MGMT) methylation 
and isocitrate dehydrogenase (IDH) mutation status (see Supplementary Materials for 
details). A p value of < 0.05 was considered to be statistically significant. Heterogeneity 
was calculated and interpreted using the Chi-squared test and I2 values with Review 
Manager. 
Quality of evidence
Quality of evidence obtained from the articles in this study was graded based on the 
Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system.(9) 
Within this system, four levels of quality rating can be assigned to studies; from ‘high’, often 
given to randomized controlled trials, to ‘moderate’, ‘low’ often given to observational 
studies, and ‘very low’. The quality of evidence was rated by F.I. and was based on 
methodological quality, risk of biases (based on ROBINS-I),10 heterogeneity, and precision 
of effect estimates.
Results
We identified 1,796 citations from Embase, 1,503 from Pubmed, 1,424 from Web of 
Science, 140 from Cochrane Central and 200 from Google Scholar. Removal of duplicate 
articles resulted in 2,346 unique citations that were screened based on title and 
abstracts. In total, 2,322 off-topic articles were excluded, leaving 24 articles that were 
read in full. (6,8,11-32) After reading, 18 articles were excluded, due to absence of SPTR (N=11), 
absence of sufficient survival data (N=4), and article type (N=3; two commentaries and 
one review). This resulted in a final total of six studies (8,12,18,19,21,28) that were included in our 
systematic review and meta-analysis. The process of study inclusion is presented in the 
PRISMA flow diagram in Figure 1 and demographics of the included studies are presented 
in Table 1. 
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Figure 1. PRISMA Flow Diagram.
Table 1. Study demographics.
Study Country GTR defined as 
resection of











Spain 100% of CE 100% of CE + 







100% of CE 100% of CE +




Germany 100% of CE 100% of CE + 

















100% of CE 100% of CE +
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GTR: Gross total resection, SPTR: Supra total resection, CE: Contrast enhancement, HR: 
Hazard Ratio * Yes: HR should be interpreted as a between group comparison, No: HR 
should be interpreted as per unit of residual T2-FLAIR volume
† Which included prognostic factors in the model such as age, tumor volume, tumor 
location, Karnofsky Performance Status,  MGMT methylation status and adjuvant therapy. 
For a full overview, see Supplementary Materials.
‡ Levels of quality: 1: high, 2: moderate, 3: low, 4: very low. For details, see Supplementary 
Materials.
Meta-analysis 
Our meta-analysis based on six studies comparing SPTR with GTR (8,12,18,19,21,28) included 
1,168 unique patients with GBM and showed that when compared with GTR, SPTR of 
GBM resulted in 53% lower risk of mortality at any time during follow up (HR = 0.47, 95% 
CI = 0.31 - 0.72, P = 0.0005, I2 = 68%) (Figure 2). 
 The median overall survival for GTR and SPTR was 15.0 months (95% CI = 2.9 – 26.1) 
and 28.3 months (95% CI = 12.5- 44.1), respectively (P < 0.0001). The survival benefit with 
SPTR was 13.3 months (95% CI = 3.6 - 23.1) when compared with GTR (P = 0.007). However, 
Esquanazi et al.(18) especially influenced the heterogeneity (I2) of the median overall 
survival analysis, possibly due to a much higher median overall survival for SPTR of 54 
months within this study. Exclusion of this study in an additional median overall survival 
analysis showed a decrease of I2 from 96% to 50%. When compared with GTR, SPTR of GBM 
resulted in a longer median overall survival of 6.4 months (95% CI = 3.2 - 9.7, P = 0.0001) 
(Figure 3). 
Figure 2. Forest plot with hazard ratio and 95% confidence interval (CI) for supratotal resection (SPTR) versus 




No randomized controlled trials were available for inclusion in this meta-analysis; all 
studies were retrospective with a non-randomized treatment assignment. Following the 
GRADE guidelines, studies were assigned as ‘low’ level (12,18,19,28) quality evidence, upgraded 
to a ‘moderate’ level(8) or downgraded to a ‘very low’ level (21) (Table 1) based on previously 
mentioned mainly methodological factors such as study design, internal validity, risk of 
biases, and precision (for details; see Supplementary Materials). 
Post-operative new neurological deficits
While in three studies incidence rates of post-operative new neurological deficits for both 
SPTR (0%-19%) and GTR (0%-8%) groups were reported, in other three studies this data 
was either not (clearly) presented or absent (Table 2). Overall, reports were limited and 
based on this data the difference in post-operative neurological outcome between SPTR 
vs GTR could not clearly be analyzed. 
Figure 3. Forest plot with median overall survival difference between supratotal resection (SPTR) versus gross 
total resection (GTR).
Table 2. Reported incidence rates of post-operative neurological deficits.
Study GTR N (%) SPTR N (%) P value Comments
Aldave 2013 (12) 2 (8) 4 (18.5) 0.27 No details on the deficits was reported.
Li 2016 (8) NA 120 (19) NA Motor deficits, speech and visual 
impairments were the most commonly 
reported 30-day post-operative 
neurological complications.
Glenn 2018 (21) 0 (0) 1 (11.1) 0,66 One patient with dysphasia.
Pessina 2017 (28) 0 (0) 0 (0) NA There were no patients that developed 
post-operative new neurological deficits in 
the GTR and SPTR groups.
Eyupoglu 2016 (19) see comments 0.47 – 1.0 Rates on post-operative new neurological 
deficits between groups was not clearly 
collectable. Overall no significant worsening 
of motor, visual, speech, cognitive deficits or 
seizures was reported in both groups.
Esquanazi 2017 (18) NA NA NA 3 (7.9%) had transient and 2 (5.3%) had 
permanent neurological deficits of all 
38 patients. Group-specific data was not 
reported.
NA: not applicable. 
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Discussion
This PRISMA guided systematic review and meta-analysis studied the association between 
SPTR and survival in patients with GBM. This study based on six articles and 1,168 unique 
patients showed that when compared with GTR, SPTR of GBM resulted in 53% lower 
risk of mortality at any time during follow-up, and 6.4 months longer median overall 
survival. The quality of evidence of the available studies, however, was moderate to very 
low. Furthermore, the incidence rates of post-operative new neurological deficits were 
minimally and only qualitatively reported, and data on quality of life were not reported in 
any of the included studies. It therefore remains unclear whether SPTR can be achieved 
as safely as GTR.
Defining SPTR
There are a multitude of definitions for SPTR. The term was first coined by Yordanova et 
al. in 2011 to explain the procedure of low grade glioma resection guided by functional 
boundaries, defined by the area of T2-FLAIR hyperintensity (33) during awake surgery, 
instead of classical neuronavigation based pre-operative MRI post-contrast scans. The 
authors showed that SPTR of low-grade glioma resulted in significant delay of anaplastic 
degeneration (P = 0.037) without causing permanent neurological deficits. 
 With SPTR of GBM, the classically used CE boundaries of the tumor are exceeded to 
include the non-enhancing hyperintense T2-FLAIR region in the resection, presumed to 
represent edematous, tumor infiltrated tissue. This region can infiltrate deep into eloquent 
brain areas(3). For our analysis, we considered any effort of resection beyond GTR of CE as 
SPTR, irrespective of the procedure that was used to achieve this. While some studies had 
a relatively conservative SPTR procedure such as resection of additional residual 5-ALA 
fluorescent tissue (12,19) or resection of an additional rim (>1cm) after GTR of CE (21), Li et 
al. and Pessina et al. defined SPTR respectively as additional FLAIR abnormality resection 
(range >0% to 100%)8 and as 100% resection of T2-FLAIR hyperintense volumes in addition 
to GTR of CE (28). Additionally, a very recent study defined SPTR differently as GTR plus 
(frontal or temporal) lobectomy, without any volumetric analysis on T2-FLAIR volumes or 
functionally defined borders during awake surgery(34). Therefore, based on literature, SPTR 
can only broadly be defined as every effort of resection after GTR of CE portion of GBM; 
no standardized definition of SPTR exists and thus needs to be defined in a prospective 
setting.
 Li et al. highlighted that in comparison with GTR, the relative low rates of post-
operative new neurological deficits in the SPTR group could probably be explained by 
the increased use of awake surgery with neurophysiological monitoring, (sub)cortical 
mapping and imaging guidance such as intra-operative MRI, fMRI and DTI navigation.(2,8) 
Although Jenkinson et al. showed in a recent Cochrane review that intra-operative MRI 
or 5-ALA fluorescent guided surgery may help to increase the extent of GBM resection, 
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reports on adverse events were incomplete and studies had very low quality evidence.(2) 
Since portions of hyperintense T2-FLAIR area may represent both tumor infiltrated 
edematous and solely edematous portions, additional methods to delineate non-CE 
tumor infiltration are important to obtain a target for SPTR. Resection of the former 
may contribute to a better patient survival, while the impact of the latter on survival will 
be limited, but would pose an unnecessary risk of complications. In addition to 5-ALA, 
physiological pre-operative MRI imaging such as positron emission tomography (PET) 
MRI may help to identify tumor infiltrated, high metabolic portions outside the CE areas 
of GBM as a specific target during surgery.(35) 
Limitations
Overall, the results of our analysis should be interpreted with caution due to several 
limitations. First, because of between study heterogeneity (I2=68%) across analyzed 
studies, which possible arose due to several factors; the differences in defining SPTR; 
the heterogeneous or limited sizes of small study populations across studies; and their 
retrospective design and non-randomized treatment assignment. Indeed, as mentioned 
earlier, different definitions of SPTR across studies, which are often retrospectively defined 
and which currently varies between additional resection of fluorescing tumor to total 
resection of T2-FLAIR hyperintensity on top of GTR of CE, makes it challenging to draw 
a clear conclusion that would benefit clinical practice of neurosurgeons. Secondly, since 
the survival benefit and safety of resecting T2-FLAIR hyperintense regions is unclear, there 
was no clinical equipoise to randomize GBM patients into SPTR or GTR groups. Therefore, 
SPTR was probably performed in only a selected group of patients, since pushing the 
limits of GBM resection beyond CE was often not the main goal of surgery, especially not 
in tumors located in eloquent brain area. 
 Finally, a heterogeneous patient population with different prognostic factors such as 
age, KPS, adjuvant therapy, IDH mutation and MGMT methylation status, tumor volume 
and location were present across studies. Although corrections for some of these factors 
were applied in multivariate analyses across studies, the real impact of these factors on 
achieving SPTR and on survival are difficult to determine due to the retrospective nature 
of the studies.  GBM location and eloquence is a known important prognostic factor. A 
very recent study suggests that GBM located in non-eloquent area such as the frontal 
or temporal pole could possibly receive safe SPTR with a total lobectomy.(34) However, 
no clear comparison with GBM located in eloquent area was available. In the articles we 
have included in our study, correction for GBM eloquence was performed only limited 
(as presented in Supplementary Materials). Furthermore, some of these factors such as 
genetic mutation, location and tumor size are inter correlated and their influence on 
survival is difficult to investigate retrospectively; GBM with IDH mutation (and MGMT 
methylation) have a significant better survival and at the same time are more often 
located in the frontal pole and have larger tumor size.(36)
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 These limitations introduced biases such as confounding by indication, information 
and selection biases in the analyzed studies, which consequently have influenced internal 
validity and the quality of the studies negatively. Indeed, since the quality of evidence 
of the analyzed studies were only moderate to very low, the benefit of SPTR of GBM on 
survival and its safety remains unclear and at this point of time and cannot be considered 
as a main goal of GBM surgery.  Taking these limitations into account, we used a random 
effect model to provide a conservative, but clinically more reliable and meaningful 
interpretation of the treatment effect of SPTR (37). The random effects model summary 
results of HR 0.47 (95% CI = 0.31 - 0.72) and median overall survival benefit of 6.4 months 
(95% CI % 3.2 - 9.7) provides a more reliable average estimate effect because it takes 
real differences in the SPTR versus GTR effect in each study into account and gives wider 
uncertainty around the estimate, as compared with fixed effects model summary results 
of HR 0.67 (95% CI = 0.58 - 0.78) and a median overall survival benefit of 4.6 months (95% 
CI = 3.9 – 6.0).  
 It should be underlined that SPTR should not be attempted at any cost. As always, 
the aim of GBM surgery remains to maximize the extent of GBM resection without causing 
new neurological deficits and by maintaining a good quality of patient’s life. Any potential 
benefit of a prolonged survival by extending tumor resection could be considered by 
exploring (functional) boundaries during awake surgery and additional imaging adjuncts 
such intra-operative MRI, ultrasound and 5-ALA. This potential benefit should be weighed, 
together with the patient, against the risk of pushing the boundaries of GBM resection 
and its effect on post-operative neurological functioning and quality of life. 
 In our study, the incidence on post-operative new neurological deficits was not well 
reported across different studies. Post-operative neurological status was reported only 
descriptively, without the use of validated tests and quantitative outcome measures. 
Additionally, no data on quality of patient lives were reported across the studies. The 
safety of the procedure can therefore not be established. 
Future Directions
Future well designed, prospective, randomized controlled trials are thus needed to 
investigate both the safety and survival benefit of SPTR of GBM. These trials should 
include prospective, and clearly defined volumetric SPTR measures in order to 
standardize the definition of SPTR. Such a standardized definition of SPTR is expected 
to improve comparability between studies and improve the quality of evidence of 
studies investigating SPTR of GBM. Advanced physiological imaging techniques could 
additionally be used to identify non-CE infiltrating, residual tumor beyond the CE margins. 
Finally, validated measures on post-operative neurological outcome and quality of life 
assessment (QLQ-C30/QLQ-BN20) corrected for important prognostic factors such as age, 
KPS, adjuvant therapy, IDH mutation, and MGMT methylation status should be used to 




To the best of our knowledge, we performed the first meta-analysis on SPTR of GBM, 
suggesting that when compared with GTR, SPTR of GBM shows lower risk of mortality 
at any time during follow-up and longer overall median survival. These results should 
however be interpreted with caution, as the quality of the available evidence was only 
moderate to very low, and importantly, there was no consensus on the definition of SPTR 
and no reliable information on the safety of SPTR was available. Therefore, based on 
current available literature, the benefit of SPTR of GBM on survival and its safety remains 
unclear at this point of time and can as yet not be considered as standard of care for GBM 
surgery. Our findings however, does encourage further investigation in well-designed, 
prospective, randomized trials to clarify whether SPTR can be achieved safely to improve 
survival of patients with GBM.
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NEAR/3 attenuat* NEAR/3  invers* NEAR/3 recover*) OR t2 OR t-2 OR gross-total OR ((exten* OR 
Supratotal* OR Supramaxim*) NEAR/3 (resect* OR remov*)) OR ((surg* OR excis* OR resect*) 
NEAR/3 margin*) OR ((beyond OR additional*) NEAR/6 (contrast OR boundar*))):ab,ti,kw) NOT 
([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
Web of Science  
 ((glioblastom* OR (maligna* NEAR/3 glioma*) OR (high* NEAR/3 grade* NEAR/3 glioma*) 
OR ((grade-iv OR grade-4) NEAR/3 glioma*) OR gbm):ab,ti,kw) AND ((surg* OR neurosurg* 
OR resect*):ab,ti,kw) AND ((flair OR (Fluid NEAR/3 attenuat* NEAR/3  invers* NEAR/3 recover*) 
OR t2 OR t-2 OR gross-total OR ((exten* OR Supratotal* OR Supramaxim*) NEAR/3 (resect* 
OR remov*)) OR ((surg* OR excis* OR resect*) NEAR/3 margin*) OR ((beyond OR additional*) 
NEAR/6 (contrast OR boundar*))):ab,ti,kw) 
Cochrane CENTRAL 
((glioblastom* OR (maligna* NEAR/3 glioma*) OR (high* NEAR/3 grade* NEAR/3 glioma*) 
OR ((grade-iv OR grade-4) NEAR/3 glioma*) OR gbm):ab,ti,kw) AND ((surg* OR neurosurg* 
OR resect*):ab,ti,kw) AND ((flair OR (Fluid NEAR/3 attenuat* NEAR/3 invers* NEAR/3 recover*) 
OR t2 OR “t 2” OR “gross total” OR ((exten* OR Supratotal* OR Supramaxim*) NEAR/3 (resect* 
OR remov*)) OR ((surg* OR excis* OR resect*) NEAR/3 margin*) OR ((beyond OR additional*) 
NEAR/6 (contrast OR boundar*))):ab,ti,kw) 
Google Scholar 
 glioblastoma|”malignant glioma”|”high grade glioma” flair|”Fluid attenuating inverse”|”gross 
total”|”Supratotal|Supramaximal resection”|”extent of resection”
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GRADE quality ranking 






Risk of bias ** Precision
Aldave 2013 (12) 3 Non-random treatment 
allocation, retrospective
Moderate Low N, wide CI
Li 2016 (8) 2 Non-random treatment 
allocation retrospective
Moderate High N, narrow CI
Eyupoglu 2016 (19) 3 Non-random treatment 
allocation retrospective
Moderate Moderate N, CI
Pessina 2017 (28) 3 Non-random treatment 
allocation retrospective
Moderate Moderate N, CI
Esquanazi 2017 (18) 3 Non-random treatment 
allocation retrospective
Moderate Low N, wide CI
Glenn 2018 (21) 4 Non-random treatment 
allocation, retrospective
Serious Low N, wide CI
N = number of patients CI = Confidence Interval
* Levels of quality (GRADE): 1: high, 2: moderate, 3: low, 4: very low
** “Risk Of Bias In Non-randomised Studies - of Interventions” (ROBINS-I), based on risks of selection, information 
and confounding biases, with summarized judgements which includes moderate, serious and critical risks of 
bias or no information.
Study Multivariate 
analysis
Prognostic factors as variables
Aldave 2013 (12) Yes age, KPS, MGMT methylation  status, tumor eloquent location,  
preoperative tumor volume, and adjuvant therapy.
Li 2016 (8) Yes unclear, at least treatment history
Eyupoglu 2016 (19) No Not performed
Pessina 2017 (28) Yes age, extent of contrast enhancement resection, tumor location
Esquanazi 2017 (18) Yes age, tumor volume, KPS, intra operative mapping, BCNU wafer
Glenn 2018 (21) Yes MGMT methylation status, tumor laterality
KPS = Karnofsky Performance Status, MGMT= methylguanine-DNA methyltransferase IDH= isocitrate 
dehydrogenase, BCNU= bis-chloroethylnitrosourea or Carmustine.

Fatih Incekara, Marion Smits, Arnaud J.P.E. Vincent 
J Neurosurg. 2019 Aug 16:1-2
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Supratotal resection of glioblastoma
TO THE EDITOR: We read with great interest the research by Roh et al. (Roh TH, Kang SG, 
Moon JH, et al: Survival benefit of lobectomy over gross-total resection without lobectomy 
in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg 2019 
Mar 1:1-7. doi: 10.3171/2018.12.JNS182558. [Epub ahead of print]) regarding supratotal 
glioblastoma (GBM) resection in non-eloquent brain area.9 
In this well written and timely article, the authors show that in patients with GBM located 
in right sided, frontal and temporal, non-eloquent brain area, supratotal resection (SupTR) 
defined as a total lobectomy improves median OS and PFS, when compared with solely 
gross total resection (GTR) of GBM. We commend the authors for critically appraising their 
clinical practice variations, which adds to our understanding on the potential value of 
SupTR of GBM in improving patient survival. 
The study however, does raise some issues which need careful consideration. First, 
studying the value of SupTR without detailed and preferably standardized assessment 
of neurological outcome (i.e. NIHSS)10 and quality of life assessments (i.e. QLQ-C30 and 
QLQ-BN20)11 remains an important limitation. Although this issue is acknowledged by the 
authors, it is only briefly discussed in the limitation paragraph. Readers should be more 
strongly notified to not draw any decisive conclusions on the safety of this procedure 
even in noneloquent area, since only KPS was measured as a global neurological outcome 
and no data was available on the quality of patient life. Within this context, it also remains 
unclear how the dominant hemisphere and eloquent brain area were determined. The 
exclusion of all-left sided tumors by definition suggests that no functional MRI was 
used to asses functional lateralization and seems to disregard the notion that the right 
hemisphere may be dominant in some patients. Additionally, it should be noted that 
despite the exclusion of “tumors involving motor or language areas”, awake surgery was 
performed when GBM “was near an eloquent area”. We think that it would be beneficial 
to read in Table 1 how many cases were classified as (near) eloquent GBM and thus how 
many cases were performed with awake surgery. If this, hypothetically, was the case in the 
majority of patients, many noneloquent GBM should in fact have been labeled as (near) 
eloquent located GBM. In such a case, the conclusion that SupTR of noneloquent GBM is a 
safe procedure would - unintentionally - mislead the reader.
Secondly, as the authors acknowledge, the definition of supratotal resection is 
ambiguous. GBM is known to infiltrate beyond the margins of contrast enhancement, 
into the surrounding edematous T2/FLAIR-weighted hyperintense area, as seen on MRI.2 
In this study, SupTR was defined as complete resection of contrast enhancement as seen 
on T1-weighted postcontrast, postoperative MRI plus (frontal or temporal) lobectomy. In 
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addition, the authors considered a resection cavity on post-operative MRI that was larger 
than the contrast enhancing tumor volume on pre-operative MRI as a criterion for SupTR. 
We think that this criterion is highly debatable because of two reasons. First, factors such 
as brain shift and swelling of brain parenchyma makes a comparison of post-surgical 
cavity with pre-operative tumor volume unreliable. Secondly, as we mentioned earlier, 
GBM can infiltrate far beyond contrast enhancement and in fact, beyond the resection 
cavity as seen on post-contrast T1-weighted images, due to expansive and large T2/FLAIR-
weighted hyperintense regions. The authors do not specify whether SupTR included the 
entire T2/FLAIR hyperintense region. In fact, unfortunately, no volumetric analysis on T2/
FLAIR abnormality was presented in this study. Previously published studies investigating 
the role of supratotal resection or post-operative residual T2/FLAIR abnormalities found 
an association with survival.1,3-8 We believe that currently no clear definition of supratotal 
resection exists and it can only broadly be defined as any effort of resection beyond 
the contrast enhancing part of GBM. In future studies it yet needs to be defined in a 
prospective setting.
Finally, we fear that the internal and external validity of the study is influenced by 
respectively confounding and selection biases. Although the authors acknowledge the 
presence of selection bias in the last sentence of the discussion, this issue needs more 
attention, since the impact of the biases on the results and the main conclusion is expected 
to be substantial. Indeed, out of 400 GBM patients only 40 patients with GTR of right-sided 
frontal or temporal noneloquent GBM were selected. It is also unclear how GBM location 
within a lobe and surgeon preference influenced SupTR vs GTR. The surgeon might have 
intended a SupTR for a GBM in the right temporal pole, whereas a more posterior and 
medial GBM within the same lobe might receive GTR instead of a lobectomy. Based on this 
highly selected group of patients, it remains unclear how to translate the potential benefit 
and the safety of SupTR for GBM surgery in general. In addition, the retrospective nature 
of the study prohibits a reliable comparison of median OS and PFS between the SupTR 
and GTR groups and raises several questions such as the impact of surgeon’s preference 
on achieving SupTR vs GTR, its influence on survival and the impact of performing 5-ALA 
fluorescence guided or awake surgery on survival. It is therefore preferable to control for 
known confounding factors in a multivariate analysis and focus on the corrected hazard 
ratio of SupTR vs GTR, as the authors rightly performed, instead of a biased improvement 
of median OS and PFS between groups as seen in the Kaplan-Meier curves.
We hope that emphasizing these issues will encourage readers to carefully consider both 
the potential benefits and the risks of SupTR, such that the conclusions of this important 
study can be fully and reliably appreciated.  
249
Letter to the Editor: Supratotal resection of glioblastoma
10.2
References
1. Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, et al: Prognostic value of residual 
fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic Acid-
guided surgery. Neurosurgery 72:915-920; discussion 920-911, 2013
2. Eidel O, Burth S, Neumann JO, Kieslich PJ, Sahm F, Jungk C, et al: Tumor Infiltration in Enhancing 
and Non-Enhancing Parts of Glioblastoma: A Correlation with Histopathology. PLoS One 
12:e0169292, 2017
3. Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N: The Survival Advantage of “Supratotal” 
Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. 
Neurosurgery 81:275-288, 2017
4. Eyupoglu IY, Hore N, Merkel A, Buslei R, Buchfelder M, Savaskan N: Supra-complete surgery via 
dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. 
Oncotarget 7:25755-25768, 2016
5. Glenn CA, Baker CM, Conner AK, Burks JD, Bonney PA, Briggs RG, et al: An Examination of the 
Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme. World Neurosurg 
114:e747-e755, 2018
6. Kotrotsou A, Elakkad A, Sun J, Thomas GA, Yang D, Abrol S, et al: Multi-center study finds 
postoperative residual non-enhancing component of glioblastoma as a new determinant of 
patient outcome. J Neurooncol 139:125-133, 2018
7. Li YM, Suki D, Hess K, Sawaya R: The influence of maximum safe resection of glioblastoma on 
survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg 124:977-
988, 2016
8. Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, et al: Maximize surgical 
resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma 
multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 
135:129-139, 2017
9. Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH, et al: Survival benefit of lobectomy over 
gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a 
retrospective study. J Neurosurg:1-7, 2019
10. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al: Fluorescence-
guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised 
controlled multicentre phase III trial. Lancet Oncol 7:392-401, 2006
11. Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al: Health-related 










This thesis assessed the value of glioblastoma imaging and resection in light of molecular 
markers. Here, I summarize and discuss the main findings in this thesis. I provide future 
perspectives on topics addressed in this thesis and I finish with a conclusion. 
In Part I, we predict molecular markers of glioma, primarily IDH mutation, 1p/19q 
codeletion and MGMT promoter methylation, and cognitive outcome of patients based 
on preoperative MRI scans. In Part II, we present the results of a randomized controlled 
trial that assesses the value of intraoperative ultrasound guided surgery on the extent of 
glioblastoma resection. We answer the question whether intraoperative ultrasound guided 
surgery enables complete tumor resection more often than standard glioblastoma surgery. 
Based on the results, we provide a recommendation to achieve maximal safe resection. 
In addition, we provide a proof of concept on the use of wearable mixed reality device 
for glioblastoma localization on the operating room. In Part III of this thesis, we study 
the association between the extent of contrast-enhancing and non-contrast enhancing 
tumor resection and survival of patients with glioblastoma. We validate our findings in a 
multi-center glioblastoma cohort. In addition, we assess the value of supratotal resection 
in glioblastoma, that is, tumor resection beyond the borders of contrast-enhancement. 
Main findings
Part I: Preoperative imaging
In Chapter 2, we re-evaluated the topographical distribution of 436 glioblastoma with 
vs. without MGMT promoter methylation using voxel-wise MRI analysis in one of the 
largest homogenous IDH wildtype glioblastoma populations. Visual inspection indicated 
that when compared with MGMT unmethylated glioblastoma, methylated glioblastoma 
were more frequently located near bifrontal and left occipital periventricular area and 
less frequently near the right occipital periventricular area. These visual appearance of 
differences, however, could not be confirmed with rigorous voxel-wise statistical testing. 
We therefore conclude that there was no statistical difference in anatomical localization 
between IDH wildtype glioblastoma with vs. without MGMT promoter methylation. Prior 
to the WHO 2016 classification update,(1) studies on this topic had reported conflicting 
results; some studies showed that glioblastoma with MGMT methylation were lateralized 
to the left temporal lobe, while other showed right hemisphere lateralization.(2-5) There 
were also studies that reported no differences in localization, in concordance with the 
findings of our study.(6-9) These conflicting results in literature may partially be explained 
by variations in glioblastoma patient populations across studies, many of which were 
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performed in the pre-WHO 2016 classification era when the impact of molecular subtyping 
of glioblastoma according to IDH mutation status was less of a consideration. 
In Chapter 3, we predicted the 1p/19q codeletion status in 284 low grade glioma patients 
on preoperative MRI scans with machine learning. We externally validated our algorithm 
on an independent dataset (n=129) and we compared the performance of our algorithm 
with that of clinical experts. We found that tumor location, heterogeneity on T2-weighted 
MRI scans, together with patient age and sex were the most important variables for our 
algorithm. We predicted the 1p/19q codeletion status of glioma with a performance 
that on average corresponded with experienced oncological neuroradiologists and 
outperformed oncological neurosurgeons. To the best of our knowledge, there are no 
prior studies predicting genetic mutations of low glioma on MRI using machine learning 
that compared their predictive performance with human performance.(10-13) Knowledge 
of the molecular profile of low grade glioma is clinically relevant, since it is recommended 
to consider them when timing postsurgical treatment with chemo- and/or radiotherapy.
(14) Before clinical implementation in the future, more research is needed to improve the 
accuracy of AI algorithms, but we showed their potential to support decision making in 
clinical care of glioma.
In Chapter 4, we have developed and externally validated a deep learning algorithm that 
can accurately predict the IDH mutation status, 1p/19q co-deletion status, and grade of 
glioma, while simultaneously providing automatic glioma segmentation, based on pre-
operative MRI scans. For patients in which tumor tissue cannot be obtained through 
surgical resection or diagnostic biopsy due to older age, poor neurological condition, or 
deep tumor localization, prediction of molecular markers on preoperative MRI scans may 
be clinically relevant in the future as an alternative.
In Chapter 5, we studied the association between the cognition of patients with a 
low grade glioma and white matter tract changes using diffusion tensor MRI and fiber 
tractography. We found that cognition in terms of language deficits in repetition of 
speech, imprinting and attention deficits were associated with changed microarchitecture 
of the arcuate fasciculus and the inferior fronto-occipital fasciculus. Our results support 
the hypothesis that glioma may infiltrate language white matter tracts and disrupt their 
microarchitecture, leading to deterioration of cognition in patients with glioma. Extensive 
glioma resection should be balanced carefully against persevering such infiltrated white 




Part II: Image-guided glioblastoma surgery
In Chapter 6, we present the results of the ultrasound trial which aimed to assess the 
value of intraoperative ultrasound guided surgery on the extent of glioblastoma resection. 
The main research question was: does intraoperative ultrasound guided surgery enable 
complete tumor resection more often than standard glioblastoma surgery? We showed that 
intraoperative ultrasound enables complete tumor resection significantly more often 
(35%) than standard glioblastoma surgery (8%). We found that intraoperative ultrasound 
guidance did not harm patients in terms of neurological outcome, functional status and 
quality of life. Therefore, we recommended intraoperative ultrasound guided surgery, 
rather than standard surgery based on neuronavigation alone, to achieve complete safe 
tumor resection. 
Complete resection of contrast-enhancing tumor has consistently been associated with 
longer overall survival in patients with glioblastoma.(16) Complete tumor resection is 
defined both qualitatively and quantitatively across studies.(17, 18) Some studies defined 
complete tumor resection as no residual contrast-enhancing tumor on a post-operative 
MRI scan, which is a stringent definition and may result in false positive assessment of 
residual tumor due to non-specific contrast enhancement such as due to ischemia, small 
vessels or unspecific reactive tissue enhancement.(19) To take interpretation variations 
into account, other studies also defined complete tumor resection as contrast-enhancing 
residual tumor <0.175 cm3(20, 21) or as a certain resection cut-off percentage (e.g. >98%).
(22) It is known that residual tumor assessment of glioblastoma has a low interobserver 
agreement, introducing some degree of subjectivity when distinguishing contrast-
enhancing residual tumor from non-specific contrast enhancement.(23) In our trial, 
we defined complete tumor resection as >99% resection of contrast-enhancing tumor 
volume, accepting residual contrast-enhancing volume smaller than one percent to 
account for non-tumor related enhancement. 
 
It is shown in two randomized controlled trials, that 5-aminolevulinic acid and intraoperative 
MRI guided surgery improve the extent of glioblastoma resection.(20, 21) However, an 
intraoperative MRI system is expensive and prolongs surgery time with approximately one 
hour.(21) This might explain why intraoperative MRI is still not implemented worldwide 
as a standard procedure during glioblastoma surgery. An alternative less-expensive, time 
effective technology that is used to acquire real-time imaging during brain tumor surgery 
is intraoperative ultrasound.(24) Real time imaging is needed, since neuronavigation 
systems are typically based on pre-operative MRI scans and due to brain shift, their 
accuracy in representing the actual situation during surgery decreases. As Jenkinson 
et al showed in a Cochrane review, no randomized controlled trial is ever performed to 
assess the value of intraoperative ultrasound to maximize tumor resection.(25) Therefore, 
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we initiated first such a trial and presented the results in this thesis. We recommend 
intraoperative ultrasound guidance as an alternative intraoperative imaging technology, 
just as intraoperative MRI or 5-aminolevulinic acid guided surgery (or a combination), to 
maximize the extent of contrast-enhancing tumor resection during glioblastoma surgery.
In Chapter 7, we tested in one of the first prospective clinical pilot studies, the clinical 
feasibility and accuracy of a wearable mixed reality device (Microsoft Hololens) for 
neurosurgical planning and glioblastoma localization on the operating room. We 
compared a wearable augmented reality headset with a standard neuronavigation system 
and showed in a proof of concept using quantitative outcome measures that augmented 
reality has a potential for glioblastoma visualization and localization during neurosurgical 
planning. We observed that manual hologram placement on the patient was a limitation 
decreasing the accuracy of tumor localization of the augmented reality device. For clinical 
implementation, the accuracy of the augmented reality device should be improved in 
future research, preferably trough automated registration of the hologram with the 
patient and through integration of augmented reality with a neuronavigation system.
Part III: Extent of resection and survival
In Chapter 8, we assessed the association between contrast-enhancing and non-contrast 
enhancing tumor resection and survival in light of MGMT promoter methylation in 
326 patients with newly diagnosed IDH wildtype glioblastoma. This study showed an 
association between maximal contrast-enhancing tumor resection, ≥30% non-contrast 
enhancing tumor resection, minimal residual contrast-enhancing tumor volume and 
longer overall survival. Kaplan Meier estimates indicated that extensive surgery was 
potentially more beneficial for patients with MGMT methylated glioblastoma. Complete 
contrast enhancing glioblastoma resection is consistently associated with patient survival.
(16) This thesis however, re-evaluates this association based on two new insights. 
First, previous studies reported limited data on molecular characteristics of glioblastoma 
(i.e. IDH mutation and MGMT promotor methylation status) since many were performed 
prior to the WHO 2016 classification update, in which molecular sub classification was 
less of a consideration.(16) Although IDH mutation within newly diagnosed primary 
glioblastoma is rare (<5%, and 3.5% in our cohort) these tumors represent a distinct 
molecular type of glioma arising from a distinct precursor lesion and the recent cIMPACT-
NOW update suggests to call these tumors astrocytoma grade IV.(26-29) Therefore, new 
series are required to answer certain questions in tumor types defined according to 
this updated classification. We confirmed the association between complete contrast-




In Chapter 9 we performed an international, multicenter, observational study including 
over one thousand patients with a newly diagnosed IDH-wildtype glioblastoma, in which 
we developed and externally validated a survival prediction model. This model included 
age, gender, preoperative Karnofsky performance status, extent of surgical resection, 
MGMT promoter methylation status, and adjuvant therapy and showed after external 
validation that survival of individual patients with a newly diagnosed glioblastoma could 
reliably be predicted. We published an online nomogram that could be useful to support 
shared decision making.
Secondly, this thesis re-evaluated the association between glioblastoma resection and 
survival by assessing the value of non-contrast enhancing tumor resection, beyond 
the borders of contrast enhancement. Glioblastoma is known to infiltrate far beyond 
the margins of contrast enhancement as seen on post-contrast T1-weighted MRI scans, 
into the surrounding edematous T2-weighted or T2-FLAIR hyperintense area.(30) This 
raises the question whether complete resection of contrast-enhancing tumor is indeed 
what is classically known as “gross total resection” or that resection should be extended 
beyond the margins of contrast enhancement, into the non-contrast enhancing area of 
signal abnormalities, to improve survival. The second question in this line, is which part 
of non-contrast enhancing tumor should be resected, as it can be hypothesized that 
only resection of tumor infiltrated, rather than edematous non-contrast enhanced tissue 
abnormalities will decrease tumor load and contribute to survival benefit. Physiological 
MRI is a promising tool to identify and distinguish tumor infiltrated portions from edema 
in non-contrast enhancing area.(31) We also showed in Chapter 8 that resection of ≥30% 
non-contrast enhancing tumor, beyond the margins of contrast enhancement, was 
associated with a longer overall survival. Other studies associated non contrast enhanced 
tumor resection percentages of 45%,(32) 53%(19) and 92%(33) with improved patient 
survival. Importantly, maximal glioblastoma resection should not be attempted at all 
cost and these studies reported very limited to no data on patient outcome. We also 
had insufficient data on patient outcome in our study, and therefore we recommended 
that intraoperative imaging and stimulation mapping should be used to pursue safe and 
maximal resection. In future research, the safety aspect of maximizing tumor resection 
needs to be further addressed. 
The concept of supratotal resection has been known for some time within low grade 
glioma surgery, but it is only being investigated fairly recently in glioblastoma.(34) 
Chapter 10.1 had the aim to study supratotal resection in glioblastoma surgery and its 
relation to patient survival in  literature. We showed in our systematic review and meta-
analysis based on six studies and 1168 glioblastoma patients that when compared with 
complete resection of contrast enhancement, supratotal resection of glioblastoma was 
associated with lower risk of mortality and longer median overall survival during follow 
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up. The quality of evidence however, was poor due to selection and confounding biases 
in the included studies.(19, 32, 35-38) In addition, there is much variation in the definition 
of supratotal resection for glioblastoma across studies. The safety aspect of supratotal 
resection was poorly reported, often lacking data on neurological outcome, complications 
or quality of patient life. Supratotal resection of glioblastoma can potentially provide 
survival benefit, however, future research is needed to assess its safety, as also addressed 
in our letter (Chapter 10.2).
Future perspectives
It can be expected that in future neuro-oncological radiogenomics research, the accuracy 
of molecular and clinical outcome predictions on MRI will increase due to 1) the rise of 
artificial intelligence 2) more patient data as a result of large multi-center collaborations 
and consortia and 3) the addition of advanced MRI techniques including physiological 
MRI scans such as perfusion and diffusion and combination of MRI with PET-scanning. 
Physiological MRI scans will not be only of benefit for radiogenomics research, but also for 
safely maximizing glioma resection due to a more accurate delineation of tumor margins 
then that we currently are able to do based on anatomical MRI scans only. (31) This may 
help us to understand which part of the non-contrast enhanced portion of glioblastoma 
is more tumor infiltrated and thus should be resected, and which part is more edema and 
can be preserved. 
We further expect that new intraoperative imaging technologies, combined with artificial 
intelligence, will be of benefit to safely maximize the extent of brain tumor resection. 
Already, a recent study showed potential benefit of near real-time intraoperative detection 
of infiltration in tumor borders within minutes using stimulated Raman spectroscopy and 
deep neural networks to pursue maximal and safe glioma surgery, which may replace 
froze sections during surgery in the future.(39) These technologies, when integrated in 
augmented reality navigation systems, may provide intraoperative guidance and decision-
making during surgery, for example by overlaying accurate predictions of algorithms over 
tissue to determine whether that last part in the resection cavity is residual or healthy 
tumor tissue, which is often difficult to see even with a trained neurosurgical eye. 
The future of neurosurgery will be shaped by new imaging technologies and artificial 
intelligence, and still with surgical experience, intuition and anatomical knowledge in its 
center, there will be a transition towards data driven surgery. It can be expected that this 
will not only contribute to maximize the extent of tumor resection, but the safety of brain 
tumor surgery will also be maintained by preserving functional brain area. Anatomical 




fluorescent guided surgery will be supported by function-guided surgery such as awake 
surgery with stimulation mapping and intraoperative physiological image-guidance.
It can hopefully be expected, in short, that new imaging technologies and artificial 
intelligence will improve the way we diagnose and resect glioma, and thus eventually the 
way we provide clinical care for patients with brain tumors. 
Conclusion
This thesis contributes to our knowledge on the value of imaging and resection of glioma, 
in particular glioblastoma. 
We presented promising results on molecular predictions based on preoperative MRI scans 
using artificial intelligence. We showed in a randomized controlled trial that intraoperative 
ultrasound enables complete tumor resection more often than standard glioblastoma 
surgery, without harming patients. We recommend intraoperative ultrasound guided 
surgery, rather than standard surgery, to achieve complete safe tumor resection. We 
found that augmented reality was potentially useful to visualize and locate glioblastoma 
for neurosurgical planning on the operating room. 
Complete glioblastoma resection was already associated with improved patient survival. 
We confirmed this association in molecularly defined IDHwt glioblastoma. We externally 
validated these results in a multi-center glioblastoma cohort and predicted survival of 
patients with a glioblastoma with nomograms. In addition, we found that resection of 
non-contrast enhanced tumor beyond contrast enhancement or supratotal resection 
showed potential survival benefit for patients with glioblastoma. We encourage further 
research on the safety of maximizing glioblastoma resection, especially beyond the 
borders of contrast enhancement. 
Finally, we shared future perspectives, in which we expect that new imaging technologies 
and artificial intelligence will improve how we understand, diagnose and surgically treat 
patients with brain tumors.
We hope that this thesis will be of benefit for future brain tumor research, clinical care and 
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Dit proefschrift heeft de waarde onderzocht van glioblastoom beeldvorming en resectie 
in het licht van moleculaire markers. Hier geef ik een samenvatting en bespreek ik 
de belangrijkste bevindingen in dit proefschrift. Ik bied toekomstperspectieven op 
onderwerpen die in dit proefschrift aan de orde zijn gekomen en ik sluit af met een 
conclusie. 
In Deel I voorspellen we moleculaire markers van gliomen, specifiek IDH-mutatie, 1p/19q 
codeletie en MGMT promotor methylering status, en cognitieve uitkomst van patiënten 
met een glioom op basis van preoperatieve MRI scans. In Deel II presenteren we de 
resultaten van een gerandomiseerde, gecontroleerde klinische studie die het nut van 
intraoperatieve echogeleide chirurgie op de uitgebreidheid van glioblastoom resectie 
onderzoekt. We beantwoorden de hoofdvraag of intraoperatieve echogeleide chirurgie 
vaker volledige tumorresectie mogelijk maakt, vergeleken met standaard glioblastoom 
chirurgie. Op basis van de resultaten geven we een aanbeveling hoe  maximale veilige 
resectie te bereiken. Daarnaast laten we voor het eerst zien middels een concept idee 
dat augmented reality gebruikt kan worden in de operatiekamer om glioblastoom mee 
te lokaliseren. In Deel III van dit proefschrift onderzoeken we de associatie tussen de 
mate van resectie van contrast aankleurende en niet-contrast aankleurende tumor en 
overleving van patiënten met een glioblastoom. We valideren onze bevindingen in een 
multicenter glioblastoom cohort. Daarnaast onderzochten we het nut van supratotale 
resectie, dus tumor resectie buiten de grenzen van contrast aankleuring, bij glioblastomen 
op levensduur van patiënten.
Hoofdbevindingen
Deel I: Preoperatief imaging
In Hoofdstuk 2 hebben we de topografische verdeling van 436 glioblastomen met vs. 
zonder MGMT promotor methylering geëvalueerd met behulp van voxel-gewijze MRI 
analyse in een van de grootste homogene IDH wildtype glioblastoom populaties tot nu toe. 
Visuele inspectie liet zien dat, vergeleken met MGMT niet-gemethyleerd glioblastomen, 
gemethyleerde  glioblastomen vaker in de buurt van het bifrontale en linker occipitale 
periventriculaire gebied lagen en minder vaak in de buurt van het rechter occipitale 
periventriculaire gebied. Deze visuele verschillen konden echter niet worden bevestigd 
met voxel-gewijze statistische testen. We concluderen daarom dat er geen statistisch 
verschil was in anatomische lokalisatie tussen IDH wildtype glioblastomen met vs. zonder 
MGMT promotor methylering. Voorafgaand aan de update van de WHO 2016-classificatie 
(1) rapporteerden studies tegenstrijdige resultaten; sommige studies toonden dat 
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glioblastomen met MGMT methylering vaker in de linker temporale kwab zaten, terwijl 
andere lateralisatie naar de rechterhersenhelft toonden. (2-5) Er waren ook studies die 
geen verschillen in lokalisatie rapporteerden, in overeenstemming met de bevindingen 
van onze studie. (6-9) Deze tegenstrijdige resultaten in de literatuur kunnen gedeeltelijk 
worden verklaard door variaties in de populaties van patiënten met glioblastoom, 
waarvan er vele werden uitgevoerd voorafgaand aan het tijdperk van de WHO van 2016 
classificatie, toen de impact van moleculaire subtypering van glioblastomen op basis van 
IDH-mutatie status minder relevant geacht werd. 
In Hoofdstuk 3 voorspelden we de moleculaire marker, 1p/19q codeletie, in 284 
laaggradige gliomen op basis van preoperatieve MRI-scans door gebruik te maken van 
machine learning. We hebben ons algoritme extern gevalideerd op een onafhankelijke 
dataset (n = 129) en we vergeleken de prestatie van ons algoritme met die van klinische 
experts. We ontdekten dat tumor lokalisatie, tumor heterogeniteit op T2-gewogen MRI 
scans, samen met leeftijd en geslacht van de patiënt de belangrijkste variabelen waren 
voor ons algoritme. De nauwkeurigheid in het voorspellen van de 1p/19q codeletie 
status kwam gemiddeld overeen met die van ervaren oncologische neuroradiologen 
en presteerde zelfs beter dan oncologische neurochirurgen. Voor zover wij weten, zijn 
er geen eerdere studies die genetische mutaties van een laaggradige gliomen op 
MRI voorspellen met behulp van kunstmatige intelligentie die tevens hun algoritme 
vergeleken met artsen. (10-13) Kennis van het moleculaire profiel van laaggradige glioom 
is klinisch relevant, aangezien het aanbevolen is om hiermee rekening te houden bij het 
timen van behandeling met chemo- en of radiotherapie na een operatie. (14) Voordat 
deze bevindingen klinisch geïmplementeerd kunnen worden in de toekomst, is meer 
onderzoek nodig om de nauwkeurigheid van algoritmen te verbeteren, maar wij hebben 
hun potentiaal hier getoond om de besluitvorming in de klinische zorg voor gliomen te 
ondersteunen.
In Hoofdstuk 4 hebben we een deep learning algoritme ontwikkeld en deze extern 
gevalideerd welke de IDH mutatie status, 1p/19q co-deletie status en glioom gradering 
nauwkeurig kan voorspellen en welke tegelijkertijd automatisch gliomen kan 
segmenteren, allemaal op basis van preoperatieve MRI scans. Voor patiënten bij wie 
tumorweefsel niet kan worden verkregen middels een operatie of diagnostische biopsie 
vanwege hogere leeftijd, slechte neurologische toestand of diepe tumor lokalisatie, kan 
een nauwkeurige voorspelling van moleculaire markers op preoperatieve MRI scans door 
algoritmen als alternatief klinisch relevant zijn in de toekomst.
In Hoofdstuk 5 onderzochten we de associatie tussen cognitie van patiënten met een 
laaggradige glioom en veranderingen in zenuwbanen (witte stofbanen) met behulp 




(herhalen van woorden), inprenting, en aandacht geassocieerd was met veranderde 
microarchitectuur van de fasciculus arcuata en de fasciculus fronto-occipitalis inferior. 
Onze resultaten ondersteunen de hypothese dat gliomen zenuwbanen verantwoordelijk 
voor taal kunnen infiltreren en hun microarchitectuur kunnen verstoren, wat leidt tot 
verslechtering van de cognitie bij patiënten met glioom. Uitgebreide glioomresectie 
moet zorgvuldig worden afgewogen tegen het intact laten van dergelijke geïnfiltreerde 
witte stofkanalen om functie te beschermen, bij voorkeur met een wakkere operatie en 
(sub)corticale stimulatie. (15)
Deel II: Beeldgeleide glioblastoom operatie
In Hoofdstuk 6 presenteren we de resultaten van de gerandomiseerde, gecontroleerde, 
klinische studie die het doel had om het nut van intraoperatieve echogeleide 
chirurgie te onderzoeken op de mate van resectie bij glioblastomen. De belangrijkste 
onderzoeksvraag was: maakt intraoperatieve echogeleide chirurgie vaker volledige 
tumor resectie mogelijk dan standaard glioblastoom chirurgie? We toonden aan dat met 
intraoperatieve echogeleiding significant vaker (35%) volledige tumorresectie bereikt 
werd dan met standaard glioblastoom chirurgie (8%). We zagen dat intraoperatieve 
echogeleiding patiënten niet schaadde in de zin van neurologische uitkomst, functionele 
status of kwaliteit van leven. Daarom bevelen we intraoperatieve echogeleide chirurgie, 
in plaats van standaardchirurgie, om volledige en veilige tumor resectie te bereiken.
Volledige resectie van contrast aankleurende tumor is vaker geassocieerd met langere 
overleving bij patiënten met een glioblastoom. (16) Volledige tumorresectie wordt zowel 
kwalitatief als kwantitatief gedefinieerd. (17, 18) Sommige studies definieerden volledige 
tumorresectie als ‘geen contrast-aankleurende tumor rest’ op een postoperatieve MRI 
scan, wat een strikte definitie is en kan leiden tot een fout-positief resultaat als gevolg 
van niet-specifieke contrast aankleuring, zoals ischemie, kleine bloedvaten of atyptische 
aankleuring van reactief weefsel. (19) Om met dergelijke interpretatie verschillen 
rekening te houden, definieerden sommige studies ook volledige tumorresectie als 
‘contrast aankleurende tumor kleiner dan 0,175 cm3 (20, 21) of als een bepaald resectie-
afkappercentage (bijv.> 98%). (22) Het is bekend dat bij het beoordelen van tumor rest bij 
glioblastomen relatief veel interpretatie verschil zit tussen beoordelaars, wat een zekere 
mate van subjectiviteit introduceert bij het onderscheiden van contrast aankleurende 
tumorrest van aspecifieke contrast aankleuring. (23) In ons onderzoek hebben we volledige 
tumorresectie gedefinieerd als een resectie van > 99% van het contrast aankleurende 
tumorvolume, waarbij we een contrast aankleurende rest volume van minder dan één 




In twee gerandomiseerde, gecontroleerde, klinische studies is aangetoond dat 
5-aminolevulinezuur fluorescentie geleide chirurgie en intraoperatieve MRI geleide 
chirurgie de mate van glioblastoom resectie verhoogt. (20, 21) Een intra-operatief MRI-
systeem is echter duur en verlengt de operatietijd met ongeveer een uur. (21) Dit zou 
kunnen verklaren waarom intraoperatieve MRI nog steeds niet wereldwijd wordt toegepast 
als standaard procedure tijdens glioblastoom chirurgie. Een alternatieve, goedkopere en 
tijdbesparende technologie die wordt gebruikt om terplekke beeldvorming te verkrijgen 
tijdens hersentumorchirurgie, is intraoperatieve echogeleide chirurgie. (24) Real-time 
beeldvorming is noodzakelijk, aangezien neuronavigatiesystemen doorgaans gebruik 
maken van preoperatieve MRI scans. Echter, door verplaatsing van de hersenen tijdens 
het opereren neemt hun nauwkeurigheid bij het weergeven van de werkelijke situatie 
tijdens de operatie af. Zoals Jenkinson et al. liet zien in een Cochrane review, was er tot 
op heden geen gerandomiseerde, gecontroleerde, klinische studie uitgevoerd om de 
waarde van intraoperatieve echogeleiding te onderzoeken om glioblastoom resectie te 
maximaliseren. (25) Daarom hebben wij voor het eerst een dergelijk studie uitgevoerd en de 
resultaten hier in dit proefschrift gepresenteerd. We raden intraoperatieve echogeleiding 
aan als alternatieve intraoperatieve beeldgeleide technologie, net als intraoperatieve MRI 
of 5-aminolevulinezuur fluorescentie geleide chirurgie (of een combinatie), om de mate 
van contrast aankleurende tumorresectie veilig te maximaliseren tijdens glioblastoom 
chirurgie.
In Hoofdstuk 7 hebben we als één van de eerste prospectieve klinische pilotstudies, 
de klinische haalbaarheid en nauwkeurigheid van een dragbare augmented reality 
bril (Microsoft Hololens) getest voor gebruik in de operatiekamer bij het plannen van 
glioblastoom operaties. We vergeleken de augmented reality bril met een standaard 
neuronavigatiesysteem en toonden in een proof of concept met kwantitatieve 
uitkomstmaten aan dat augmented reality potentieel gebruikt kan worden voor 
visualisatie en lokalisatie van glioblastomen in het kader van neurochirurgische planning. 
We vonden dat het handmatig plaatsen van een hologram op de patiënt een beperking 
was die de nauwkeurigheid van de augmented reality bril verminderde. Voor klinische 
implementatie moet de nauwkeurigheid van de augmented reality bril daarom nog 
worden verbeterd in toekomstig onderzoek, bij voorkeur door geautomatiseerde 
registratie van het hologram op de patiënt en eventueel door integratie van augmented 
reality met een neuronavigatiesysteem.
Deel III: Mate van resectie en levensduur
In Hoofdstuk 8 hebben we de associatie tussen contrast aankleurende en niet-contrast 
aankleurende tumor resectie en overlevingsduur onderzocht in het kader van MGMT 




glioblastoom. Dit onderzoek toonde een verband aan tussen complete contrast 
aankleurende tumor resectie, ≥30% niet-contrast aankleurende tumor resectie, minimaal 
contrast aankleurende tumorrest en langere overlevingsduur van patienten. Kaplan Meier 
grafieken lieten zien dat uitgebreide chirurgie mogelijk gunstiger was voor patiënten met 
een MGMT gemethyleerd glioblastoom.
Volledige contrast aankleurende tumor resectie was voorafgaand aan dit proefschrift al 
vaker geassocieerd met langere levensduur van patiënten. (16) Dit proefschrift onderzocht 
deze associatie echter op basis van twee nieuwe perspectieven.
Ten eerste rapporteerden eerdere studies beperkte gegevens over de moleculaire 
classificatie van glioblastomen (op basis van IDH-mutatie en MGMT-promotor-
methylerings status) aangezien er veel werden uitgevoerd voorafgaand aan de 
update van de WHO 2016 classificatie, waarbij moleculaire sub classificatie minder een 
relevant geacht werden. (16) Hoewel IDH-mutatie bij nieuw gediagnosticeerd primair 
glioblastoom zeldzaam is (<5% en 3,5% in ons cohort), vertegenwoordigen deze tumoren 
een andere moleculaire glioomtype, afkomstig van een andere precursorlaesie. (26, 27) 
Daarom is onvolledig of ontbreken van moleculaire gegevens over IDH mutatie en MGMT 
methylerings status, of het mengen van moleculaire subtypes bij het onderzoeken van 
het effect van glioblastoom resectie op overleving, ongewenst. In dit proefschrift hebben 
we de associatie tussen complete contrast aankleurende tumorresectie en langere 
overleving bevestigd in patiënten met een moleculair gedefinieerd glioblastoom. 
In Hoofdstuk 9 hebben we een internationale, multicenter, observationele studie 
uitgevoerd met meer dan duizend patiënten met een nieuw gediagnosticeerd IDH-
wildtype glioblastoom, waarin we een voorspellingsmodel hebben ontwikkeld en deze 
extern hebben gevalideerd. Dit model omvatte leeftijd, geslacht, preoperatieve Karnofsky 
performance status, mate van chirurgische resectie, MGMT-promotor methylatiestatus 
en adjuvante therapie en toonde na externe validatie dat de overleving van individuele 
patiënten met een nieuw gediagnosticeerd glioblastoom betrouwbaar kon worden 
voorspeld. We hebben een een online nomogram gepubliceerd dat bruikbaar kan zijn om 
gedeelde besluitvorming te ondersteunen.
Ten tweede liet dit proefschrift zien dat glioblastoom resectie geassocieerd is met 
overlevingsduur, door het nut van niet-contrast aankleurende tumor resectie te laten zien, 
voorbij de grenzen van contrast aankleuring. Het is bekend dat glioblastoom ver voorbij 
de contrast aankleurende grenzen, in de omgevende oedemateuze gebieden, infiltreert, 
wat zichtbaar is als T2-gewogen of FLAIR gewogen hyper intense gebieden op MRI 
scans.(28) Dit roept de vraag op of complete resectie van contrast aankleurende tumor 
daadwerkelijk compleet is, of dat resectie voorbij de grenzen van contrast aankleuring, in 
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de niet-aankleurende delen, uitgebreid moet worden om overlevingsduur van patiënten 
te verbeteren. De tweede vraag in deze lijn is welk deel van de niet-aankleurende tumor 
dan gereseceerd zou moeten worden, aangezien verondersteld kan worden dat alleen 
resectie van tumor geïnfiltreerde weefsel, en niet het oedemateuze hersenweefsel, de 
hoeveelheid tumor zal verminderen, en dus zal bijdragen aan het overlevingsvoordeel. 
Fysiologische MRI is een veelbelovend techniek om tumor geïnfiltreerde hersenweefsel 
te onderscheiden van oedeem in niet contrast aankleurende gebieden.(29) In Hoofdstuk 
8 toonden we ook aan dat dat ≥30% niet-aankleurende tumor resectie, voorbij de 
grenzen van contrast aankleuring, was geassocieerd met een betere overlevingsduur. 
Andere studies hebben gevonden dat niet-aankleurende tumor resectie percentages van 
45%,(30) 53%(19) en 92% (31) was geassocieerd met betere levensduur voor patiënten. 
Belangrijk is dat maximale resectie van glioblastoom niet koste wat het kost nagestreefd 
moet worden en over het algemeen wordt in voorgaande studies slechts beperkt over 
patiënt uitkomsten gerapporteerd. Ook wij hadden onvoldoende gegevens over patiënten 
uitkomsten in ons onderzoek en daarom adviseren we intraoperatieve beeldvorming 
en (sub)corticale stimulatie om functionele gebieden te identificeren en daarmee veilig 
en compleet te opereren. In toekomstig onderzoek moet de veiligheid van uitgebreide 
glioblastoom resectie verder onderzocht worden. 
Binnen de laaggradige glioom chirurgie is het concept van supratotale resectie al langer 
bekend, maar bij glioblastomen wordt dit nog pas vrij recent onderzocht.(32) Hoofdstuk 
10.1 had tot doel om supratotale resectie bij glioblastomen en de relatie tot levensduur 
van patiënten te onderzoeken in de literatuur. We lieten in onze systematisch reviewe 
en meta-analyse gebaseerd op zes studies met 1168 glioblastoom patiënten zien, dat 
vergeleken met totale resectie, supratotale resectie van glioblastomen geassocieerd was 
met lager risico op overlijden en langere mediane overleving gedurende follow up. De 
kwaliteit van het beschikbare bewijs was echter laag door selectiebias en confounding 
in de geïncludeerde studies.(19, 30, 33-36) Daarbij was er veel variatie in hoe supratotale 
resectie bij glioblastomen werd gedefinieerd tussen de studies onderling. De veiligheid 
van supratotale resectie was slecht gerapporteerd, waarbij vaak gegevens misten over 
neurologische uitkomst, complicaties en kwaliteit van leven van patiënten. Supratotale 
resectie van glioblastomen kan potentieel bijdrage aan het verbeteren van prognose van 
patiënten met een glioblastoom, maar meer onderzoek is nodig in de toekomst om de 






We verwachten dat in toekomstig neuro-oncologisch radiogenomics onderzoek de 
nauwkeurigheid van moleculaire en klinische uitkomst voorspellingen op basis van MRI 
scans zal toenemen als gevolg van 1) de opkomst van kunstmatige intelligentie 2) meer 
patiëntgegevens als gevolg van grote multicenter samenwerkingen en consortia en 3) de 
toevoeging van geavanceerde MRI technieken, waaronder fysiologische MRI scans zoals 
perfusie en diffusie MRI gecombineerd met PET scan. Fysiologische MRI scans zal niet alleen 
nuttig zijn voor radiogenomics onderzoek, maar ook voor het veilig maximaliseren van glioom 
resectie door een nauwkeurigere detectie van de tumor grenzen, beter dan we momenteel 
kunnen op basis van alleen anatomische MRI-scans. (29) Dit kan ons helpen te begrijpen 
welk deel van het niet-contrast aankleurende deel verwijderd moet worden vanwege 
tumor infiltratie en welk deel gespaard kan blijven, omdat er alleen sprake is van oedeem. 
 
We verwachten verder dat nieuwe intraoperatieve beeldvormende technologieën, 
gecombineerd met kunstmatige intelligentie, nuttig zullen zijn om de mate van tumor 
resectie veilig te maximaliseren. Een recent onderzoek toonde al het potentiële voordeel 
aan van intra-operatief beoordelen van tumor grenzen op infiltratie, waarbij binnen 
enkele minuten met behulp van gestimuleerde Raman-spectroscopie en kunstmatige 
intelligentie informatie werd verkregen om zo maximale en veilige glioomchirurgie na 
te streven, die in de toekomst mogelijk vriescoupes zou kunnen vervangen. (37) Deze 
technologieën, eventueel geïntegreerd met augmented reality-navigatiesystemen, 
kunnen intraoperatieve navigatie en besluitvorming tijdens chirurgie ondersteunen, 
bijvoorbeeld door nauwkeurige voorspellingen van algoritmen over weefsel te projecteren 
om te beslissen of dat laatste deel in de resectieholte resterend tumor of gezond 
weefsel is, wat vaak moeilijk is te zien zelfs voor een geoefend neurochirurgisch oog. De 
toekomst van neurochirurgie in die zin zal worden gevormd door nieuwe beeldvormende 
technologieën en kunstmatige intelligentie, waarin een transitie zal plaatsvinden naar 
data gedreven chirurgie, waarin nog altijd chirurgische ervaring, intuïtie en anatomische 
kennis centraal zullen staan in besluitvorming. 
Er kan verwacht worden dat dit niet alleen zal bijdragen aan het maximaliseren van de mate 
van tumor resectie, maar dat ook de veiligheid van hersentumorchirurgie ook zal worden 
verbeterd door behoud van functioneel hersengebieden. Anatomische beeldgeleide 
chirurgie zoals intra-operatieve MRI, intraoperatieve echografie en fluorescente geleide 
chirurgie zullen worden ondersteund door functiegeleide chirurgie zoals een wakkere operatie 
met elektrische (sub) corticale stimulatie en intraoperatieve fysiologische beeldgeleiding. 
Kortom, er kan verwacht worden dat nieuwe beeldvormende technologieën en 
kunstmatige intelligentie de manier waarop we glioblastomen diagnosticeren, reseceren 
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en daarmee uiteindelijk de manier waarop we klinische zorg bieden aan patiënten met 
hersentumoren, zullen verbeteren.
Conclusie
Dit proefschrift draagt bij aan de kennis over de waarde van beeldvorming en resectie van 
gliomen, in het bijzonder van glioblastomen. 
We presenteerden veelbelovende resultaten over moleculaire voorspellingen van 
gliomen op basis van preoperatieve MRI scans met kunstmatige intelligentie. We 
toonden aan dat intraoperatieve echogeleide chirurgie vaker tot volledige tumor resectie 
resulteerde dan met standaard glioblastoom chirurgie, zonder daarbij patiënten te 
schaden in de zin van neurologische uitkomst, functionele status en kwaliteit van leven. 
We bevelen intraoperatieve echogeleide chirurgie aan in plaats van standaardchirurgie 
om een  volledig veilige tumorresectie te bereiken. We hebben laten zien dat augmented 
reality potentieel nuttig was om glioblastomen op de operatiekamer te visualiseren en te 
lokaliseren in het kader van neurochirurgische planning. 
Voorafgaand aan dit proefschrift, was volledige glioblastoom resectie al vaker geassocieerd 
met een betere prognose voor patiënten met een glioblastoom. We bevestigden deze 
associatie in moleculair gedefinieerde glioblastomen volgens de geupdate WHO 
2016 classificatie. We hebben deze resultaten extern gevalideerd in een multicenter 
glioblastoom cohort en we voorspelden de overleving van patiënten met een glioblastoom 
met nomogrammen. Bovendien lieten we zien dat resectie van niet aankleurende tumor 
deel voorbij de grenzen van contrast aankleuring, dus supratotale resectie, potentieel 
bijdraagt aan een langere overleving bij patiënten met een glioblastoom. We moedigden 
verder onderzoek aan naar de veiligheid van het maximaliseren van glioblastoom resectie, 
vooral buiten de grenzen van contrast aankleuring.
Ten slotte deelden we toekomstperspectieven, waarin we verwachten dat nieuwe 
beeldvormende technologieën en kunstmatige intelligente zullen bijdragen aan onze 
kennis, diagnostiek en chirurgische behandeling van patiënten met een hersentumor. 
We hopen dat dit proefschrift nuttig zal zijn voor toekomstig hersentumoronderzoek, 
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